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MANAGING SUSCEPTIBILITY
TO HEREDITARY BREAST AND OVARIAN CANCER
Abstract
The recent identification of Breast Cancer 1 (BRCAl) and BRCA2 genes offers
an opportunity for high-risk individuals to learn whether they may be genetically
predisposed to develop breast and/or ovarian cancer. The purpose of this study was to
examine how unaffected women, identified as BRCA positive and variant of uncertain
significance (VUS) mutation carriers, managed their susceptibility to hereditary breast
and ovarian cancer (HBOC). Thirty North American women ranging in age from 22 to 60
years responded to open-ended interviews. These interviews were analyzed using
constant comparative method to generate a grounded theory.
Managing Susceptibility was identified as the basic social process, which
characterized how these unaffected women responded to genetic testing and managed
their risk of HBOC. Five categories were found that explain the actions, interactions, and
consequences of managing susceptibility. These were: (a) gaining awareness, (b)
confronting uncertainty and getting tested, (c) disclosing results, (d) deliberating and
making risk management decisions, and (e) reflecting on actions.
These women regarded breast and/or ovarian cancer as a predictable outcome,
given their family history, and felt they had a responsibility to their family to prevent this
danger if possible. After gaining awareness of their increased risk, they sought genetic
counseling to take responsibility for their perceived susceptibility and were influenced by
feelings of obligation to their family. Participants disclosed their test results to seek
support and because of a sense of duty to inform their family members of their risks, no
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matter how difficult it was for them personally. They also felt they had a responsibility to
persuade their family to act on the information. Past family and personal experiences,
present view of themselves and their relationships, and aspirations for the future were all
part of their complex risk management decision making. Engaging in risk management
was seen as providing them with control over their susceptibility to HBOC. Those
choosing prophylactic surgeries wanted to prevent cancer, as they were not satisfied with
the limitations of vigilant surveillance which provided only early detection. By taking
these measures they not only gained some control over their lives, but as importantly,
could maintain their identity as mother and nurturer.
The study's findings support other research in genetic testing and risk
management and have important implications for health policy, nursing practice, and
future research.
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CHAPTER 1
Focus of the Inquiry
The revolution in genetics and molecular biology over the last ten years provides
new opportunities for the prevention of hereditary breast and ovarian cancer. The recent
identification of Breast Cancer 1 (BRCAI) and Breast Cancer 2 (BRCA2) susceptibility
genes offers an opportunity for high risk individuals to learn whether they may be
genetically predisposed to develop breast or ovarian cancer. Although these advances
may represent major steps forward in the battle against cancer, they also raise
complicated questions about the value and consequences of genetic testing. The impact of
this new genetic knowledge on client experiences of genetic testing and risk management
is not well understood. This dissertation sought to fill part of this gap by proposing a
grounded theory of how unaffected BRCA positive and variant of uncertain significance
(VUS) mutation carriers conceptualized their breast and/or ovarian cancer risk,
interpreted and coped with BRCA test information, and managed their susceptibility to
breast and ovarian cancer.
Background
During the average lifetime, one in eight women will be affected by breast cancer
(Feuer & Wun, 1999). It is the second most common cause of cancer-related death in
1
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women, with an estimated 211,240 new cases and 40,410 fatalities in 2005 (American
Cancer Society, 2005). Ovarian cancer accounts for 4% of all cancers among women and
causes more deaths than any other cancer of the female reproductive system. In 2005, it is
estimated that ovarian cancer will be diagnosed in 22,220 women and almost 16,210 will
die from it (ACS, 2005).
One of the major advances in the understanding of breast and ovarian cancer
during the past 10 years is the recognition that some of these cancers have a genetic basis.
Because genes predispose to cancer, the evolving technology of genetic testing allows
presymptomatic testing of persons at high risk. This testing provides information about a
person's susceptibility to a disease and is referred to as predictive or susceptibility
testing. Approximately 5% to 10% of breast and ovarian cancers are hereditary (Krainer
etal., 1997).
Identification of the Breast Cancer 1 (BRCAl) and Breast Cancer 2 (BRCA2)
gene mutations in 1994 and 1995, respectively, has enabled women to obtain more
precise estimates of their risk of developing breast and/or ovarian cancer (Miki et al.,
1994; Wooster et al., 1994). Women with a mutation in the BRCAl and BRCA2 genes
are at an increased lifetime risk for developing breast and ovarian cancer. This risk varies
according to age, ethnicity, and family history (Ford, Easton, Stratton, Narod, Goldgar, &
Devilee, 1998; Struewing et al., 1997). Based on pooled data from 22 studies, among first
degree relatives of 500 index patients with BRCA mutations, the average cumulative
risks of breast and ovarian cancer by age 70 years in BRCAl carriers were 65% and 39%
respectively. The risk estimates for BRCA2 mutations were 45% and 11 % respectively
(Antoniou et al., 2003). This is the situation likely to be encountered in clinical genetics
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situations. Higher estimates were reported in the New York Breast Cancer Study (King,
Marks, & Mandell, 2003) of 104 mutation-positive Ashkenazi Jewish women with breast
cancer. Estimates were based only on relatives whose mutation status were known. These
breast cancer estimates were 69% and 74% by age 70 years, for BRCAl and BRCA2
mutation carriers, respectively, and 46% and 12% for ovarian cancer for BRCAl and
BRCA2, respectively (King et al., 2003).
Family history characteristics that have been associated with an increased
likelihood of carrying a BRCA mutation include the following (a) multiple cases of
breast cancer in the family, (b) both breast and ovarian cancer in the family, (c) one or
more family members with 2 primary cancers, and (d) Ashkenazi Jewish background
(Couch, 1997; Frank et al., 1998; Shattuck-Eidens et al., 1997).
Hereditary breast and ovarian cancer (HBOC), like that caused by the BRCA
mutations, is characterized by early onset of breast cancer (5-15 years earlier than nonhereditary cases), bilateral breast involvement, a history of both breast and ovarian
cancer, breast cancer in male family member(s), vertical transmission through both
maternal and paternal lines, and familial association with tumors of other organs,
especially the ovary and prostate gland (Couch, 1997; Frank et al., 1998; Narod et al.,
1991; Parmigiani, Berry, & Aguilar, 1998; Sellers et al., 1994; Shattuck-Eidens et al.,
1997)
One of the major benefits of BRCA genetic testing is the possibility of more
individually tailored interventions to reduce breast and ovarian cancer mortality.
However, the optimal strategy for achieving this goal remains unresolved. Today, women
with positive BRCA mutations must make a decision between risk reduction and early

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4

detection. The risk reduction options are chemoprevention and surgical interventions with
bilateral prophylactic mastectomy (BPM) and bilateral prophylactic oophorectomy
(BPO). Early detection involves vigilant breast and ovarian screening, including self- and
clinical breast exams, mammography, magnetic resonance imaging, transvaginal
ultrasound, and cancer antigen 125 testing (Burke et al., 1997).
Although recent studies (Hartmann et al., 2001; Hartmann et al., 1999; Kauff et
al., 2002; Meijers-Heijboer et al., 2001; Rebbeck et al., 2004; Rebbeck et al., 2002;
Scheuer et al., 2002) indicate that surgical interventions may reduce the incidence of
breast and ovarian cancer, the available screening and chemoprevention options have
unproven effectiveness in women with BRCA mutations (Brekelmans et al., 2001; King
et al., 2001; Komenaka et al., 2004; Kuhl et al., 2000; Meijers-Heijboer et al., 2001;
Narod et al., 2000; Scheuer et al., 2002; Tilanus-Linthorst, Obdeijn, Bartels, de Koning,

& Oudkerk, 2000; Warner et al., 2001). As a result, recommendations for management
are generally based on expert opinion (Burke et al., 1997).

Decision Making in a BRCA Context
Predictive genetic testing informs us only about a future condition that may (or
may not) develop. Although the lifetime risk is high, there is always a substantial
component of uncertainty. There is uncertainty about whether the condition will develop,
when, and how severe it will be. There is further uncertainty about the risk reduction and
disease detection interventions available. Thus decision making has the potential to elicit
a state of uncertainty or decisional conflict about which course of action to take
(Guerriere & Llewellyn-Thomas, 2001; O'Connor, 1993).
In BRCA related decisions, options are risky, as any choice involves negative
aspects which may contribute to avoidance-avoidance conflict. Outcomes for these
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decisions are multidimensional, involving potential consequences at many levels (e.g.
health, emotional well-being, or insurance loss). The decisions are linked sequentially:
first there is the decision to get tested, and next the behavioral decision of what to do with
the results.
Genetic counseling and testing rely heavily on risk communicatio n to provide
information about personal and familial cancer risk (Botkin et al., 1996; Peters & Stopfer,
1996). An accurate understanding of risk among participants may be critical to their
decision making about whether to test, and for those who receive positive or variant of
unknown clinical significance test results, to their decision making about risk
management (Croyle & Lerman, 1999). The emerging literature on risk communicatio n
suggests that most individuals with some family history of cancer, including those at low
to moderate risk, overestimate their personal cancer risk. This finding of exaggerated
perceptions of personal risk has been documented in research on hereditary breast and
ovarian cancer families (Berry, Parmigiani, Sanchez, Schildkraut, & Winer, 1997;
Bluman et al., 1999; Hallowell, Statham, & Murton, 1998b; Schwartz et al., 2000;
Struewing, Lerman, Kase, Giambarresi, & Tucker, 1995; Winer, Borstelmann, &
Bluman, 1997). Participant decision making about genetic testing is influenced less by
their actual risk than by their perceived risk and emotional factors (Lerman, Tercyak,
Croyle, & Hamann, 2002). A meta-analysis of 12 studies of outcomes of genetic
counseling for breast/ovarian cancer showed that counseling improved the accuracy of
risk perception (Meiser & Halliday, 2002).
In addition, cancer worry and cancer specific distress have been shown to
motivate use of BRCA genetic testing in high risk families (Durfy, Bowen, McTieman,
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Sporleder, & Burke, 1999; Lennan, Schwartz et al., 1997). Skirton (2001) in a grounded
theory study of genetic counseling found the need for certainty emerged as a powerful
factor that motivated clients to pursue genetic counseling. Webster and Kruglanski (1994)
describe the need for cognitive closure as an individual drive for certainty and a
discomfort with ambiguity. Skirton proposed that clients who request a referral to genetic
services may have a greater need for closure than those at genetic risk who avoid or do
not seek genetic counseling. This could account for the variability in approaches to
genetic counseling between different members of the same family. Obtaining certainty
may be a way of enabling a client to gain control of the situation. Berkenstadt, Shiloh,
Barkai, Katznelson, and Goldman (1999) found that counselees who obtained a more
certain diagnosis or specific recurrence risk felt a greater sense of control.
Research suggests that emotional factors can modify the cognitive processing of
risk-related information when an individual is faced with a personally relevant health
threat (Croyle, Yi Chun, & Hart, 1997; Leventhal, Safer, & Panagis, 1983). This is
common in risky decisions made under emotional stress (Janis & Mann, 1977). Given the
possibility of receiving a positive genetic test, one would expect genetic testing to be
particularly stressful and effect cognitive processing.
Important to a client's decision making after BRCA mutation testing is to
understand the impact of undergoing predictive testing upon emotional state. Knowledge
of anxiety and distress are important because psychological distress has the potential to
interfere with the clients' understanding and synthesis of genetic and medical
information, and to impair adherence to recommendations for screening and possible
prevention (Lennan & Schwartz, 1993; Lennan, Trock, & Rimer, 1991).
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The few studies of psychological outcomes associated with genetic testing for
BRCA mutations have shown no increase in distress among those who receive positive or
negative test results (Croyle, Smith, Botkin, Baty, & Nash, 1997; Lerman & Croyle,
1996; Schwartz et al., 2002). This was also true in one long-term study (n= 65 female
participants) that explored the psychosocial consequences of carrying a BRCA mutation.
Five years after genetic testing, BRCA carriers did not differ from non-carriers on several
distress measures (van Oostrom et al., 2003). This is consistent with the psychological
consequences (including anxiety, depression, general distress, and situational distress) of
predictive genetic testing in general. Test results did not predict emotional consequences
in two systematic review of predictive genetic testing (Broadstock, Michie, & Marteau,
2000; Butow, Lobb, Meiser, Barratt, & Tucker, 2003). Despite findings of diminished
distress in tested individuals, most studies also report increased distress among small
subsets of tested individuals. However, most of these increases are within the normal
range of distress (CancerNet, 2005; Smith, West, Croyle, & Botkin, 1999). In interpreting
these studies, the authors caution that all are from programs in which results disclosure
were preceded by extensive genetic counseling about risks and benefits of BRCA testing
and psychological assessment.
These studies on psychological consequences indicate that obtaining genetic
testing may be less stressful than living with the awareness of familial risk for cancer
(Coyne, Kruus, Racioppo, Calzone, & Armstrong, 2003). Mediating factors include the
test result status of other family members. Female BRCA carriers who were the first in
their families tested or whose siblings were negative, had significantly higher distress
than other female BRCA carriers (Smith et al., 1999). Wylie, Smith, and Botkin (2003)
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reported significantly higher levels of distress in BRCA mutation carriers whose spouse
was highly anxious and non-supportive. Thus it is important that research consider the
context of the individual tested to determine which individuals requesting genetic testing
may require additional emotional support.
While the motivation given for pursuing genetic susceptibility testing includes
improving health behaviors (Isaacs et al., 2002; Jacobsen, Valdimarsdottier, Brown, &
Offit, 1997; Lerman, Seay, Balshem, & Audrain, 1995; Struewing et al., 1995), it remains
unclear to what degree BRCA mutations carriers will alter their breast and ovarian cancer
risk management behaviors. Three of four studies have reported increased screening
behavior from baseline in BRCA mutation carriers. Mammography screening uptake
ranged from 59% to 93.4%, with lower uptake rates in younger carriers. These results are
far from ideal.
Breast Cancer Screening

Lerman et al. (2000) reported that disclosure of positive BRCA mutation test
results did not lead to increased use of annual mammograms or ovarian cancer screening
tests in women (n=29) in a hereditary cancer registry. Sixty eight percent complied with
mammography recommendations before BRCA testing and 68% reported adherence one
year after receiving positive test results. Use ofCA-125 testing and transvaginal
ultrasound (TVUS) were 21 % and 15%, respectively, one year post testing.
Peshkin et al. (2002) determined from a prospective observational study of 41
BRCA carriers, overall, the use of breast cancer screening was good (clinical breast exam
uptake for carriers: 95%; noncarriers: 77%), including mammography uptake (in carriers:
59%, in noncarriers: 47%). However, there was a relatively low uptake rate of
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mammography in younger carriers (ages 25-39: 39% versus age~ 40: 74%). Schwartz et
al. (2003) reported that CA-125 and TVUS screening was 43% and 40% respectively,
both reflecting an increased use compared with the year prior to testing.
Botkin et al. (2003) studied women for two years following BRCA 1 testing. Both
carriers and non-carriers significantly increased their use of mammography and breast
self-exam from baseline. For women 40 years and older, 82% of mutation carriers
obtained a mammogram in each year following testing. Younger carrier women also
significantly increased their mammography utilization from baseline. However, overall,
29% of the carrier women did not obtain a single mammogram by 2 years post-testing. At
one and two years post testing, they reported TVUS use of 26% and 11 % respectively,
and CA-125 use of32% and 37% respectively.
Scheurer (2002) also presented prospective evidence that BRCA testing and
genetic counseling increased screening in 251 BRCA mutation carriers followed over a
mean of24.8 months. There was an overall significant increase in mean number of
mammograms, clinical breast exams (CBE), ovarian ultrasonograms, and CA-125
determinations after genetic testing. On average after 15 months, 93.4% had a screening
mammogram, 83.3% were performing breast self exam (BSE), 97.4% had a screening
CBE, 67.6% had CA-125 testing and 72.9% had a TVUS.
One concern about genetic testing for cancer risk is the possibility that testingrelated distress would reduce adherence to cancer screening. However, this has not been
demonstrated among participants who have been tested in either Botkin et al. (2000) or
Lerman et al. (2000) studies. It may be that genetic information leads to risks being
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perceived as unmodifiable and to less adherence to behaviors that would lower health
risks (Senior, Marteau, & Peters, 1999).
Although these are the first studies to characterize screening behaviors following
BRCA mutation testing, they shed little light on the factors that influenced these
surveillance decisions. Limitations of these studies are the relatively short timeframe for
follow-up and that most data were obtained from clinical research programs involving
very high-risk families. Results from clinical settings remain to be reported.
Prophylactic Surgeries
A few studies have recently been published indicating the extent to which
prophylactic surgeries are chosen as HBOC prevention options in BRCA mutation
carriers. These studies also included factors that influenced the decisions for prophylactic
surgeries and the psychosocial implications of these surgeries for women with BRCA
mutations.
Studies from the Netherlands demonstrate different results in the selection of
prophylactic surgeries by women with BRCA mutations than the United States. In the
Netherlands, Meijers-Heijboer et al. (2000) reported that 51 % of unaffected (cancer free)
BRCA mutation carriers chose BPM over screening and 64% chose BPO within 2 years
after testing. Parenthood was found as a predictor for BPM and age was associated with
BPO.
Studies from the United States have reported fewer women choosing prophylactic
surgery following BRCA mutation testing. Scheuer et al. (2002) studied 233 affected and
unaffected women with BRCA mutations over a mean period of 24.8 months. They
reported that 14.9% underwent BPM at a median of 5.3 months after test results and
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50.3% underwent salpingo-oophorectomy at a median of 3.4 months after receiving
genetic test results. Women electing BPM were younger and had a stronger family
history of breast and ovarian cancer than those opting for screening. Those electing BPO
were older (64% >40years) and more likely to have had a prior breast cancer diagnosis
than those not opting for surgery. Lerman et al. (2000) reported only 3% of unaffected
carriers had undergone BPM within a year of learning their BRCA mutation status and
13% obtained BPO. In a Utah kindred of BRCAl mutation carriers followed for two
years, Botkin et al. (2003) found that oophorectomy was obtained by 46% (12/26) of
carriers, including 78% (7/9) of women 40 years of age and older. It was also noted that
an additional 30% (11/37) of the women in this study had obtained BPO before testing. In
contrast, mastectomy was not utilized within the first 2 years following testing, although
11 % were considering this procedure.
Lodder et al. (2002), from the Netherlands group, indicated that BPM decisions
were not only related to higher general and cancer-related distress but women opting for
this choice were more often in their thirties, had young children, and had a longer
awareness of the genetic nature of cancer in the family, than those opting for screening.
This finding, that the level of general and cancer related distress influences the degree to
which BPM is chosen as a risk reduction intervention in women at risk for HBOC, has
been reported in other studies (Lodder et al., 2002; Meiser, Butow, Freidlander et al.,
2000; Scheuer et al., 2002; Stefanek, Hartmann, & Nelson, 2001; Stefanek, Helzlsouer,
Wilcox, & Houn, 1995; Wagner et al., 2000).
The psychological sequelae of BPM in high and moderate risk women, including
those with BRCA mutations, is starting to be reported in the literature. Collectively data
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suggest that women report satisfaction with their decision to undergo BPM and adjust
well emotionally after surgery, although satisfaction with reconstruction may be less
optimal (Borgen et al., 1998; Frost et al., 2000; Stefanek et al., 1995). These outcomes
must be weighed against the irreversibility of the decision, potential problems with
implants and reconstructive surgery, and the occurrence of adverse psychological and
social outcomes in some women (Frost et al., 2000).
In Lodder et al.'s (2002) study above it is unclear why most women who
underwent BPM (54%) were satisfied with the decision, despite a negative impact on
body image, intimate relationship with their partner, and physical well being. Other
reports suggest that although BPM may have psychological benefits for some (Hatcher,
Fallowfield, & A'Hem, 2001) between 10% and 25% of women who choose BPM report
dissatisfaction or an adverse psychological impact (Frost et al., 2000; Payne, Biggs, Tran,
Borgen, & Massie, 2000). Although the clinical significance of elevated distress in
choices for prophylactic surgery is unclear, it is likely that those who receive positive and
VUS BRCA test results could benefit from decision making support.
Socio-economic Factors

In addition to the geographic variation in the United States and Netherlands
studies, prophylactic surgery may vary according to culture, healthcare system, insurance
coverage, provider attitudes, and other socio-economic factors (Eisinger, Geller, Burke,

& Holtzman, 1999). The nature of these socio-economic factors have received little
attention in the literature.

An international research study in three genetic clinics located in Montreal
(Quebec, Canada), Marseilles (France) and Manchester (Great Britain) by Julian-Reynier
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et al. (2001 ), demonstrated the existence of variations in the acceptability of the
preventive strategies in English, French, and Canadian women at risk for HBOC,
attending a cancer genetics clinics for the first time. British women were more in favor of
BPO and chemoprevention than the French and Canadian women. The British and
Canadian women were more in favor of BPM than the French. It was hypothesized that
differences in prophylactic surgery by the French women was that they attach more
importance to their breasts and ovaries than the British or Canadian women, who have a
greater tendency to value life itself most of all (Julian-Reynier et al., 2001 ).
Bouchard et al. (2004) reported substantial differences in the way cancer
geneticists deal with environmental risk factors, breast and ovarian cancer testing,
chemoprevention, and prophylactic surgery. This team suggested that attitudes towards
preventive measures may be partially explained by cultural factors. Cultural differences
included the social representation of risk and health. Physicians from Canada and Anglo
Saxon countries promote a model of health that suggests individual responsibility for risk
management. In France, more emphasis seems to be put on medical authority in the
relationship between providers and patients. In addition, body integrity and the symbolic
value of the breasts may carry a different value for French physicians, which may explain
differences in acceptability of BPM. Also, interpretations of scientific evidence and
medical uncertainties and the impact of leadership, with respect to new ideas and
technology innovation, could contribute to the context in which BRCA testing is
disseminated in the different countries (Bouchard et al., 2004).
Cost may also be a factor in the higher use of prophylactic surgery in the
Netherlands, where universal health coverage is available to women with BRCA
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mutations. As health insurance coverage may affect patient decision-making, current
information regarding reimbursement practices of third-party payers is needed. A
retrospective study by Kauff et al. (2001) of hospital billing records of 3 8 women with
BRCA mutations who underwent either a risk-reducing BPM or BPO revealed that 38 of
39 (97%) prophylactic surgeries were covered in full, minus applicable deductibles or
coinsurance. The rate of insurance reimbursement did not vary with type of insurance,
personal history of cancer, or type of procedure. Updated studies on the influence of
health insurance on BRCA testing and risk management options selected, need to be
reported.
Although these first studies to characterize screening and prophylactic surgery
behaviors following BRCA testing have been reported, they shed little light on how
women interpret and respond to genetic risk information and the factors that influenced
their risk management decisions. The reason for the different behavioral responses
between the women followed at different research hereditary cancer clinics is unclear.
How they arrived at their choices is even less clear. Certainly socio-cultural differences
are a factor as suggested above. Furthermore, most studies only provide evidence of the
emotional impact of BRCA mutation testing in the short term, which as studies of
predictive testing indicate may change over time (Butow et al., 2003).
An understudied area of BRCA research is the family and contextual factors
involved in genetic testing and risk management of women with positive and variant of
uncertain significance test results. Initial data suggest that genetic testing for breast
cancer susceptibility is motivated partly by the desire to help other family members
(Geller, Doksum, Bernhardt, & Metz, 1999). Although the majority of genetic testing
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participants communicate their risk to other family members, only recently has data been
reported on BRCA mutation carriers about the content, process, and impact of these
communications (Bonadona et al., 2002; d'Agincourt-Canning, 2001; Hamilton, Bowers,

& Williams, 2005; Hughes et al., 2002; Segal et al., 2004; Smith et al., 1999; Tercyak,
Peshkin, DeMarco, Brogan, & Lerman, 2002; Wagner Costalas et al., 2003; Wylie et al.,
2003). These studies reinforce that the familial context in which genetic testing is
conducted may be important for understanding how individuals react to their genetic test
results.
Studies on unaffected women who receive BRCA variant of uncertain
significance results could not be found, however, two qualitative studies were found in
affected women. A qualitative pilot study of 6 affected women with variants of uncertain
significance described how these women were unaware their test results could be
indeterminant, thus they were unable to process the information in terms of health care
decision making (Frost, Venne, Cunningham, & Gerritsen-McKane, 2004). Another
study included 12 affected women with "inconclusive" test results, but whether these
were noninformative results or inconclusive results from a variant of uncertain
significance is not clear. The definition given for the inconclusive result was "a known
BRCAl/2 mutation was not identified" (Hallowell et al., 2002, p.79). In the case of these
affected women, a noninformative result is one in which no mutation is identified when
they are from a family that fits a familial cancer syndrome (Sadler, Wasserman,
Fullerton, & Romero, 2004). It is noninformative in that it is not helpful in defining the
genetic risk, for the rest of the family. This lends credence to the fact that possible
outcomes of genetic testing can be confusing, for all of us, including the patient. There is
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a need for more in-depth research that explores unaffected women with BRCA VUSs'
experiences of managing their susceptibility to hereditary breast and ovarian cancer,
particularly those who have been in receipt of their test result for some time.
Rees, Fry, and Cull (2001) identified that the influence of personal experience of
cancer, through involvement with affected relatives, has been neglected in the literature
and found strong theoretical grounds for the hypothesis that dimensions of personal
experiences may influence response to cancer risk. "Perceptions of breast cancer and
beliefs about the disease are likely to influence how an individual reacts (in terms of
thoughts, feelings, and decisions) to their own risk status" (Rees, Fry, & Cull, 2001).
As a nurse practitioner with a focus on health promotion entering the field of
cancer genetics, what intrigued me from the beginning was an awareness that the
knowledge gained by BRCA genetic diagnosis was breaking down the traditional
boundaries between prevention and early detection. In cancer susceptibility testing, in
order to target disease prevention or health promotion interventions, individuals are being
categorized according to genetic risk. These are not like the traditional environmental
risks that are external to the individual and over which an individual often has little
control, or lifestyle risk factors over which one has some control. This genetic risk resides
within one's physical being, putting them in a state between health and illness, their body
existing as a constant source of danger. One of the questions that concerned me was what
this new technology would do to one's sense of self and social relationships.
Although genetic professionals are concerned that clients accurately evaluate their
risk of breast and/or ovarian cancer, from a practical standpoint an individual is likely to
evaluate their risk within the context of a broad range of other commitments and concerns
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that relate to values, employment, and relations with family and friends. Considering that
a woman's view of her future life may be altered by the risk knowledge of a BRCA
mutation, the scores on traditional psychometric instruments, as scores on depression
scales used in previous research, seemed a minor reflection of the impact of BRCA
testing. Thus the influence of family and social contextual factors on women's decision
making became the focus of this research. Although my initial plan was to explore
unaffected womens' risk management decision making after testing with a positive or
VUS BRCA mutation, it became obvious after a few interviews that some women came
to BRCA testing with plans for prophylactic surgery. To better understand these apriori
decisions, the focus changed to explore the broader context of genetic testing in which
unaffected woman make risk management decision.
Much of the current research is based on a static view of genetic testing use,
largely from the perspective of health care providers and researchers, using standardized
instruments. What is lacking are examinations of the total genetic testing experience,
including risk management, that focus on the clients' perspective, as well as an
understanding of the evolving process as clients move through a trajectory of managing
their susceptibility to hereditary breast and ovarian cancer.
Lines ofInquiry
As a result of broadening the study's scope, the purpose of the study was
expanded to explore the influence of family and social contextual factors in how
unaffected BRCA positive and VUS carriers conceptualized their cancer risk, interpreted
and coped with BRCA test information, and made subsequent risk management
decisions; and to develop a grounded theory based on the perceptions, beliefs, and actions
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of these women. The questions which were addressed included: (a) Given the benefit of
hindsight, how would unaffected BRCA positive and VUS carriers describe their
experience of discovering their BRCA status? (b) What is the influence of womens'
experiences of breast cancer in their family in how they conceptualized their breast and
ovarian cancer risk? (c) How do women interpret, assign meaning, and act on the
complex information about positive and VUS test results and risk management? (d) What
is the decision making process through which they arrive at these actions? and (e) What
are the roles their family and others played in their decision making?
As this study was primarily concerned with obtaining the client's perspective, it
was important to use a method that enabled clients to express themselves freely and to
raise issues of relevance to them. Use of the grounded theory approach allowed the
researcher to be guided and directed during the research process by the data, and was
suitable for use in this area in which there has been little previous research. It also offered
an opportunity to develop a theory for managing susceptibility to hereditary breast and
ovarian cancer. This methodological approach has its theoretical underpinnings in
symbolic interactionism which brings meaning, identity, and experience of everyday life
to explain the social world (Blumer, 1969).

Theoretical Underpinnings ofMethodology
Grounded theory method was introduced by Glaser and Strauss in 1967 as a
process that provides the discovery of theory from qualitative data (Glaser & Strauss,
1967). Pragmatism and symbolic interactionism are the theoretical bases of grounded
theory, and the phenomena of concern are patterns and processes of social units (Strauss
& Corbin, 1994).
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Symbolic interactionism is an approach to the study of human conduct and human
group life, focusing on the meaning of events to people in natural settings. It is concerned
with the study of the inner or "experiential" aspects of human behavior, that is, how
people define events or reality and how they act in relation to their beliefs (Chenitz &
Swanson, 1986).
Symbolic interactionism is strongly influenced by the work of George Herbert
Mead (1934), a philosopher and psychologist at the University of Chicago during the first
third of the twentieth century. Symbolic interactionism is a perspective in social
psychology that is relevant to the concerns of nursing. Charon (1998) identifies five
central ideas of symbolic interactionism:
1. Symbolic interactionism focuses on social interaction in its human
understanding, rather than on personality characteristics, or how society or
social situations cause human behavior. People constantly undergo change in
their interactions, and society arises and changes through social interaction.
Interaction means that individuals are not only influenced by others, but
individuals constantly influence one another. A more active and dynamic
human emerges, rather than an individual simply responding to others in the
environment.
2. Human action is caused not only by social interaction but also from interaction
within oneself. We act based on how we are thinking in the present situation.
Although our thinking may be influenced by others with whom we interact, our
own thinking always matters.
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3. Humans define their situation as they go along rather than sensing the
environment directly. As we interact with others and ourself, we develop our
definitions of what is taking place and decide how to act in that situation. We
do not respond to reality as it is, but to reality as we define it.
4. Our actions are always caused by what happens in the present, specifically,
how we are defining what is happening in the present situation. We are not
simply products of our past. It is what is happening right now that matters in
what we end up doing. Like everything in the environment, our past is defined
by us and it is applied to the situation at hand.
5. Humans are seen as always active and dynamic rather than passive and static,
able to take an active part in their own action. The human is 'emergent',
always changing as he or she deals with situations encountered.
Mead's work was heavily influenced by pragmatism. Pragmatism is important to
symbolic interactionism in its approach to how humans relate to their environment.
Pragmatism teaches that we always intervene in determining what 'real' is, that
knowledge is believed and remembered because of its usefulness to us, that objects are
defined according to their use to us, and humans must be understood primarily by
focusing on what they do in real situations (Armour, 1969; Charon, 1998; Kaplan, 1964).
According to Blumer (1969), symbolic interactionism views human behavior as
"the result of a vast interpretive process in which people, singly and collectively, guide
themselves by defining the objects, events, and situations they encounter" (Blumer, 1969,
p. 132). The human being interacts, uses perspectives, defines situations, acts according
to the present, and is agentic. The symbolic interactionism perspective conceptualizes the
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individual as more complex, contradictory, situational, dynamic, and less predictable and
passive than other social-scientific perspectives (Blumer, 1969).
Using a symbolic interactionist perspective, grounded theory provides a way to
study human behavior and interaction. It describes an approach to study basic social and
psychosocial processes which account for variation in interaction around a phenomenon
or problem. Chenitz and Swanson (1986) indicate grounded theory is particularly useful
to conceptualize behavior in complex situations, to understand unresolved or emerging
social problems, and to understand the impact of new ideologies. It can also form the
basis for interventions and social policy related to phenomena studied.
Grounded theory, like other forms of qualitative research, makes its greatest
contribution in areas in which little research has been done. In these areas, theory testing
cannot be done since the variables relevant to the concepts have not yet been identified
(Chenitz & Swanson, 1986). The specific focus of grounded theory on theory generation
adds an important dimension to data analysis. This method stresses that theory must come
from data, not prior knowledge, and that the operations leading to theoretical concept
formation must be revealed (Robrecht, 1995). It does this by interpreting and explaining
the perspectives and actions of multiple subjects, by clarifying "patterns of action and
interaction between and among various types of social units" (Strauss & Corbin, 1994), p.
278).
In summary, grounded theory offers a systematic method to collect, organize, and
analyze data derived from women with positive and VUS BRCA mutation test results.
Grounded theory can provide an approach to theory development based on this study of
BRCA genetic testing and risk management and the contexts and social forces that
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impinge on this process. Such theory can provide a means of conceptualizing the
interacting influences of personal characteristics and social processes, as they bear on the
decisions of women with this new information.
Significance of the Study
Until recently, genetic testing for BRCA mutations was conducted only in
medical research settings. Because of the commercialization of these genetic tests, testing
for BRCA mutations are available to most clinicians. Findings from this community
study are timely and of importance in the current clinical environment where clients are
asking informed questions about HBOC genetic testing.
Beginning knowledge about cancer genetic testing exists in these areas (a)
emotional factors which predict use of BRCA genetic testing, (b) psychological outcomes
of BRCA genetic testing, (c) family communication about results of BRCA testing, (d)
emotional factors which predict use of prophylactic surgery, (e) risk reduction
effectiveness of prophylactic surgery, and (f) behavioral outcomes ofBRCA testing.
Individuals at increased risk of breast and/or ovarian cancer face uncertainty
about if and when cancer will develop and decisions about how to manage their risk.
Personal cancer risk estimates are imprecise. We are unable to predict which women
receiving genetic test results will have difficulties adjusting to their genetic risk. There
are concerns that inaccurate risk perceptions and distress may interfere with
recommended risk management for women at increased risk. For those receiving
uncertain test results, like a variant of uncertain clinical significance, the way these
uncertain results are interpreted and used by clients in their decision making process is
unknown. It is imperative that women who have had genetic testing and are currently
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managing their susceptibility to HBOC be given a voice. Their experiences have
relevance for others seeking predictive cancer testing. No specific study has examined the
overall genetic testing experience, including risk management, from the perspective of
unaffected positive and VUS mutation carriers.
This study provides insight into the lives of two groups of women and how their
personal and family past and present experiences with breast and/or ovarian cancer
influenced how they conceptualized their cancer risk, interpreted and coped with BRCA
test information, and made subsequent decisions to manage their susceptibility to HBOC.
Recent studies have begun to examine the impact of BRCA genetic testing.
This study has added to the increasing body of literature addressing cancer genetic
susceptibility testing. Grounding the theory of managing susceptibility to hereditary
breast and ovarian cancer in unaffected women with positive and VUS BRCA mutations
permits a better understanding of this experience from the perspective of these high risk
women. This understanding enables nurses in genetics to plan, implement, and evaluate
strategies for nursing interventions, as well as influence social and political policies
which affect women seeking to manage their susceptibility to hereditary breast and
ovarian cancer. Improved knowledge about risk management decision making should
lead to development of decision aids, as well as other informational and emotional
support therapies.
Nurses are instrumental in the assessment and identification of women at high risk
for breast and ovarian cancer, for whom genetic testing is an option to be considered.
They can help individuals make decisions about initiating genetic testing, interpreting the
genetic information received, disclosing this information to family, and risk management

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

24

options. Nurses have an important role in helping clients by providing informational and
emotional support while the client is considering risk management strategies. The nurse
is also instrumental in helping clients cope with the consequences of their decisions and
ensuring coordinated follow-up. Through nursing advocacy, social policy can be
generated for ethical practices to prevent insurance and employment discrimination and
for the just distribution of health care dollars so all high risk women have access to this
new technology.
To broaden the focus of this study a comprehensive review of the literature on
breast and ovarian cancer genetic testing, risk management options and their
effectiveness, decision making, and risk management behaviors was undertaken from a
variety of perspectives. These perspectives are discussed and synthesized in the following
chapter.
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CHAPTER II
CONTEXT OF THE INQUIRY
The purpose of this chapter is to provide a background for this study derived from
four bodies of literature. First, the current literature on genetic testing for hereditary
breast and ovarian cancer (HBOC) with an emphasis on the BRCAl and BRCA2
mutations are explored. Second, the risk reduction and early detection management
options and the effectiveness of these interventions are examined. Third, literature related
to decision theory with a review of decision making in a genetics context is analyzed.
Fourth, a look at how predictive genetic testing is affecting health behaviors to reduce
risk ofHBOC is reviewed. The resulting analysis and critique of this literature provides
the background and justification for this study.
Genetic Testing for Breast and Ovarian Cancer
One of the major advances in the understanding of breast and ovarian cancer
during the last ten years is the recognition that these cancers have a genetic basis.
Because genes predispose to cancer, the evolving technology of genetic testing allows
presymptomatic testing of persons at high risk of developing cancer. This testing
provides information about a person's susceptibility to breast and ovarian cancer.

25
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Breast and Ovarian Cancer Susceptibility Genes

Breast cancer is considered a multifactorial disease caused by genetic and nongenetic factors. Clinicians and clients have long recognized familial patterns of breast
cancer. Since December 1990, genetic epidemiology has improved our understanding and
ability to assess the risk of women with a family history of breast cancer (GauthierVillars et al., 1999). Seven genes that predispose women to breast cancer have been
identified: tumor suppressor protein (p53), BRCA 1, BRCA2, and PhosphataseTENsin
(PTEN), MSH2, STKl 1/LKBl and ATM. Of these, BRCAl and BRCA2 mutations are
the most common of the dominantly inherited genes (Domchek & Garber, 2001). Current
research also suggests a possible risk association between breast cancer and a number of
common genetic VUSs, which are likely to vary with environmental exposures and other
non-genetic risk factors. The contribution of these genetic VUSs to multifactorial cancer
risk is yet to be determined (Culver, Hull, Levy-Lahad, Daly, & Burke, 2000).
Localization of the BRCAl gene on chromosome 17q12-21 in 1990 provided the
evidence for transmission of breast and ovarian cancer susceptibility (Narod et al., 1991).
BRCAl is associated with disease in 45% of families with multiple cases of breast cancer
and up to 90% of families with both breast and ovarian cancer (Easton, Ford, & Bishop,
1995). BRCA2 was identified in 1994 and localized on the long arm of chromosome
13q12-13. Mutations in BRCA2 account for approximately 35% of multiple-case breast
cancer families. These mutations are also associated with male breast cancer, ovarian
cancer, prostate cancer, and pancreatic cancer (Gayther et al., 1997; Wooster et al., 1994).
These susceptibility genes demonstrate a pattern of autosomal dominant inheritance, with
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approximately 50% of susceptible individuals inheriting the predisposing mutation
(Noorani & McGahan, 1999).
The discovery ofBRCAl and BRCA2 affords an opportunity for identification of
a subset of women at very high risk of developing breast or ovarian cancer (Easton et al.,
1995). Five to ten percent of women with breast cancer in the United States have BRCAl
or BRCA2 mutations. This translates to a prevalence of about 1 in 800 among the general
population (Amlung, Huelman, & Skinn, 1998; Peto, Easton, Matthews, Ford, &
Swerdlow, 1996). Based on pooled data from 22 studies, among first degree relatives of
500 index patients with BRCA mutations, the average cumulative risks of breast and
ovarian cancer by age 70 years in BRCAl carriers were 65% and 39% respectively. The
estimates for BRCA2 mutations were 45% and 11 % respectively (Antoniou et al., 2003).
This is the situation likely to be encountered in clinical genetics situations. BRCA 2
mutations are also associated with a 10% increased lifetime risk of breast cancer in male
carriers (Begg, 2002). Higher estimates were reported in the New York Breast Cancer
Study of 104 mutation-positive Ashkenazi Jewish women with breast cancer (King et al.,
2003). Estimates were based only on relatives whose mutation results were known. These
estimates were 69% and 74% for breast cancer by age 70 years for BRCAl and BRCA2
mutation carriers, respectively, and 46% and 12% for ovarian cancer for BRCAl and
BRCA2, respectively (King et al., 2003).
Family history characteristics associated with an increased likelihood of carrying
a BRCA mutation include (a) multiple cases of breast cancer in the family, (b) both breast
and ovarian cancer in the family, (c) one or more family members with 2 primary
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cancers, and (d) Ashkenazi Jewish background (Couch, 1997; Frank et al., 1998;
Shattuck-Eidens et al., 1997).
Hereditary breast and ovarian cancer (HBOC), like that caused by the BRCA
mutations, is characterized by early onset of breast cancer ( 5-15 years earlier than nonhereditary cases), bilateral breast involvement, a history of both breast and ovarian
cancer, breast cancer in male family member(s), vertical transmission through both
maternal and paternal lines, and familial association with tumors of other organs,
especially the ovary and prostate gland (Couch, 1997; Frank et al., 1998; Narod et al.,
1991; Parmigiani et al., 1998; Sellers et al., 1994; Shattuck-Eidens et al., 1997).
These characteristics are predicted by the Knudson model, in which individuals
with an inherited predisposition carry one mutated allele in the germline and therefore all
of their cells. Acquisition of a mutation that inactivates the second copy of the
susceptibility gene in a single cell, usually with other genetic changes, results ultimately
in cancer. Most cancer susceptibility genes (including BRCAl and BRCA2) behave as
tumor suppressor genes and fit this model (Knudson, 1989).
Hereditary Breast and Ovarian Cancer Risk Assessment

Individuals seeking hereditary breast and ovarian cancer (HBOC) risk assessment
are not all looking for the same information. Some are seeking specific information about
cancer risk to make decisions about prophylactic surgery and to improve their health
behaviors. Others want to learn about risk for their children, while others are looking for
reassurance that they have overestimated their risk (Garber, 2000; Jacobsen et al., 1997;
Lerman, Lustbader et al., 1995; Lerman, Seay et al., 1995; Struewing et al., 1995). Some
women consider the availability of genetic testing an opportunity while others view it as a
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threat to self-concept, family relationships, or insurability. Once people understand and
assimilate the potential outcomes of testing, fewer undergo testing (Ajzen & Fishbein,
1980; Biesecker et al., 2000). Age (over 40 years) and strong family cohesion have been
shown as predictors ofBRCAl and BRCA 2 testing (Biesecker et al., 2000).
Genetic Testing

The sensitivity of tests for detecting BRCAl and BRCA2 mutations is dependent
on the method used for genetic analysis and the prior risk of the person tested (based on
the person's cancer history, family history, and ethnic background). Testing an individual
affected with breast or ovarian cancer is the most effective way of determining if a
BRCAl or BRCA 2 mutation is the cause of breast and/or ovarian cancer within the
family (Culver et al., 2000).
A mutation has been identified in the family. Once a mutation is identified, other

family members are tested for the same mutation. In most populations, mutations are rare
so that only one mutation will be present in the family. A negative test in this situation is
definitive. A family member with a negative result does not share the predisposing family
mutation and does not have increased risk of breast or ovarian cancer. Their risk is the
same as the general population (Singletary & Robb, 2000).
A mutation has not been identified in the family. A person tested in this situation

will have one of three possible results:
1. A genetic mutation is present. A positive result means that a deleterious
mutation in the BRCAl or BRCA2 gene was found. A deleterious mutation is one that
causes loss of the gene's tumor-suppressor function and therefore increases the risk of
breast and ovarian cancer.
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2. A genetic mutation is not present. When a cancer-predisposing BRCAl or
BRCA2 mutation is not identified in a cancer-affected individual in a family with an
increased risk ofHBOC, negative results are uninformative (Culver et al., 2000). Current
BRCA analysis may not detect some types of abnormalities in the BRCAl and BRCA2
genes. Also, some women who have negative test results may still be at high risk for
HBOC by mutations in other genes. This result provides limited information because the
family mutation is unknown. This individual could be truly negative, or there could be a
mutation in a different gene, or the cancer could have a nonhereditary origin. Thus, when
a negative result is obtained, it could be good news fraught with survivor guilt (as is the
case of some true negatives for a familial mutation) or a negative result could be
ambiguous and raise more questions than answers (Peshkin, DeMarco, Brogan, Lerman,

& Isaacs, 2001). Studies have demonstrated that 16% to 66% of high-risk families do not
carry detectable mutations in BRCAl or BRCA 2 (Ford, Easton, Stratton, Narod,
Goldgar, Devilee et al., 1998; Frank et al., 1998). It is important that these individuals
understand that a negative test is not reassurance that breast or ovarian cancer will never
develop.
3. A genetic test result is inconclusive. Since BRCAl and BRCA 2 are large
genes, the laboratory may uncover a new sequence alteration, generally involving a single
nucleotide change in the gene, which may or may not disrupt the function of the protein.
There are no validated functional assays to evaluate this further. The individual then must
be told that the result could be either a functional mutation or a polymorphism of no
clinical significance. About 13% ofBRCA analysis results are reported as genetic
variants of uncertain significance (Frank et al., 2002). With additional research, it may be
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possible to define the majority of these VUSs, but this may require years (Singletary &
Robb, 2000).
When a genetic mutation cannot be ruled out, an individual may still be at
increased risk for cancer and therefore need to obtain appropriate surveillance (Peshkin et
al., 2001). Although case studies have been reported, studies on unaffected women with a
BRCA VUS and their genetic testing and risk management experiences could not be
found. However, two studies were found in women affected with breast cancer. A
qualitative pilot study of 6 affected women with VUSs described how these women were
unaware their test results could be indeterminant, thus they were unable to process the
information in terms of health care decision making (Frost et al., 2004). Another study
included 12 affected women with "inconclusive" test results, but whether these were
uninformative results or inconclusive results from a VUS is not clear. The definition
given for the inconclusive result was "a known BRCAl/2 mutation was not identified"
(Hallowell et al., 2002, p. 79). In the case of these affected women, a uninformative result
is one in which no mutation is identified when they have a family history that fits a
familial cancer syndrome (Sadler et al., 2004). It is uninformative in that it is not helpful
in defining the genetic risk, for the rest of the family. This lends credence to the fact that
possible outcomes of genetic testing can be confusing, for all of us, including the patient.
There is a need for more in-depth research that explores unaffected women with BRCA
VUSs' experiences of managing their susceptibility to hereditary breast and ovarian
cancer, particularly those who have been in receipt of their test result for some time.
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Options for Risk Reduction and Early Detection
The available management options for women with BRCAl or BRCA2 mutations
are limited. These women must make a decision with a primary focus on either HBOC
risk reduction (prophylactic surgeries or chemoprevention) or early detection (intensive
surveillance) (Burke et al., 1997). Minimal data exist on the outcomes of interventions to
reduce risk in clients with a genetic susceptibility to breast or ovarian cancer. However,
prospective research results for 1-8.8 years post BRCA testing, in affected and unaffected
BRCA mutation carriers, are starting to be reported. Retrospective and prospective
evidence for BPM in women with BRCA mutations has been reported for 13 .4 years and
5.5 years respectively. Due to short term and limited evidence, the clients' preferences,
therefore, are important factors in their risk management decisions.
In 1997 the Cancer Genetics Studies Consortium, a task force organized by the
National Human Genome Research Institute, made recommendations for cancer
surveillance and risk reduction for individuals carrying mutations in BRCAl or BRCA2
genes. Based on the group's expert opinion and observational studies, early breast and
ovarian cancer screening are recommended for individuals with BRCAl mutations and
early breast cancer screening for those with BRCA2 mutations (Burke et al., 1997). These
recommendations are in need of updating (Domchek & Garber, 2001).
Screening
Current screening recommendations for HBOC include monthly breast self
examination by 18-21 years of age, semi-annual clinical breast examination, and annual
mammography beginning between the age of25 and 35 years for carriers (Burke et al.,
1997). For ovarian cancer screening, transvaginal ultrasound and CA 125 are
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recommended annually or semi-annually, beginning at age 25-35 years (Burke et al.,
1997). The following review explores the effectiveness of these modalities for women
withHBOC.
Breast Cancer Surveillance
Brekelmans et al. (2001) reported the results from a HBOC surveillance program
that included monthly breast self-examination (BSE), semi-annual clinical breast
examination CBE), and yearly mammography for a median follow-up of three years. In
118 BRCAl and BRCA2 carriers, 9 cases of breast cancer were diagnosed, 5 of which
were diagnosed in the screening program (this is a 56% sensitivity). However, 4 of the 9
tumors in mutation carriers were interval cancers, not detected in the course of screening.
An interval malignancy is one that becomes evident between annual screening
mammography, which indicates the malignancy either went undetected by the last
mammogram or developed during the interval since the last screen (Komenaka et al.,
2004). In addition, there were more lymph node positive tumors in the group of known
mutation carriers than in the high-risk or moderate-risk groups (56% versus 33% versus
25%). Therefore, in BRCAl and BRCA2 mutation carriers, this type of surveillance may
have a lower sensitivity and also might result in detection of later-stage tumors.
Brekelman et al. concluded that to reduce breast cancer mortality a substantial proportion
of small cancers have to be detected in the BRCA 1 and BRCA2 group. He indicated that
a more intensive screening program might be warranted. Two early-detection options are
in the process of being evaluated, digital mammography and magnetic resonance imaging
(Lewin et al., 2001; Tilanus-Linthorst et al., 2000).
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A similar surveillance sensitivity of 50% was reported by Scheuer et al. (2002),
who followed 165 male and female BRCA mutation carriers in a surveillance program
that included annual mammography, monthly BSE, and CBE 2 to 4 times annually. After
24.8 months of follow-up, breast cancer was diagnosed in 12 women: 6 tumors were
diagnosed by mammography and 6 were interval cancers.
These studies indicate that cancers in BRCA mutation carriers grow rapidly; half
appear in the interval between annual mammograms, and half have spread to axillary
lymph nodes by the time they are detected. Komenaka et al. (2004) suggest that strong
consideration should be given to screening BRCA positive women at more frequent
intervals and to using additional imaging techniques, such as breast ultrasonography
and/or breast magnetic resonance imaging (MRI), as a part of this screening.
Ziv, Shepherd, Smith-Hindman, & Kerlikowske (2003) postulated that the lower
sensitivity of mammography in BRCA mutation carriers may result from higher breast
density in women with a family history of breast cancer. Tilanus-Linthorst et al. (2002)
suggested that a decreased probability of detection by mammography was due to the
morphological features of BRCA related tumors (less spiculated masses due to lack of
tumor surrounding fibrosis).
Recent evidence indicates that magnetic resonance imaging (MRI) offers better
sensitivity than mammography for the early detection of breast cancer in BRCA mutation
carriers, however specificity is generally lower (Kriege et al., 2004; Kuhl et al., 2000;
Stoutjesdijk et al., 2001; Tilanus-Linthorst et al., 2002; Warner et al., 2001). Magnetic
resonance imaging of the breast provides information about breast tissue vascularity that
is not available from mammography (Liberman, 2004).
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In the largest prospective study comparing mammography, CBE, and MRI,
Kriege et al. (2004) examined 1909 women who had a genetic or familial predisposition
to breast cancer. Of these women, 358 had BRCA mutations, twice as many as in all
previously published evaluations of MRI in high risk women. In this analysis, MRI,
compared to mammography, had higher sensitivity (71 % versus 40%) but lower
specificity (90% versus 95%). Of the 45 breast cancers found, 22 (49%) were identified
by MRI but not mammography, 10 (22%) were identified by both modalities, and 8
(18%) were identified by mammography, but not MRI. In other studies, MRI sensitivity
was reported at 86% to 100%, and specificity ranged from 91 % to 99% (Kuhl et al.,
2000; Podo et al., 2002; Warner et al., 2001). In studies by Kuhl et al., Podo et al.,
Warner et al., and Stoutjesdijk et al. (2001) mammography was shown to have a
sensitivity in the range of 13% to 43% and a specificity range of93% to 100%. Although
breast MRI is highly sensitive, its disadvantages include cost ($700 to $1000, about 10
times the cost of a mammogram), variation in enhancement during the menstrual cycle
(midcycle is optimal), and imperfect specificity (Liberman, 2004).
None of the surveillance studies among BRCA mutation carriers have addressed
the effectiveness of screening methods in terms of outcomes, such as breast cancer
mortality or quality of life. In addition, most studies did not delineate whether tests were
done in healthy (unaffected) women or were part of a work up for breast cancer
(Liberman, 2004).
Ovarian Cancer Surveillance

Screening and early detection of ovarian cancer are more difficult than for breast
cancer. The majority of ovarian tumors are diagnosed at stage III and IV disease (about
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70%), and mortality for these high stage cancers is high (Greenlee, Hill-Harmon, Murray,

& Thun, 2001; Rebbeck et al., 2002). Clinical recommendations are even more limited in
ovarian cancer screening. Neither transvaginal ultrasound (TVUS) nor serum tumor
marker, cancer antigen 125 (CA-125) measurement, have been shown to reduce
morbidity or mortality from ovarian cancer, and the efficacy of these approaches have not
been reported in women with BRCA 1 and BRCA2 mutations (Cherry & Vacchiano,
2002; Offit, 1998).
CA-125 testing. The value and limitations of CA-125 were reported in a study of

5550 women by Einhorn et al. (1992) who found a false positive rate of96.6%. Also
concerning, was the fact that three women who tested negative subsequently proved to
have ovarian cancer. A similar lack of specificity was reported by Troiano, QuedansCase, and Taylor (1997) and DePriest, Gallion, Pavlik, Kryscio, and Van Nagell (1997).
DePriest et al. made screening available to 6470 women who were either postmenopausal
or greater than 30 years old with a family history of ovarian cancer. A total of 90
participants underwent surgery which showed 3 7 serous cystadenomas and 6 primary
ovarian cancers, 5 which were stage lA. Only one cancer was detected by pelvic
examination, and none had an elevated serum CA 125, further demonstrating the
limitation of these methods. In contrast, Jacobs et al. (1996) measured CA 125 levels
annually in 22,000 women over 45 years old. They reported the serum CA 125 level
correlated well with the cumulative risk of developing ovarian cancer.
Zurawski, Orjaseter, Andersen, and Jellum (1988) found overall that the CA 125
antigen test lacks sensitivity in stage 1 ovarian cancers where it is elevated in only 50%
of cases. It also lacks specificity because several benign conditions elevate CA-125
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levels, such as fibroids, endometriosis, pregnancy, and liver disease (Cherry &
Vacchiano, 2002; Zurawski, Knapp et al., 1988; Zurawski, Orjaseter, Andersen, &
Jellum, 1988)
Transvaginal ultrasound (TVUS). There is limited data regarding the potential
benefit of transvaginal ultrasound in screening women at inherited risk of ovarian cancer.
Limitations of TVUS include a lack of specificity and inability to detect primary
peritoneal cancer or cancer in normal-size ovaries (Tailor et al., 2003; van Nagell et al.,
2000). Peters and Stopfer (1996) reported a study in which 1061 women with a family
history of ovarian cancer were screened with pelvic ultrasound. Only 3 of 61 women with
abnormal results had ovarian cancer, 2 with stage I and 1 with stage III. Tailor et al.
(2003) reported a 10 year observational study of2500 asymptomatic women, with at least
one affected relative with ovarian cancer, in which ultrasound test sensitivity was 92%
and specificity 97 .8%. There were 11 screening detected cancers, 1 false negative, and 93
false positives.
Currently underway in the United Kingdom is a phase II trial evaluating the
effectiveness of ovarian cancer screening using annual TVUS and serum CA 125 levels.
Also in the United States, the National Cancer Institute is conducting a controlled clinical
trial in which 74,000 women are randomized to regular medical care or research-based
screening for ovarian and other cancers. Because the efficacy of the ovarian cancer
screening approaches are not known, high risk women are often advised to undergo
bilateral prophylactic oophorectomy when childbearing is complete (Rebbeck, 2000).
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Chemoprevention
The use of chemoprevention in BRCA mutation carriers is in its infancy. To
reduce morbidity and mortality, a chemopreventive agent must arrest carcinogenesis
before the emergence of an invasive or clinically detectable cancer (Sporn, 1993). The
only Food and Drug Administration (FDA) approved risk reduction agent for women at
high risk of breast cancer is tamoxifen (Stefanek et al., 2001). Tamoxifen is an estrogen
receptor (ER) antagonist. It is thought to be effective because the risk of breast cancer is
related to levels of endogenous and exogenous hormones (Cauley et al., 1999;
Henderson, Ross, & Bernstein, 1988; Schairer et al., 2000).
In the Breast Cancer Prevention Trial (BCPT), tamoxifen administered to healthy
high risk women for 5 years was shown to reduce the risk of invasive breast cancer by
49% and non-invasive breast cancer by 50% (Fisher et al., 1998). Reduction in breast
cancer risk was noted among women with a family history of breast cancer, as well as
those without a family history. In this randomized controlled trial of288 incident breast
cancer cases, only 19 were BRCA mutation cases (8 BRCAl and 11 BRCA2). A higher
proportion of BRCA 2 patients were ER positive compared to BRCAl patients, which
may explain the benefit from tamoxifen. Although there was a reduced incidence of 69%
in estrogen receptor-positive tumors, there was no difference between the treatment and
placebo group in the occurrence of ER negative tumors. The benefits of tamoxifen were
countered with an increased incidence of adverse events of endometrial cancer and
vascular events (stroke, pulmonary embolus, and deep venous thrombosis) and cataracts
among women over 50 years. Due to the small sample size, the study did not reach
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statistical significance and thus only suggests the preventive role of tamoxifen in BRCA2
carriers (Fisher et al., 1998).
In a matched case-control study, Narod et al. (2000) investigated the preventive
effect of tamoxifen in BRCA carriers, comparing 209 participants with bilateral breast
cancer with 384 mutation carriers with unilateral disease. Tamoxifen was associated with
a 50% reduction in contralateral breast cancer, with greatest reduction following 2-4
years of use. BRCAl mutation carriers had greater protective effects oftamoxifen in this
study. Two biases may have occurred in these results. Because this study was restricted to
living women, selection bias may have occurred if those who died were different from
the study population in terms of tamoxifen use and contralateral breast cancer outcome.
Also information bias may have occurred, as questionnaires were completed on average
11.8 years after diagnosis (Calderon-Margalit & Paltiel, 2004).
These contradictory results do not provide conclusive evidence of efficacy of
tamoxifen. Other small studies have suggested tamoxifen may have some efficacy in
BRCAl carriers, despite estrogen receptor status (Daidone et al., 2002; Eisinger et al.,
2001; Foulkes et al., 2002). Because tamoxifen appears to be most effective at preventing
breast cancers with estrogen receptors, and because 70% to 80% ofBRCAl associated
breast cancer lack estrogen receptors, its effectiveness is unknown (Johannsson, Idvall, &
Anderson, 1997; Lippman & Brown, 1999). Chemoprevention in BRCA2 carriers seems
more plausible than in BRCAl carriers, since BRCAl carriers are more likely to be
estrogen receptor negative. In fact, in a pilot survey of physicians Peshkin, Isaacs, Finch,
Kent and Schwartz (2003), found they were more likely to recommend tamoxifen to a
BRCA2 carrier than to a BRCAl carrier (73% versus 57%).
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Another estrogen-receptor modulator that acts as both an agonist and antagonist to
estrogen, raloxifene, holds promise as an agent for breast cancer risk reduction. The
Study of Tamoxifen and Raloxifene for the Prevention of Breast Cancer (STAR), a
randomized double-blind trial, will help determine whether raloxifene is more or less
effective than tamoxifen in reducing the incidence of invasive breast cancer in
postmenopausal women (Brown & Lippman, 2000).
Prophylactic Surgery
Several studies have evaluated bilateral prophylactic mastectomy (BPM) in
women with BRCA mutations. Retrospective and prospective studies show a high degree
of risk reduction with this procedure.
In a subset analysis of Hartmann et al. (1999) retrospective cohort study of 214
high risk women who underwent BPM, BRCA mutations were found in 26 women (18
BRCA positive and 8 variants of uncertain significance). None of these 26 women had
developed breast cancer at median follow-up of 13.4 years (Hartmann et al., 2001).
Hartmann's results have been supported by Meijers-Heijber et al. (2001) in a
prospective study from the Netherlands. Seventy-six unaffected BRCAI and BRCA2
mutation carriers were followed for three years after BPM and 63 mutation carriers had
regular surveillance follow-up. Although six cases of breast cancers would have been
expected in the BPM group had the procedure not been done, none were reported in the
BRCA carriers. However, 8 breast cancers were identified in women using regular
surveillance. Fifty eight percent of the BPM group had also undergone bilateral
prophylactic oophorecomy (BPO).
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In a recent study in medical centers in the Netherlands, North America, and the
United Kingdom, the efficacy of BPM for risk reduction in women with BRCA mutations
was analyzed (Rebbeck et al., 2004). This Prevention and Observation of Surgical End
Points (PROSE) study compared breast cancer in 105 unaffected BRCA mutation
carriers, who underwent BPM, with 378 unaffected mutation carriers who did not choose
BPM. Breast cancer was diagnosed in two (1.9%) women who had BPM and in 184
(48. 7%) of matched controls who did not have BPM, during a mean follow-up of 6.4
years. The two breast cancers in women with BPM occurred in women with
subcutaneous mastectomies. Subcutaneous BPM leaves substantial breast tissue intact,
including the nipple-areolar complex. Total BPM removes substantially more breast
tissue and thus requires more extensive reconstruction. Bilateral prophylactic mastectomy
reduced the risk of breast cancer in BRCA mutation carriers by approximately 90% in
women with intact ovaries and by approximately 95% in women with prior or concurrent
BPO. This data suggests that BPM may significantly reduce the risk of breast cancer for
women with BRCAl and BRCA2 mutations.
Bilateral Prophylactic Oophorectomy (BPO)

Although the Cancer Genetics Studies Consortium concluded there was
insufficient evidence to recommend BPO for reducing ovarian cancer risk, the NIH
Consensus statement on Ovarian Cancer recommended that women at inherited risk for
ovarian cancer undergo BPO after child-bearing or age 35 years (Burke et al., 1997; NIH,
1995). Since publishing of these statements, two recent studies among BRCA carriers
have demonstrated its effectiveness.
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Rebbeck and colleagues (2002) reported a multicenter, case control study (n=259
with BPO and n=292 controls without BPO) in which BPO reduced the risk of ovarian
cancer or papillary serous peritoneal cancer associated with BRCAl or BRCA2
mutations by 96%, and the risk of breast cancer by 53%. The average length of follow-up
was 8.2 years for those undergoing surgery and mean age at surgery was 40.9 years.
However, papillary serous peritoneal cancer did occur in eight (3.1%) women who had
undergone BPO. Six of these cancers were stage I and diagnosed at the time ofBPO.
After a mean follow-up of 8.8 years, 58 ovarian cancers (19.9%) were found among the
BRCA controls. None of 124 BRCA carriers who had BPO by age 35 years had
developed cancer, suggesting that timing of BPO may be important. This study provides
support for significant ovarian cancer risk reduction with BPO.
Kauff et al. (2002) in a prospective study, compared the effect of risk-reducing
salpingo-oophorectomy (RRSO) with that of surveillance for ovarian cancer, on the
incidence of subsequent breast and BRCA-related gynecologic cancers, in BRCA
mutation carriers 35 years of age or older. During a mean follow-up of 24.2 months,
breast cancer was diagnosed in 3 of 98 (3.1 % ) women who chose bilateral RRSO and
peritoneal cancer was diagnosed in 1 (1 %). In the 72 women that chose surveillance for
ovarian cancer, breast cancer was diagnosed in 8 (11 %) women, ovarian cancer in 4
(5.5%), and peritoneal cancer in 1 (1.4%). The 5 year cancer free survival estimates for
unaffected BRCA mutation carriers who had RRSO was 94% compared to 69% for
mutation carriers that chose surveillance. The complication rate was minimal, as only 4
of 98 (4.1 %) women had any surgical complications. Thus, BPO can reduce the risk of
breast and ovarian cancer, but cannot confer complete ovarian cancer prevention.
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Although BPO is an option offered to women at high risk for ovarian cancer, it is
unclear to what extent this surgery is discussed with women in the context of breast
cancer risk reduction. A BRCAl and BRCA2 mutation carrier may choose this surgery
alone because BPO may substantially reduce breast cancer risk, without incurring the
possible impact ofBPM on body image. However, this surgery has to be weighed against
the consequences of surgical menopause after BPO, with all its associated sequelae.
Unresolved issues include: (a) the best type of oophorectomy; salpingo-oophorectomy, or
BPO, or BPO with removal of the uterus, and (b) use of hormone replacement therapy
after BPO, to ameliorate the symptoms of menopause.
The above studies showing the efficacy of prophylactic surgeries lends evidence
of the need for revision of the Cancer Genetics Studies Consortium recommendations for
women who are BRCA mutation carriers. In light of the unfolding evidence on efficacy
of prophylactic surgical treatment options, how do women with BRCAl and BRCA2
mutations sort out the information and make decisions about risk management? The next
section will review the literature on decision theory and decision making in a genetic
context.
Decision Theory
Both methods and theories in modem studies of decision making are highly
diverse. Philosophers, psychologists, economists, and mathematicians all have different
ideas about what decision and choice are, and about how they are to be understood and
incorporated into a larger theoretical context (Rachlin, 1989). Decision research has
traditionally explored two questions. The first is normative: how can decisions best be
made? The second is descriptive: how are decisions actually made (Baron, 1994;
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Chapman & Sonnenberg, 2000)? These broad types of decision research provide the
framework for this decision theory literature review.

Normative Theories
Normative models of decision making describe what people ought to do if they
wish to be rational decision makers (von Neumann & Morgenstern, 1947). These rational
theories of choice (e.g., expected utility theory, multiattribute utility theory, probability
theory) are based on mathematical and statistical proofs and propose that decision makers
follow a highly rational procedure for making decisions (Bekker et al., 1999). They
assume decision processes that are consequential and preference-based. They are
consequential in that alternatives are interpreted in terms of their expected consequences.
They are preference-based in that consequences are evaluated in terms of personal
preferences. March (1994) described rational choice as based on the answers to four basic
questions: (a) Alternatives: what actions are possible? (b) Expectations: what future
consequences might follow from each alternative? How likely is each possible
consequence, assuming that alternative is chosen? (c) Preferences: how valuable (to the
decision maker) are the consequences associated with each alternative? and (d) Decision
rule: how is a choice to be made among the alternatives in terms of the value of their
consequences?
Classical decision theory assumes that people have consistent preferences, know
their preferences, are familiar with all the alternatives that are available to them, have
information about the consequences of the alternatives, and combine the information
according to the expected utility rule, which weights outcomes by their probability of
occurrence (Carroll & Johnson, 1990). The rational or best course of action is the one that
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has the highest expected utility (personal value) (Bekker et al., 1999; Hastie & Dawes,
2001).
Although these models are logical and appealing, research data show that actual
decisions do not always follow the rational model (Kahneman, Slovic, & Tversky, 1982).
Rational choice theories have adapted to such observations by introducing the idea that
rationality is limited. Although decision makers try to be rational, they are constrained by
limited cognitive capability and incomplete information, and thus their actions may be
less than rational despite their best intentions (Hastie & Dawes, 2001; Kahneman et al.,
1982).
Descriptive Theories
Descriptive theories, in contrast to normative theory, describe how people actually
make decisions, not how they ought to decide. In cases of uncertain information, both
rational and irrational mechanisms influence judgments and behavior (Kahneman et al.,
1982). Cognitive psychology research over the last forty years has shown that decision
makers have biological limitations on information processing, in their attention, memory,
comprehension, and communication (Carroll & Johnson, 1990; Newell & Simon, 1972;
Simon, 1955). Instead of considering all alternatives, decision makers appear to consider
only a few and to look at them sequentially rather than simultaneously (Simon, 1982).
They do not consider all consequences of their alternatives. They focus on some and
ignore others. Instead of a complete, consistent set of preferences, decision makers seem
to have incomplete and inconsistent goals, not all of which are considered at the same
time (March, 1994). The first alternative that meets or exceeds a specific aspiration level
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is selected. This "satisficing" helps to terminate the search for alternatives and speeds the
decision making process (Simon, 1982).
The effects of these limitations on judgment and decision making are important.
Since we cannot process large amounts of information at one time, we tend to simplify
situations, to formulate decisions through limited viewpoints that highlight some aspects
of the situation but ignore others. We have developed a variety of logical shortcuts, rules
of thumb, or heuristics for making good decisions with our limitations (Kahneman et al.,
1982; Simon, 195 5). These procedures form the core of theories of limited rationality.

Limited Rationality
Decision makers use various information and decision strategies to cope with
their limitations in information and information-handling capabilities. Psychological
studies of individual decision making have identified numerous ways in which they react
to cognitive constraints (Kahneman et al., 1982). The present intention is to characterize
only a few of these principal speculations developed as a result of psychological studies
of individual information processing. Two of the fundamental simplification processes
are framing and heuristics.

Framing. Framing involves how you see the problem. People respond to
situations as they interpret them, not as they exist in some objective reality. Tversky and
Kahneman (1981) discuss the 'frame' that people use to identify decision problems and
their components. Decision makers adopt paradigms to tell themselves what perspective
to take on a problem, what questions should be asked, and what technologies should be
used to ask the questions. These frames focus attention, simplify analysis, and direct
attention to different options and preferences. A decision will be made in one way if it is
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framed as a gain (e.g., survival rates) and another if as a loss (e.g., mortality rates) (Hastie

& Dawes, 2001). Decision makers typically frame problems narrowly, rather than
broadly. Many times they are content to find a set of sufficient conditions for solving a
problem, not the most efficient set of conditions (March, 1994).

Heuristics. Decision makers recognize patterns in the situations or problems they
face and apply rules-of-thumb to solve the problem or make the decision. These
heuristics reduce complex mental processes to simpler cognitive tasks saving time and
cognitive resources (Kahneman et al., 1982). An example in consumer purchases might
be 'judge quality by price'. Tversky and Kahneman's research in heuristics showed that
people's reasoning is influenced by prior experiences with similar events. This
'representativeness' heuristic involves the recognition of patterns in the situation and
application of rules of appropriate behavior to those situations. Characteristics of the
representativeness heuristic have been strongly reflected in descriptions and discussion of
intuitive judgments in nursing practice (Cioffi, 1997). Benner and Tanner's (1987)
descriptive study of the use of intuition by expert nurses discussed 'similarity
recognition' as recognition of 'fuzzy' resemblances despite marked differences in the
objective features of past and current situations. Studies of expertise generally reveal that
experts substitute recognition of familiar situations and rule-following for calculation
(March, 1994).
A classic form of heuristic is 'availability', which involves the assessment of the
probability of an event based on the ease with which instances come to mind (Friedlander

& Stockman, 1983). This retrieval and construction of similar instances has been shown
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to be affected by recency (Slovic, Fischhoff, & Lichenstein, 1982), vividness (Nisbett &
Ross, 1980), and salience (Arkin & Duval, 1975).
Affective reactions are also a means to facilitate information processing and
decision making. The 'affect heuristic' represents the contribution of feelings in decision
making and refers to the "goodness" or "badness" of feelings experienced (Slovic,
Finucane, Peters, & MacGregor, 2004, p.312). It is a conscious or unconscious feeling
state (e.g. fear, relief) that the person experiences while making a decision. Zajonc (1980)
argued that affective reactions to stimuli occur automatically and subsequently guide
information processing and judgment. Thus they may serve as orienting mechanisms,
helping to quickly and efficiently evaluate complex and uncertain situations.
A key feature of heuristics is they usually do a good job, but not necessarily the
best job given the information at hand (and they sometimes do poorly). Katapodi,
Facione, Humphreys, and Dodd (2005) have identified heuristics that create biases in
perceived breast cancer risk. Heuristics are also easier to use than sophisticated decision
rules, such as those proposed by economists and management scientists (Kahneman et al.,
1982).
These existing decision theories indicate that decision making is a highly complex
concept. This body of knowledge and related analytical techniques of different degrees of
formality are designed to help a decision maker choose among a set of alternatives in
light of their possible consequences (Web Dictionary of Cybernetics and Systems, 2002).
Most of the research in nursing science is grounded in either normative (analytical)
decision making theory or in information processing theory.
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Most nursing research has been done on professional decision making in clinical
settings (Benner, 1984; Benner, Tanner, & Chesla, 1996; Hannah, Reimer, Mill, &
Letourneau, 1987; Lauri & Salantera, 1998; Luker, Hogg, Austin, Ferguson, & Smith,
1998; Narayan & Corcoran-Perry, 1997; Tanner, 1986; Watkins, 1998). In this research,
expert practitioners are able to make accurate decisions about clinical problems based on
accumulated knowledge of similar cases, and patients and novice practitioners do not
have the same knowledge and experience to readily determine what is happening and
action required.
Although researchers in other disciplines have made significant contributions to
building decision science over the last 40 years, only a few nurse researchers have
focused their research in patient decision making (Degner et al., 1997; Degner, Davison,
Sloan, & Mueller, 1998; Hollen, 1994; Kelly-Powell, 1997; Llewellyn-Thomas et al.,
1991; O'Connor et al., 2002; Pierce, 1993; Pierce & Hicks, 2001; Pierce, 1996). This
research has not been focused on women with the BRCA susceptibility genes. The degree
to which findings associated with these patient and professional clinical reasoning are
applicable to the context of patient genetic decision making is unknown. A better
understanding of the family and social context in which patient genetic testing and risk
management decision making takes place can add to this body of knowledge.

Decision Making in a Genetics Context
Difference in the Nature ofGenetic Disease
Genetic disease does not fit the traditional medical model of disease. In this
traditional model, disease was an 'individualized' phenomenon, the patient was an
individual with a disease who was receiving treatment. Genetic problems may be shared
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with family members and future offspring and the genetic treatment(s) may have benefits
or liabilities for others (Hamilton et al., 2005; Kegley, 2000).
Further, genetic testing may reveal the gene carrier, which may lead to some guilt
and negative feelings. In fact, various studies have revealed feelings of guilt and a sense
of defectiveness among people tested with genetic disease (Dorval, Patemade et al.,
2000). Mutation carriers who passed on the genetic susceptibility to their child may suffer
from transmitter guilt, and those who have not inherited the genetic mutation may
experience survivor guilt (Offit, 1998; Terdiman, Conrad, & Sleisenger, 1999). This guilt
phenomenon is less true in the traditional biomedical model, as disease is seen as
something which happens to someone, and for which there is usually no personal
responsibility. Genetic disease, unlike other disease, is seen as closely tied to personal
identity and personal destiny. This identification of genes with self, not only promotes the
guilt phenomenon, but also brings forth concerns about autonomy and decisional privacy.
In addition, most genetic diseases have an open-ended quality. That is, genetic
factors interact among themselves in complex ways and these genetic factors interact in
multiple ways with environmental factors. This makes the prognosis of genetic disease
problematic. Lappe (1987) states this poetically, "Genes are like the dots on a pointillist
painting: without their context and interaction with other genes, the picture remains an
abstraction" (p. 5). Holtzman (1989) argues that in dealing with genetic diseases the
doctrine of specific etiologies needs to be replaced with three categories of etiologies:
genetic, environmental, and modulating (i.e. age, family, race, climate, stress).
A final difference with genetic disease, such as with BRCA mutations, is the fact
that the person involved may be asymptomatic, they have a genetic defect, but may not
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now nor may ever have, the disease in the future. Disease is not only a pathologic entity,
it is a social construct, almost always accompanied by a change in the ontologic status of
the ill person (Rollin, 1979). The change which occurs when the symptom experienced is
labeled as a disease, is likely to happen now on the basis of genetic information. An
asymptomatic person may be given the social status of 'sick', which may lead to selfimage or identity problems, loss of employment, and insurance. Thus social contexts and
actions may impact heavily on this person, their autonomy, and privacy (Surbone, 2001,
2004).
Decision Making In A BRCA Context

BRCAl and BRCA2 mutation testing is considered predictive testing.
Specifically, genetic testing is obtained by affected and unaffected individuals to predict
future risk of breast and ovarian cancer. The hope with this type of testing is that early
identification of clients at risk for breast and ovarian cancer will lead to reduced
morbidity and mortality through risk identification, targeted surveillance, and risk
reduction (Evans, Skrzynia, & Burke, 2001). It is hoped that by informing people of their
genetic susceptibility to disease, they will be motivated to reduce their risks.
What is decided? BRCAl and BRCA 2 mutation testing and presymptomatic

diagnosis have brought such questions as (a) should I do the test? (b) at what age? and (c)
what protective or preparative measures should I take if I am at increased risk (Shiloh,
1996)? Although the cumulative lifetime risk is high (45%-65% for breast cancer and
11 % to 39% risk for ovarian cancer with BRCAl and BRCA2 mutations, respectively),
there is always a substantial component of uncertainty (Antoniou et al., 2003; Easton et
al., 1995; Ford, Easton, Stratton, Narod, Goldgar, & Devilee, 1998; Struewing et al.,
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1997). Not only is there uncertainty about whether a breast and/or ovarian cancer will
develop, but also when it may appear and how severe it will be. As noted previously,
there is further uncertainty with the risk management options available.
In BRCA related decisions, options are risky, as any choice involves negative
aspects and may result in avoidance-avoidance conflict. Some decisions are of the riskversus-risk type in which one decides between two risks: risk of breast cancer versus risk
of the side effects of a chemoprevention agent (tamoxifen) which increases the risk of
endometrial cancer. Other decisions belong to the difficult category of risk-versus-cost,
where the client chooses between the risk of ovarian cancer and not having children, as
the result of a BPO (Lave, 1987).
Outcomes from these decisions are frequently multidimensional, involving
potential consequences at many levels (e.g. health, emotional well-being, or insurance
loss). Many times the decisions are linked sequentially, like deciding to get BRCA
genetic testing and then deciding what to do with the results. Decisions involve other
members of the family and future generations and are related to personal values about
self and family. These factors have the potential to create decisional conflict (Guerriere &
Llewellyn-Thomas, 2001; Janis & Mann, 1977; O'Connor, 1995; Shiloh, 1996).

Who makes the decision? In the context of genetic risk, who makes the decision is
not as straightforward as it may seem. Traditionally, genetic counseling has been nondirective, with the provider refraining from recommending which option should be
chosen, and leaving the responsibility with the client. In part, this is a result of specific
sociological movements, like individualism and feminism that have influenced clientprovider relationships (Gortner, 1990; Zussman, 1997). This approach, based on values
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of autonomy and the legal imperative of informed consent, is not always welcomed.
Lippman-Hand and Fraser (1979) described frequent requests for guidance by clients.
Similarly Karp (1983) described the frequently asked question, "What would you do in
my place?" Denying clients' request for advice may impede the counseling relationship
or be interpreted as lack of care. Clients may also interpret this as indicating the
counselor's judgment about the severity of the information provided (Shiloh & Saxe,
1989). Lippman and Wilfond (1992) wrote that "no single story, however balanced, can
ever be neutral or value free" (p. 936-937). Additional studies showed that different ways
of presenting genetic risks (e.g. percentages-odds, words-numbers, positive-negative
presentations) result in differing perceptions and choice of options by clients (Kessler &
Levine, 1987; Marteau, 1989; Robinson, Bender, & Linden, 1989; Shiloh & Sagi, 1989).
Robinson, Bender, and Linden (1989) showed that in prenatal genetic counseling, clients'
decisions depended on who provided the counseling.
Patients' involvement in healthcare decisions appears to be related to the way
patients approach the decision problem and the amount of control they prefer in making
decisions. In addition, individuals seem to have certain styles for approaching decision
problems. These styles influence how they structure the decision problem, gather
information, and determine their level of involvement (Pierce, 1993; Pierce & Hicks,
2001). Decision styles range from avoidance to engagement in the decision problem.
These styles are dynamically influenced by: "deferring responsibility, avoidance,
information seeking, and deliberation" (Pierce, 1993; Pierce & Hicks, 2001 p. 270;
Pierce, 1996).
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Degner (1998) indicates that the degree of control desired by an individual in a
decision can be classified as passive, collaborative, or active. Level of control desired
appears to vary according to several factors. Passivity is encouraged by the novelty of the
disease and its severity (Davidson, Degner, & Morgan, 1995; Degner & Sloan, 1992).
Younger, well-educated women tend to prefer a more active role in decision making
(Benbassat, Pilpel, & Tidhar, 1998).

An important aspect of the decision making process is the healthcare provider and
client interaction. The exchange of information between client and provider in the
decision context has been well studied, including the client preferences for type and
amount of information (Benbassat et al., 1998). Clients preferred information on the
course of their disease, available treatment options, and likelihood of cure (Davison &
Degner, 1998; Degner et al., 1997). Although it seems the amount of information
provided does not necessarily affect preferences, the manner of presentation and level of
explanation does (Llewellyn-Thomas et al., 1991; Mazur & Hickman, 1994).
Miller, Brody and Summerton (1988) postulated a minimax hypothesis, where
individuals are motivated by a desire to minimize the maximum danger to themselves.
When faced with a medical decision, a client may prefer to relinquish control over the
decisional process to an identified expert, whose decision is perceived to be a more
reliable guarantee of minimizing aversiveness than one's own (Carver, Scheier, &
Weintraub, 1989; Miller et al., 1988).
How are decisions made? There are few studies of information processing leading

to decisions involving genetic risks. A systematic review of 54 7 randomized studies of
informed decision-making, concluded there was a "paucity of well-designed,
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theoretically driven, and adequately operationalized research assessing informed client
decision making" (Bekker et al., 1999).
There is little guidance in the literature to explain how a client goes about
evaluating alternatives, though it is suboptimal by decision analysts standards if all
alternatives are not given adequate consideration. The way a client understands the
alternatives and their implications is even more unclear (Pierce & Hicks, 2001 ).
Individuals often make decisions based on what they believe is important for themselves
and their families (Baron, 1994). Their satisfaction with the decision process is often
determined by the degree to which the decision made is consistent with their values
(O'Connor & O'Brien-Pallas, 1989).
An understanding of how decisions are made regarding BRCA susceptibility
testing also requires an understanding of how the client understands risk information.

Risk and Decisions
Protocols for genetic counseling and testing rely heavily on risk communication
to provide information about personal and familial cancer risk (Botkin et al., 1996; Peters
& Stopfer, 1996). In pretest counseling, sessions focus on the client's family history of
cancer and their risk of having inherited a cancer mutation. Post test counseling focuses
on interpreting the test results, of individual and family risks for developing cancer, and
on options for risk management. An accurate understanding of risk among participants
may be critical to their decision making about whether to test, and for those who test
positive, to their decision making about risk management (Croyle & Lerman, 1999).
To the lay person, the calculations of risks are averages that have limited value.
Risk is experienced as a symptom of a hidden or future disease, as a subjective
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personalized experience (Gifford, 1986). According to Gifford (1986), risk for breast
cancer becomes internalized and is experienced as a state of being, which leads to an
ambiguous relationship between health and ill-health. Personal experiences, as well as
social and cultural background, mediate an understanding of clinical risk. 'Unmeasured
ambiguity and uncertainty' surround the meaning of risk to the lay public (Gifford,
1986). Cultural systems create collective notions of risk and help in evaluating which
risks are worth taking, who should take them, who is accountable for them, and whether a
danger is possible to control (Douglas & Wildavsky, 1982; Jacobs, 2000).
Yates and Stone (1992) analyzed risk in various situations. They defined a risktaking problem as a special kind of decision problem, because the relevant options
include other considerations besides risk. That is, the worth of an alternative is a function
of the risk and of other considerations with positive benefits, as well as possible negative
features. Yates and Stone proposed that risk is characterized by three critical elements
that interact to reduce an option's worth (a) potential losses, (b) the significance of the
losses, and (c) the uncertainty of those losses. Risk is an inherently subjective construct:
what is considered a loss is specific to the individual, as are the significance of the loss
and its chance of occurring. Although Yates and Stone's work is based on experimental
data, other studies support their ideas on genetic risk. It is perceived by clients as: (a) a
global concept, sometimes interpreted as severity (Lippman-Hand & Fraser, 1979;
Teigen, 1988); (b) as one of many considerations that complicates the decision (Frets,
Duivenvoorden, Verhage, Ketzer, & Neirmeijer, 1990); and (c) as subjective by nature
and relevant in decision making only in so far as it is subjective (Sagi, Shiloh, & Cohen,
1992; Shiloh & Saxe, 1989). Yates and Stone also emphasized the importance of the
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multidimensionality of the risk concept. A single number ignores the multi-dimensional
nature of the significance of the negative outcome and uses probabilities for specific
outcomes as representations of uncertainty, whereas uncertainty is a larger concept
(McCormick, 2002; Mishel, 1990; Morse & Penrod, 1999; Penrod, 2001).
The emerging literature on risk communication suggests that most individuals
with some family history of cancer, including those at low to moderate risk, overestimate
their personal cancer risk (Martin & Lobchuk, 2003). This finding of exaggerated
perceptions of personal risk has been documented in studies about genetic testing
(Andrykowski, Munn, & Studts, 1996), breast cancer (Black, Nease, & Tosteson, 1995;
Lerman, Kash, & Stefanek, 1994; Smith et al., 1996), and in research on hereditary breast
and ovarian cancer families (Berry et al., 1997; Blum.an et al., 1999; Hallowell, Statham,

& Murton, 1998a; Schwartz et al., 2000; Struewing et al., 1995; Winer et al., 1997).
Black et al. (1995) found in women between 40 and 50 years of age, without a family
history of breast cancer, respondents overestimated their probability of dying of breast
cancer within the next 10 years by more than 20 fold.
Participants' decisions about genetic testing are influenced less by their actual risk
than by their perceived risk and emotional factors (Lerman et al., 2002). Studies of breast
cancer risk counseling programs are mixed on their reported effectiveness in changing
perceptions of personal risk of cancer through standard education and counseling
approaches (Lerman, Biesecker et al., 1997; Lloyd et al., 1996; Meiser & Halliday, 2002;
Morris, Johnson, Krasikov, Allen, & Dorsey, 2001; Watson et al., 1999). However, a
meta-analysis of 12 studies of outcomes of genetic counseling for women at increased
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risk of developing breast cancer showed that counseling improved the accuracy of risk
perception (Meiser & Halliday, 2002).
Sociocultural Context of Breast Cancer Risk

A look at the sociocultural context of breast cancer offers some insight into
women's exaggerated perceptions of personal risk of breast cancer.
Exaggerated perception of risk has been mediated by a discourse of fear of breast
cancer. Breast cancer is a symbolic issue in women's health and many emotionally
charged political battles center around prevention, early diagnosis and treatment, and
access to research (Surbone, 2001). In addition, breast cancer screening has developed in
the context of risk and fear of breast cancer.
Through the success of American women activists, large sums of money have
been earmarked for breast cancer research and have moved breast cancer to center stage
as a public health concern in the United States. Yet through these successes, through the
adoption of the term 'epidemic' and the 'risk' paradigm of biomedicine, these same
actions have unintentionally reinforced exaggerated fears of breast cancer as an epidemic
that threatens all women, especially younger women (Lerner, 1999).
Despite tremendous research efforts, science has not cured or prevented breast
cancer. Instead, it has offered an elaboration of breast cancer risk factors and programs of
vigilant surveillance via mammography, breast examination, and genetic testing.
Attempts to reduce women's fear of breast cancer, through an elaboration of risk
statistics, may exacerbate this fear through the increasing screening and surveillance
recommendations that accompany designations of risk. This increasing fear in turn
precipitates a greater desire for certainty. Ironically, increasing certainty and control can
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be achieved by providing probabilistic risk information, including predictive genetic
testing (Press, Fishman, & Koenig, 2000).
Lastly, the suffering and death from metastatic breast cancer are devastating and
its image is imposed on many women with BRCA mutations. Current studies which
attempt to address some of the psychosocial and interpersonal aspects of genetic testing,
do not consider the sociocultural climate within which BRCA genetic decisions are made.
The social and cultural context of genetic testing for breast cancer, specifically women's
fear and use of individualized risk statistics, have implications for women making
decisions about BRCA mutations.
Most research on how genetic-related decisions are made attempt to relate
antecedent factors influencing the decisions. This previous research examines the
correlation between specific choices and relevant psychosocial variables. Important to
decision making is to understand the impact of undergoing predictive genetic tests upon
emotional state and thus upon decisions leading to risk reduction and detection of disease.
Psychological Factors Influencing BRCA Decisions
Emotional Factors Motivating Genetic Testing

Research suggests that emotional factors can modify the cognitive processing of
risk-related information when an individual is faced with a personally relevant health
threat (Croyle, Yi Chun et al., 1997; Leventhal et al., 1983). This is common in risky
decisions that are made under emotional stress (Janis & Mann, 1977). Given the
possibility of receiving a positive or VUS BRCA mutation test result, one would expect
genetic testing to be particularly stressful.
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Janis and Mann (1977), in their conflict theory, used experiments to test the
deleterious effects of high levels of stress on decision-making and risk-taking. Stress
interferes with one's ability to consider the most relevant features of the situation and to
carefully consider the pros and cons of alternate options. The conflict model maintains
that extremely low stress and extremely intense stress lead to defective decision patterns,
whereas moderate levels of stress are more adaptive and enhance vigilant decision
making patterns.
Cancer worry, cancer specific distress, and frequent intrusive thoughts have been
shown to motivate use ofBRCA genetic testing in high-risk families (Durfy et al., 1999;
Lerman, Schwartz et al., 1997). The specific effects of distress and emotional factors on
genetic testing decisions and outcomes may depend on the level and type of distress, and
on beliefs about being able to control the risk (Croyle & Lerman, 1999).
When outcomes are perceived as controllable, cancer-specific distress may
motivate coping strategies, including genetic testing. McCaul, Branstetter, Schroeder, and
Glasgow (1996) reported this in a meta analysis on mammography screening in women at
risk. However, global distress, a perceived lack of control, may promote feelings of
fatalism that interfere with health protective behaviors and thus avoidance of genetic
testing. Lerman et al. (1998) found more frequent depression symptoms at six month
follow-up in individuals who had high levels of cancer-related distress at baseline, but
declined testing, than those who received positive test results. Their analysis suggested
that those who declined testing were motivated to be tested to reduce distress, however,
because of fears of discrimination and other adverse outcomes, they avoided testing.
Thus, their cancer risk status remained uncertain and depression levels increased over
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time. This suggests that genetic testing is a coping response that may be facilitated by
disease-specific distress, if this action is perceived as leading to increased control over
disease outcomes (Lerman et al., 2002).
Distress, Anxiety, and Depression After BRCA Testing

When clients were asked to speculate about what their reactions would be to
disclosure of positive BRCA mutation carrier status, they expected depression (80%),
anxiety (83%), and impairment in their quality oflife (46%) (Lerman, Seay et al., 1995).
In contrast to their expectations, the few studies of psychological outcomes associated
with genetic testing for BRCA mutations, have shown low levels of distress among those
found to be carriers and noncarriers (Croyle, Smith et al., 1997; Lerman et al., 1996;
Schwartz et al., 2002).
Broadstock, Michie, Marteau (2000) in a systematic review of psychological
consequences of predictive genetic testing found that none of the 15 studies reported
increased distress (including anxiety, depression, general distress, and situational distress)
in carriers or non-carriers at any point during the 12 months post testing. No differences
were found at 12 months (three analyses) or at 3 years (three analyses) in any of the
psychological outcomes measured. In all studies, emotional states remained within
normal ranges. Both carriers and non-carriers showed decreased distress after testing,
with this decrease being greater and more rapid among non-carriers. Test results did not
predict emotional consequences in the majority of studies. Only three studies in this
predictive genetic testing review were of HBOC, but the results are consistent with
genetic testing results from Huntington's disease, spinocerebellar ataxia, and familial
adenomatous polyposis. In the first long term study, Van Oostrom et al. (2003) reported
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the psychosocial consequences of carrying a BRCA mutation 5 years after genetic
testing. On several distress measures, there was not a difference between carriers and
non-carriers.
Despite positive outcomes regarding distress in most studies, there were small
subgroups of those tested with increased distress (Lerman et al., 2002). However, most
increases were within the normal range of distress. Coyne, Kruus, Racioppo, Calzone, &
Armstrong (2003) surveyed women in a high risk clinic and found that obtaining genetic
testing may be less stressful than living with the awareness of a familial risk for cancer.
The test result status of other family members is highly influential on the psychological
impact of an individual's test result (Smith et al., 1999). Female BRCA carriers, who
were the first in their families tested or whose siblings were negative, had significantly
higher distress than other female BRCA carriers. Also, in those who were the first in the
family tested, some distress related to the burden of conveying genetic information to
relatives has been noted (Bish et al., 2002). Wylie, Smith, and Botkin (2003) reported
significantly higher levels of distress in BRCA mutation carriers whose spouse was
highly anxious and non-supportive. Thus it is important that research consider the family
context of the individual tested to determine which individuals requesting genetic testing
may require additional emotional support.
Broadstock et al. (2000) proposed several factors which may influence emotional
consequences of genetic testing (a) awareness of pre-test risk status, (b) psychological
coping mechanisms, (c) sample selection, and (d) counseling. Another explanation for
test results not predicting emotional outcomes is the coping mechanisms that many
individuals use in the face of a threat. One such mechanism is threat minimization,
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whereby those facing a positive threat perceive it to be less serious that those not facing
the threat (Croyle, Yi Chun et al., 1997).
Most of the studies reviewed on psychological factors were of self-selected
populations, many in research registries, who had agreed to participate in psychological
studies and have been followed up for no more than 5 years. Most of the studies had
optimal models of genetic counseling that may have more beneficial outcomes than those
in a clinic setting. Also, it may be that genetic mutation carriers experience more distress
as they approach the likely onset of their condition (or the age of an affected relative).
Although research on behavior change after genetic testing is limited, initial
results do not support substantial effects (Marteau & Lerman, 2001 ). In the next section,
risk management behavior after genetic testing will be considered in greater detail.
Risk Management Decisions in BRCA Mutation Carriers
Screening Behavior

While motivation given for pursuing BRCA genetic testing included increased
motivation to do self breast exams, and get regular clinical breast examinations and
mammograms (Durfy et al., 1999; Jacobsen et al., 1997; Lerman, Seay et al., 1995;
Struewing et al., 1995), limited data exists as to what degree clients participating in
BRCA genetic testing will alter their breast and ovarian screening behavior over time.
Although cancer screening behaviors have been examined in women with a
family history of breast and ovarian cancer, studies of breast and ovarian cancer
screening in BRCA mutation carriers are few. Five such studies have been reported with
varying results.
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Breast Cancer Screening
Lerman et al. (2000) reported breast and ovarian cancer surveillance practices one
year after BRCA mutation testing. They found that in 29 mutation carriers, disclosure of
positive BRCA mutation test results did not lead to increased use of annual
mammograms or ovarian cancer screening tests (68% complied with mammography
recommendations before BRCA testing and 68% reported adherence one year after
receiving positive test results).
Peshkin et al. (2002) determined from a prospective observational study of 41
BRCAl/2 carriers, overall the use of breast cancer screening was good (CBE uptake for
carriers: 95%; noncarriers: 77%; and mammography uptake in carriers: 59%, in
noncarriers: 4 7%). However, there was a relatively low uptake rate of mammography in
younger carriers (ages 25-39 years: 39% versus age::::. 40 years: 74%).
Botkin et al. (2003) studied a kindred of women in Utah for two years following
BRCA 1 testing. Both carriers and non-carriers significantly increased their use of
mammography and breast self-exam from baseline. For women 40 years and older, 82%
of mutation carriers obtained a mammogram in each year following testing. Younger
carrier women also significantly increased their mammography utilization from baseline.
Overall, 29% of the BRCA carrier women did not obtain a single mammogram by 2 years
post-testing. At 2 years, 83% of the carrier women reported adherence to
recommendations for breast self-exam and over 80% had obtained a clinical breast
examination each year following testing.
Scheuer et al. (2002) also presented prospective evidence that BRCA testing and
genetic counseling increased screening in 251 BRCA mutation carriers followed over a
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mean of 24.8 months. There was an overall significant increase in mean number of
mammograms, clinical breast exams, ovarian ultrasonograms, and CA-125
determinations after genetic testing. Breast self exam (BSE) was practiced by greater than
75% of the women at the time of genetic testing. The importance ofBSE is supported in
this group by the fact that it led to the diagnosis of five interval cancers, with four of the
five tumors lymph node negative.
Ovarian Cancer Screening
In reports of ovarian screening behavior in BRCA carriers, compliance has been
relatively low. At one year follow up, Lerman et al. (2000) reported BRCA carriers use of
CA-125 testing and TVUS at only 21 % and 15% respectively. Botkin et al. (2003) found
that 19 BRCA carriers, at one and two years post testing, reported TVUS use of 26% and
11 % respectively and CA-125 use of 32% and 37% respectively. In a clinical sample
(n=79) of affected and unaffected BRCA participants, followed for 12 months after
receipt of positive test results, Schwartz et al. (2003) found that CA-125 and TVUS
screening was reported at 43% and 40% respectively, both reflecting an increased use
compared with the year prior to testing. Scheuer et al. (2002) reported an overall increase
in mean number ofCA-125 and TVUS screening performed after genetic testing. On
average after 15 months, 67.6% of participants were performing CA-125 testing and
72.9% were performing TVUS.
In the Botkin et al. (2003) and Lerman et al. (2000) studies above, they examined
whether testing-related distress reduced adherence to cancer screening. This was not
demonstrated among participants tested in either study. It may be that genetic information
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leads to risks being perceived as unmodifiable and to less adherence to behaviors that
would lower health risks (Senior et al., 1999).
Although these are the first studies to characterize screening behaviors following
BRCA mutation testing, they shed little light on the factors that influenced these
surveillance decisions. Limitations of these studies are: the relatively short timeframe for
follow-up, most data were obtained from clinical research programs involving very highrisk families, and some studies mixed affected and unaffected BRCA carriers together in
the reports.
Prophylactic Surgery
A few studies have recently been published about the extent to which prophylactic
surgeries are chosen as HBOC prevention options in BRCA mutation carriers. Also
included are factors that influence the decisions for prophylactic surgeries and the
psychosocial implications of these surgeries for women with BRCAl and BRCA2
mutations. Two recent studies indicate that the degree to which BPM is chosen as a risk
reduction intervention may vary according to culture, healthcare system, insurance
coverage, provider attitudes, and other social factors (Bouchard et al., 2004; JulianReynier et al., 2001).
Studies from the United States have reported fewer women choosing BPM than
BPO following BRCAl and BRCA2 mutation testing. Scheuer et al. (2002) studied 233
affected and unaffected women with BRCA mutations over a mean period of 24.8
months. These researchers reported that 14.9% underwent BPM at a median of 5 .3
months after test results (prior to testing: 8.6% had BPM and 8% had undergone BPM for
breast cancer) and 50.3% underwent risk reducing salpingo-oophorectomy (RRSO) at a
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median of 3.4 months after receiving genetic test results. Women electing BPM were
younger and had a stronger family history of breast and ovarian cancer than those opting
for screening. Those electing RRSO were older (64% >40years) and more likely to have
had a prior breast cancer diagnosis than those not opting for surgery. They did not have
more family members affected with breast or ovarian cancer than those not opting for
RRSO.
In a prospective observational study, Lerman et al. (2000) found only 3% of
unaffected BRCA mutation carriers (n=29) had undergone BPM within a year of learning
their BRCA mutation carrier status. A small subset (n=8) of these women had received
BPM prior to genetic testing. Thirteen percent of carriers obtained BPO within a year
following BRCA testing.
In a Utah kindred, Botkin et al. (2003) found in BRCAl mutation carriers that
BPM was not utilized within the first 2 years following testing, although 11 % were
considering this procedure. These researchers also reported that 46% (12/26) chose BPO,
including 78% of women 40 years of age or older. In this study an additional 30%
(11/37) had obtained BPO prior to testing. Income, education, family cancer history,
personal cancer history, general distress, and test specific distress were not predictive of a
decision to obtain BPO.
In the year following BRCA testing, Schwartz et al. (2003) reported that 27% of
affected and unaffected mutation carriers and 5% of uninformative patients received
BPO. Perceived risk for ovarian cancer, family history of ovarian cancer, ovarian cancer
worries, age, and test results predicted undergoing BPO.
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Studies from the Netherlands demonstrate higher selection rates of prophylactic
surgeries in women with BRCA mutations than the United States. In the Netherlands,
(Meijers-Heijboer et al., 2000) reported that 51% of unaffected (cancer free) BRCAl and
BRCA2 mutation carriers chose BPM over screening and 64% chose BPO within 2 years
after testing. Parenthood was found as a predictor for BPM and age was associated with
BPO.
Lodder et al. (2002), also from the Netherlands group, described follow-up of26
BRCA carriers (some were the same as above study), assessing the influence of
psychological distress on risk management options chosen. The 51 % who chose BPM
had significantly higher general and cancer-related distress levels than mutation carriers
who opted for surveillance. A higher distress level in women opting for BPM was also
observed in other studies (Meiser, Butow, Freidlander et al., 2000; Scheuer et al., 2002;
Stefanek et al., 2001; Wagner et al., 2000). This difference in level of distress was highest
at pre- and post-test and had almost disappeared at one year follow-up. Also, mutation
carriers opting for BPM were more often in their thirties, had young children, and had a
longer awareness of the genetic nature of cancer in the family than those opting for
regular screening. Fear of leaving young children was an important independent factor in
deciding for surgery (Lodder et al., 1999).

Psychosocial Outcomes
The psychosocial sequelae of BPM in high and moderate risk women, including
those with BRCA mutations, have been reported in a few studies. Collectively data
suggests that high risk women report satisfaction with their decision to undergo BPM and
adjust well emotionally after surgery, although satisfaction with reconstruction may be
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less optimal (Borgen et al., 1998; Frost et al., 2000). These outcomes must be weighted
against the irreversibility of the decision, potential problems with implants and
reconstructive surgery, and the occurrence of adverse psychological and social outcomes
in some women (Frost et al., 2000). Moreover, two decades of research have shown that
most women with breast cancer can safely be treated with breast-conserving surgery
instead of mastectomy (Eisen & Weber, 2001). Thus it is difficult to accept that
prevention of HBOC should be more extreme than the cure.
In Lodder et al. (2002) study above, about half the BRCA carriers who underwent
BPM (n=l4) reported a negative influence on body image, intimate relationship, and
physical well-being. For spouses, surgery did seem to have a negative effect on the
frequency of intimate contact with their spouses up to eight months after surgery. From
interviews, the impression was that this reduction in intimate relationship was due more
to the woman feeling inhibited to have intimate contact, than due to the partner's.
However, all but one did not regret their decision at 1 year after testing. The major reason
for the Dutch women's overall satisfaction may be due to a sense of relief as a result of
significant risk reduction of developing breast cancer. Research by van Oostrom et al.
(2003) corroborated these findings. These researchers reported a follow up study of
women who had undergone BPM. At 5 years they reported a significant reduction in fear
of cancer, but had a less favorable body image and changes in their sexual relationship.
One explanation for the few regrets reported after BPM might be that regretting
one's autonomous decision for an irreversible surgical intervention may lead to
'cognitive dissonance' (Croyle, Smith et al., 1997). People want consistency between
their cognitions (i.e. attitude, emotion, and behavior) as inconsistencies create
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dissonance, which leads to uncomfortable and tense experiences (Festinger, 1957).
Cognitive dissonance is assumed to be smaller if one feels less autonomy in making a
decision (e.g. because of external pressure). This could be seen in a large retrospective
study of370 high risk women who underwent BPM over a mean of 14.8 years (Stefanek
et al., 1995). Of21 (5.6%) women who regretted having undergone BPM, the subject of
surgery had been initiated by their physicians (instead ofby themselves) and they had
insufficient information about surgery. Stefanek et al. (1995) also reported these
womens' reasons for regretting BPM as (a) severe emotional trauma and/or lack of
psychological support after surgery, (b) complications of surgery and reconstruction, (c)
dissatisfaction with cosmetic effect, (d) residual or phantom pain, (e) fears that implants
would impede the adequacy of detecting cancer in residual breast tissue, and (f)
diminished self-image or sexual satisfaction.
Cultural and Socio-Economic Differences
In addition to the geographic differences noted between Dutch and United States
BRCA mutation carriers, prophylactic surgery may also vary according to culture,
healthcare system, insurance coverage, provider attitudes, and other socio-economic
factors (Eisinger et al., 1999). Minimal research has been done related to these factors.
In an analysis of the differences between United States (US) and French
consensus statements (Burke et al., 1997; Eisinger et al., 1998) about clinical
management of women with BRCA mutations, Eisinger, Geller, Burke, and Holtzman
(1999) speculated that the difference in regard to prophylactic surgery partly reflected the
cultural context in which physician and patients make decisions and health policies are
formed. Although both consensus statements conclude that BPM and BPO are an option
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for women despite incomplete evidence, the approach to decision making differs
significantly. The French document describes each procedure as "a mutilation ... (which)
should be envisaged for medical reasons only" (Eisinger et al., 1998). It further indicates
that doctors should "oppose" BPM under age 30 and BPO under age 35 years, and should
consider them only when the risk of breast cancer is more than 60% and the risk of
ovarian cancer is more than 20%. French law requires clear therapeutic justification for
physicians to invade a patient's body, even if the patient has given permission for the
procedure. The French document also recommends that women wait several months
before considering either procedure. In the US, only informed consent is required for
these surgeries and does not speak to the possibility of active opposition to a woman's
intention or suggest a delay. Eisinger et al. (1998) suggest cultural differences related to
the symbolic value of the breasts, attitudes toward fertility (French conservative attitude
due to concern about low birth rate), and more general cultural norms of paternalism
(French physicians) versus autonomy (US physicians) in decision making, resulting from
values of communitarianism (French) versus individualism (US).
In the first international comparison of preventive strategies, Julian-Reynier et al.
(2001) demonstrated the existence of variations in acceptability in English, French, and
Canadian women at risk for HBOC attending three genetic clinics for the first time.
These clinics were located in Montreal (Quebec, Canada), Marseilles (France) and
Manchester (Great Britain). French women were the most reluctant about prophylactic
surgeries, moderately favored chemoprevention, and highly favored mammography.
British women were more in favor of prophylactic surgery and chemoprevention, but
were least positive about mammography. Women from Quebec, Canada resembled the
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French attitudes toward mammography and chemoprevention, but agreed more with the
British about early BPM. Quebec women's attitudes toward BPO resembled the British
for early age indications and with the French for indications for women over age 35
years. It was hypothesized that differences in prophylactic surgery by the French women
was that they attach more importance to their breasts and ovaries than the British or
Quebec women, who may have a greater tendency to value life itself over breasts and
ovaries (Julian-Reynier et al., 2001).
The second part of this international research study was reported by Bouchard et
al. (2004). Substantial differences in the way cancer geneticists deal with environmental
risk factors, breast and ovarian cancer testing, chemoprevention, and prophylactic surgery
were found. Cultural differences included the social representation of risk and health.
Physicians from Canada and Anglo Saxon countries promote a model of health that
suggests individual responsibility for risk management, where the physician instructs the
patient about his/her health status and instructs him/her to take the necessary measures to
avoid or restrict the effects of illness. In France, more emphasis seems to be put on
medical authority in the relationship between providers and patients. In addition, body
integrity and the symbolic value of breasts may carry a different value for French
physicians, which may explain differences in acceptability of BPM. Also, interpretations
of scientific evidence and medical uncertainties and the impact of leadership with respect
to new ideas and technology innovation could contribute to the context in which BRCA
testing is disseminated in the different countries, resulting in geographic variability
(Bouchard et al., 2004).
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Cost of genetic testing and prophylactic surgeries may also be a factor in the
differences noted between countries. In the Netherlands, costs for genetic testing,
surveillance, and prophylactic surgery are covered by both public and private health
insurances. Kuerer et al. (2000) evaluated health insurance coverage policies in the US
for BPM and BPO. This cross-sectional nationwide survey of 481 medical directors from
the American Association of Health Plans, Medicare, and Medicaid showed significant
variation for health insurance coverage for prophylactic surgery. Only 44% of private
plans had specific policies for coverage of BPM for clients with a strong family history of
breast cancer and 38% of plans had coverage for a BRCA mutation. Only 20% of total
responding plans had a policy for coverage of BPO under any clinical circumstances. A
more recent retrospective study by Kauff et al. (2001) at Memorial Sloan Kettering
Hospital in New York reported that 38 of 39 risk reducing surgeries in women with
BRCA mutations were covered in full, less deductibles and copayments. Rates of
insurance reimbursement did not vary by type of insurance, personal history of cancer, or
type of procedure. Information on insurance coverage needs to be updated, as both of
these studies are dated and may not reflect current insurance policies.
Analysis and Critique ofthe Literature

Genetic testing is being applied to detect individual susceptibility to breast and
ovarian cancer with a focus on individual risk management. The hope is that awareness
of genetic risk will enhance informed risk management by clients. Researchers have
recognized the movement of predictive genetic testing from the research to the clinical
environment. There is an emerging body of literature which addresses data derived from
clinical research programs involving very high risk families, some of whom were
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members of cancer genetic registries. These research programs have included protocols
for extensive pre-and post-test counseling about risks and benefits of testing, protections
of ethical review, psychological assessment, and follow-up, staged over months. Few
studies have presented data from clinic-based genetic testing programs, where the lack of
protective factors associated with the research environment may have higher rates of
adverse consequences for clients tested (Dorval, Patemade et al., 2000; Schwartz et al.,
2002).
Additionally, literature exists which indicates that overestimated perceived risk,
cancer worry, and cancer-specific distress motivate use ofBRCA genetic testing in highrisk families (Durfy et al., 1999; Lerman, Schwartz et al., 1997; Lerman et al., 2002).
This research further suggests that genetic testing is a coping response that can be
facilitated by disease-specific distress, if this action is perceived as leading to increased
control over disease outcomes. Although these studies shed some light on predictors of
the use of BRCA genetic testing, little is known about the mechanisms by which risk
perceptions, cognitive factors, and the influence of family and others affect a woman's
management of her susceptibility to HBOC. No studies to date have addressed the genetic
testing and risk management decision making experiences of unaffected women who
receive variant of uncertain clinical significance BRCA test results.
A few studies have addressed the short term psychological impact of receiving
BRCA mutation test results among research and clinic based families (Croyle, Achilles,
& Lerman, 1997; Dorval, Patemade et al., 2000; Lerman & Croyle, 1996; Marteau &

Croyle, 1998; Schwartz et al., 2002). This literature suggests that the severity of
psychological risks posed by genetic testing is not great. Although some studies report an
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initial increase in anxiety following predictive testing, this tends to be transient and not
clinically significant. However, subgroups of individuals with certain psychological traits
may be more vulnerable to adverse effects. Standardized measures of distress may not be
sensitive enough to determine more subtle changes in functioning. It is unknown how
individual differences in tolerance for uncertainty or need for information may moderate
of the impact of genetic test results on psychological functioning (Croyle, Dutson, Tran,
& Sun, 1995).
In addition, emerging data is mixed on providing evidence that genetic testing
promotes changes in risk management (Botkin et al., 2003; Lerman et al., 2002; MeijersHeijboer et al., 2000; Peshkin et al., 2002; Scheuer et al., 2002; Schwartz et al., 2003).
Although the first studies to characterize screening and prophylactic surgery behaviors
following BRCA testing have been reported, they shed little light on the factors that
influenced these risk management decisions. Furthermore, the studies are complicated by
mixing unaffected and affected women in the same report. Hallowell, Foster, Eeles,
Ardem-Jones, and Watson (2004) in a qualitative study of affected womens' responses to
BRCA genetic testing, indicated that a majority of women adopted a fatalistic approach
with regard to their future health and did not regard their genetic risks as a threat to self.
The data suggested that affected women understand genetic risks of HBOC within the
context of their previous disease experience.
An understudied area of BRCA research is the family and social contextual
factors involved in genetic testing and risk management by women with positive and
VUS BRCA test results. Initial data suggest that genetic testing for breast cancer
susceptibility is motivated partly by the desire to help other family members (Geller et
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al., 1999). Although the majority of genetic testing participants communicate their risk to
other family members, only recently has data been reported on BRCA mutation carriers
about the content, process, and impact of these communications (Bonadona et al., 2002;
Croyle & Lerman, 1999; d'Agincourt-Canning, 2001; Hamilton et al., 2005; Hughes et
al., 1999).
Rees, Fry, and Cull (2001) identified that the influence of personal experience of
cancer, through involvement with affected relatives, has been neglected in the literature
and found strong theoretical grounds for the hypothesis that dimensions of personal
experiences may influence response to cancer risk. "Perceptions of breast cancer and
beliefs about the disease are likely to influence how an individual reacts (in terms of
thoughts, feelings, and decisions) to their own risk status" (Rees et al., 2001).
Much of the current research is based on a static view of genetic testing use,
largely from the perspective of health care providers and researchers, using standardized
instruments. Current research describes pieces of the process, but does not attempt a view
of the total experience of genetic testing. What is lacking is a focus on the clients'
perspective, as well as an understanding of the evolving process as clients move through
a trajectory of managing their susceptibility to hereditary breast and ovarian cancer.
Although this researcher's initial plan was to explore unaffected womens' risk
management decision making after testing with a positive or VUS result, it became
obvious after a few interviews that some women came to BRCA testing with plans for
prophylactic surgery. To better understand these apriori decisions, the focus changed to
explore the broader context of genetic testing in which unaffected positive and VUS
carriers came to manage their susceptibility of hereditary breast and ovarian cancer.
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The purpose of the study then became to explore the influence of family and
social contextual factors in how unaffected BRCA positive and VUS carriers
conceptualized their cancer risk, interpreted and coped with BRCA test information, and
made subsequent risk management decisions; and to develop a grounded theory based on
the perceptions, beliefs, and actions of these women. With a broader scope, questions
were added and included: (a) Given the benefit of hindsight, how would unaffected
BRCA positive and VUS carriers describe their experience of discovering their BRCA
status? (b) What is the influence of womens' experiences of breast cancer in their family
in how they conceptualized their breast and ovarian cancer risk? (c) How do women
interpret, assign meaning, and act on the complex information about positive and VUS
test results and risk management? (d) What is the decision making process through which
they arrive at these actions? and (e) What are the roles their family and others played in
their decision making? The following chapter will explain the methodology used to
explore these questions.
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Chapter III
METHODOLOGY
This qualitative study was guided by the theoretical perspective of symbolic
interactionism (Blumer, 1969) and the research approach of grounded theory (Glaser &
Strauss, 1967; Strauss & Corbin, 1998). Symbolic interactionism is a useful perspective
for the study of the meaning and consequences ofBRCA mutation testing in unaffected
women. By emphasizing personal interactions, this perspective encourages the researcher
to study how people think, communicate, and interact and what effect these processes
have on how they perceive their BRCA genetic testing and risk management experiences.
Blumer (1969) explained about symbolic interactionism, "(it) .. .lodges its problems in
this natural world, conducts its studies in it, and derives its interpretations from such
naturalistic studies." The method for this study is based on this philosophical perspective.
Specifically, grounded theory approach was used in collecting data from unaffected
BRCA positive and VUS mutation carriers in their own environments and in analyzing
these data using constant comparative analytic techniques (Glaser, 1995; Strauss &
Corbin, 1998).
This chapter describes the grounded theory method, discusses participant
inclusion criterion, and entree to the specific population addressed. Protection of the
78
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participants is addressed and the progression of data collection and analysis is described.
Finally the methods which provided methodological rigor are explained.
Grounded Theory
Interpretive inquiry, using grounded theory, is particularly suited to the study of
BRCA genetic testing and risk management in unaffected women susceptible to breast
and ovarian cancer, for three reasons. First, because of its focus on meaning defined
through interaction, and its sensitivity to the evolving and unfolding nature of events, and
to the interrelationships among conditions, actions, and consequences (Strauss & Corbin,
1998). Second, it is useful in conceptualizing behavior in complex situations and in
understanding the impact of new technology on the health care system and the client
(Swanson, 1986). Lastly, this method allows the researcher to obtain the intricate details
about phenomena such as feelings, thought processes, and emotions that are difficult to
learn about through more conventional research methods (Strauss & Corbin, 1998). It can
also form the basis for interventions and social policy.
Strauss and Corbin (1998) use the term "grounded theory" to mean theory
inductively derived from data ("grounded" in the data collected), systematically gathered,
and analyzed through the research process. A researcher does not begin with a
preconceived theory in mind, as in deductive reasoning. Instead, the research begins with
an area of study and allows the theory to emerge from the data. It results in the
development of middle-range theories to explain behavior and processes (Charmaz,
2000). Grounded theory, because it is drawn from data, offers insight, enhances
understanding, and provides a meaningful guide to action for unaffected women
undergoing genetic testing and managing their susceptibility to breast and ovarian cancer.
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Nursing theory focuses on meaning and is developed for describing, explaining,
predicting, or prescribing nursing care (Meleis, 1997; Parker, 2001). The primary purpose
of this study was to enhance understanding of the social processes involved in BRCA
genetic testing and managing susceptibility to hereditary breast and ovarian cancer. Since
there is minimal knowledge about how BRCA genetic testing effects unaffected women's
lives, this methodological approach is appropriate, as it helps to shed light on the basic
social processes involved in BRCA genetic testing and managing susceptibility, including
interactions with family, friends, and health care professionals.
Research Strategies

Sample Selection
As is consistent with grounded theory methodology, study participants were
selected based on their ability and interest in explaining and articulating their experiences
ofBRCA genetic testing and how they came to manage their risk of hereditary breast and
ovarian cancer. Therefore, the initial sample was a convenience sample. Subsequent
sampling was based on the grounded theory process of theoretical sampling (Glaser &
Strauss, 1967). Theoretical sampling is the process of deciding on who and what to
sample, based on previously collected and analyzed data. This sampling was used to
collect more data to test and develop categories and their relationships and to assure that
the full range and variation in the categories existed. Theoretical sampling, intensive
interviewing, and data analysis were concurrent, repeating processes and driven by the
theoretical coding scheme that emerged. As the theoretical scheme emerged from the data
analysis, through the process of constant comparison, more focused interview questions
and specific types of participants were selected to broaden an understanding of womens'
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experiences of BRCA genetic testing and risk management of HBOC. Sample size was
determined when no new conceptual data (information redundancy) was reached, and the
requirement of data saturation was met.
Participant inclusion criteria for this study included (a) female age 18 and older,

(b) carrier of a BRCA 1 or BRCA2 mutation or a variant of uncertain significance, (c) not
affected with breast or ovarian cancer prior to genetic testing, and (d) no psychiatric or
cognitive disorder which would preclude informed consent.
Protection ofParticipants

After obtaining approval of the Committee on the Protection of Human Subjects
at the University of San Diego and the Human Research Protection Program's
Institutional Review Board at a large metropolitan medical center with a genetic
screening program (see Appendix A), data were collected using semi-structured in-depth
interviews of the participants (Appendix B). Prior to interviewing, the purpose of the
study and assurance of confidentiality were explained to each participant. Also, their
rights to refuse to answer any question or decide to terminate the interview at any point,
if desired, were explained. Any questions were answered and each participant signed a
consent form (see Appendix C). Out-of-state/country participants either faxed or mailed
their signed consent forms to the researcher. A copy of the researcher signed consent
form was then mailed to each participant, along with a check for $50, in appreciation for
their participation. Coded numbers provided confidentiality and anonymity of all
participants so that no names or other identifying descriptions were present on the data.
Only the researcher knew the list of names with corresponding codes. Identifying
information was kept in a locked cabinet in the researcher's office.
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Recruitment

Participants were recruited over a thirteen month period (May 2003 through June
2004) from multiple sources. Initially to gain entree to a cancer genetics setting the
principal investigator (Pl) set up an independent study with the Director of the Clinical
Cancer Genetics Specialized Clinical Unit and the cancer genetic counselor at a local
university comprehensive cancer center. The PI continued monthly meetings with the
director and cancer genetic counselor throughout the research data collection and analysis
and attended all BRCA support group meetings sponsored by these professionals. Clients
from this testing and counseling program were the first to be interviewed. However, only
5 clients were recruited from this program, so the PI continued recruitment using the
following additional strategies: (a) posting on a national BRCA peer support internet
website research page, (b) sending letters, flyers, and subsequent follow-up letters from
the director of a cancer genetics program in a large tertiary medical center in the
southwest (see Appendix D), (c) obtaining referrals from genetic counselors from a
posting on the National Society of Genetic Counselors (NSGC) Cancer Genetics
Research Directory, (d) sending letters and flyers from a nurse genetic counselor in the
Midwest; and (e) writing an article in the online journal NurseZone which recruited for
participants. Three participants were recruited by snowball sampling. The last three
strategies were added to meet the needs of theoretical sampling. That is sampling was
continued to explore and compare the dimensions in unaffected womens' interpretation
of their VUS mutations and to achieve a broader age range of participants. This was
important to give variation and density to the categories, because information about
unaffected VUS carriers had not been previously reported in the literature.
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To recruit from the online website, the executive director of the national support
organization for women with hereditary breast and ovarian cancer gave approval for
posting a flyer on their research page. An announcement describing the study was also
sent by electronic mail from the executive director to members of the organization. An
application was made and approval was also obtained for posting on the National Society
of Genetic Counselors' (NSGC) Cancer Genetics Research Directory. This
announcement described the study for referral by genetic counselors and solicited
participants for the study.
Particularly difficult to recruit were unaffected women with a genetic variant of
uncertain significance. Correspondence with Myriad Genetics laboratories indicated that
12% of patients who have BRCAl/2 testing, receive the variant of uncertain significance
result. Of these patients who specify their personal history of cancer, 32% do not have a
diagnosis of breast or ovarian cancer and 68% do (A. Deffenbaugh, personal
communication, 21 October 2004). Based on these figures, only about 570 women tested
through Myriad Genetics Laboratories (who hold the patent worldwide for BRCA genetic
testing) would have met the criterion for this study in May 2002, when the study began.
Data Collection Procedure

Data were collected from individual interviews and observational memos.
Unaffected women, who were BRCA or VUS carriers and chose to participate, contacted
the interviewer by phone or e-mail. For local participants (n=8), a convenient time was
determined for a 60 to 90 minute audiotaped, face-to-face interview conducted in their
home. Informed consent was obtained at the time of the interview. For out-of-state and
out-of-country participants (n=22), a convenient time was determined on intake for a
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telephone interview from their home. Also requested at intake was a copy of the
participant's BRCA test result, permission to audiotape the telephone interview, and their
consent to participate. A copy of the consent form was sent to the participant by
facsimile, postal mail, or e-mail and returned to the PI by facsimile or postal mail. During
the telephone interview, informed consent was obtained and any questions the participant
had were answered. The telephone interviews lasted from 60 to 160 minutes. The
interviews were audiotaped and the researcher recorded socio-demographic and family
history data, as well as observational and methodological notes.
Responding to open-ended, semi-structured interview questions (Appendix B),
participants provided verbal descriptions of how they came to have BRCA testing, how
they learned their test results and from whom, with whom they shared their results with,
what measures, if any, they took to reduce their risk for breast and ovarian cancer, how
they considered the advantages and disadvantages of the risk management options, what
role their family and others played in their decision making, and what was needed to
manage their health in the future. A short second interview was conducted with three
participants to clarify if they had carried out their intended surgical procedures after the
initial interview. Participants' not recruited through the two medical centers provided
copies of their BRCA genetic test results for validation.
Data Management
Socio-demographic Data
Participants provided socio-demographic and family cancer history information
(Appendix B). Variables included age, marital status, age and gender of children,
occupation, education, race, ethnicity, family income level, history of cancer in self and
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family, initial family member tested, BRCA results and date of testing, surgical history,
current use of estrogen, and menopausal status. A family cancer history was obtained of
first, second, and third degree relatives.
Qualitative Interview

Interviews evoked ideas, thoughts, and memories in the participants own words.
The interviews were guided by open-ended questions designed to educe the meaning of
the participant's genetic testing and subsequent risk management decision making
experiences. The researcher endeavored during the interview to maintain enough
flexibility to elicit individual stories while gathering information consistently to allow for
comparison between and among participants. A copy of the interview guide is at
Appendix B. Thirty interviews were audiotaped and later transcribed by a professional
transcriptionist. Observational and methodological notes were recorded and kept with the
transcribed notes of participants.
Participant Characteristics

A total sample of 30 participants was the data source. The sample consisted of
two groups (a) unaffected females (no history of breast or ovarian cancer prior to genetic
testing) who tested positive for a BRCAI or BRCA2 mutation (N=21); and (b) unaffected
females who tested with a genetic variant of uncertain significance (N=9). These VUS
test results are those in which the lab identifies a new sequence alteration, which may or
may not disrupt the function of the protein, and whose clinical significance has not yet
been determined. Test results indicate a "genetic variant of uncertain significance"
(Myriad Genetics, 2004). The women who participated in this study had genetic testing
between 1994 and 2003, with the majority tested in 2002 and 2003.
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The women ranged in age from 22 to 60 years, with a mean age of 40 years. The
mean age of women in the BRCA positive group was younger (39 years) than the VUS
group (43 years). Twenty (66%) were married, 3 were single, 3 were divorced, 3 were
partnered same sex, and 1 was widowed. The median number of children was 2, with a
range of 0-6. The mean age of their children was 17 years, with the mean age of children
of women in the BRCA positive group younger than the VUS group (11.1 years versus
20.2 years, respectively). The mean years of education was 15.8, with a range of 11-21
years. The majority of the group were Caucasian (90%), 2 were Black, and 1 was
Hispanic. Eight (27%) were of Ashkenazi Jewish descent, all in the BRCA positive
group. The median family income range was $50,000 to less than $75,000. The majority
of women had professional careers (e.g. teacher, speech pathologist, registered nurse,
molecular biologist). The mean number of first degree relatives with breast or ovarian
cancer was 1.5 (range 0-4) for BRCA positive carriers and 1.1 for BRCA VUS carriers.
Twenty one participants had mothers with breast cancer, 1 with ovarian cancer, 1 had
both ovarian and breast cancer, and five had neither parents with cancer. Table 1 presents
participants' socio-demographic characteristics. Table 2 provides participants' family
cancer histories.
Data Analysis
Analysis of the data was accomplished using grounded theory method.
Transcriptions of the interviews and observational memos were analyzed using constant
comparative analysis (Glaser & Strauss, 1967; Strauss & Corbin, 1998). Data were
analyzed as they were collected, through the process of coding, for the purpose of
generating conceptual categories. Common themes of the BRCA testing and risk
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Table 1
Participants' Socio-demographic Characteristics
Total Sample n=30

BRCA Positive n= 21
BRCA 1= 12; BRCA 2= 9

Variants of Uncertain
Significance
n=9

Age (mean)
(ran2e)

40 years
22-60 years

39 years
22-54 years

43 years
29-60 years

Marital Status

Single n=3
Married n=20
Divorced n=3
Partnered same sex n=3
Widowedn=l

Single n=3
Married n= 14
Divorced n=l
Partnered same sex n=3

Married n=6
Divorced n=2

Number of children (median)
(rane:e)

2
0-6

1
0-6

2
2-4

Children ae:e (mean)

17 years

11.1 years

20.2 years

Years of education (mean)
(rane:e)

15.8 years
11-21 years

16.l years
12-21 years

15 years
11-19 years

Race

Caucasian n= 27
Blackn= 2
Hispanic n= 1

Caucasian n= 21

Caucasian n= 6
Blackn=2
Hispanic n= 1

Ashkenazi Jew

n=8

n=8

n=0

Family income (median range)

$50,000-<$75,000

$75,000-<$ l 00,000

$50,000-<$75,000

Widowedn=l
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Table 2
Participants' Family Cancer Histories
Total Sample n= 30

BRCA Positive n= 21
BRCAl= 12; BRCA2= 9

Variants of uncertain
significance
n=9
Mother cancer n= 6

Mother cancer n= 17
Father cancer n= 1
Both parents cancer n= 7
Neither parents cancer n= 5

Mother cancer n= 11
Father cancer n= 1
Both parents cancer n= 5
Neither parents cancer n= 4

Both n= 1
Breast n= 21
Ovariann= 1
Neithern = 7

Bothn= 1
Breast n= 14
Ovarian n= 1
Neither n = 5

Father's cancer type

Breast n= 1
Lungn= 1
Prostate n=2
Colonn=l
Skin n= 1
Precancer skin n= 1
Kidney n=l

Breast n= 1
Prostate n= 1
Colonn=l
Skinn= 1
Precancer skin n=l
Kidney n=l

Lungn= 1
Prostate n= 1

Mother's age at cancer
diagnosis: mean (range)

48.5 years
(33-77 years)

46 years
(34-66 years)

53.4 years
33-77 years

Number of first degree
relatives with breast or
ovarian cancer: mean
(range)

1.4

1.5

(0-4)

(0-4)

1.1
(1-2)

2.6

2.7

(0-5)

(0-5)

Parents with cancer

Mother with breast or
ovarian cancer

Total of first and second
degree relatives with
breast or ovarian
cancer: (mean range)

Both parents cancer n= 2
Neither parents cancer n= 1

Breast n= 7
Neithern= 2

2.3
(1-5)
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management experience were identified that provided the context to meanings,
circumstances, and conditions of what it was like to obtain a positive or VUS test result
and make decisions about managing hereditary risk. As the data were collected through
open-ended questions, interviews were coded using open, axial, and selective coding
(Strauss, 1987). For purposes of clarity, these types of coding are presented as unique
steps of the process, however these steps are not distinct or linear. Qualitative Solutions
and Research's (QSR) software, NUD·IST VIVO 2.0 was used for data management.
Initially data (transcripts and observational memos) were examined line-by-line
for any and all categories, and the categories were assigned names or codes through
'open coding'. This helped to break down, examine, and compare events, activities, and
interactions for their similarities and differences. Conceptually similar events, activities,
and interactions were then grouped together to form categories and subcategories (Strauss
& Corbin, 1998). Samples of concepts with their properties and variations were drawn
and theoretical ideas, questions, and codes were recorded and tracked using theoretical
memoing. Once the initial set of categories were developed, using axial coding, the
researcher searched for verification, saturation, and relevance of the categories.
Eventually certain categories were found from various interviews (verification), were
observed to be supported over and over again by data with no new information emerging
(saturation), and were found to be related to other categories of data (relevance). Thirty
interviews (21 positive and 9 variants) were reviewed and coded before saturation was
reached. Interviews were reviewed, comparing and contrasting women in various age
categories (20-29, 30-39, 40-49, 50-59; and one age 60 years) and by positive and VUS
mutation status. The categories that were v~tified, reached saturatwn, and seemed to have
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particular importance in relation to the phenomenon ofBRCA genetic testing and risk
management were tentatively labeled "central" or "core" categories. This then led to
selective coding, a process of searching for the linkages among the various sub-categories
and sub-processes in relation to the core category (Strauss & Corbin, 1998). The result of
selective coding was theoretical integration and formation of a substantive grounded
theory. A core variable was identified and theoretical scheme of categories and
subcategories were organized around the core variable. Identifying a core variable in
grounded theory consists of coding the data according to how the participants define or
describe their central phenomenon of concern and asking the data a series of questions:
"What is going on with the participants? What are the main problems? Why do these
women need to be studied and interventions developed?" This category best explained
how BRCA genetic testing, including risk management decision making was experienced
and acted upon in women with positive and inconclusive BRCA test results (Corbin &
Strauss, 1990; Swanson, 1986).
Methodological Rigor

By design, qualitative research involves interpretive description which requires
attention to rigor. Thus for grounded theory to be accepted as methodologically sound,
trustworthiness must be established. Lincoln and Guba (1995) identify four factors to
ensure trustworthiness: credibility, transferability, dependability, and confirmability.
Krefting (1991) indicates that credibility may be established by spending time with the
informants, using reflexive analysis or continual examination of the researcher's
knowledge influence, writing memos, using peer examination, and employing consistent
interviewing techniques. This research employed these techniques.
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Guba and Lincoln (1989) propose that incorporating reflexivity will enhance the
rigor associated with grounded theory studies. They maintain that objectivity can be
addressed by coming clean about predispositions so readers can adjust offered
interpretations in suitable ways.
The researcher is not a genetic oncology nurse. However, as an experienced
medical surgical clinical nurse specialist, family nurse practitioner, educator, and
administrator, with a career-long interest in genetics and primary and secondary disease
prevention, the researcher has certain beliefs and preconceptions (feelings, theories, and
inclinations) which were brought to this study. In the various nursing roles, the researcher
has observed client decision making. Therefore, the following biases are disclosed to
increase researcher sensitivity to beliefs and preconceptions.
Five researcher beliefs are identified. First, decision-making experiences vary
among clients. Those experiences are influenced by a variety of personal, as well as
professional experiences. Second, regardless of decision making ability, external forces
such as physician, nurse, and genetic counselor style or insurance protocol can impact the
process by which clients make decisions. Third, clients integrate many human
experiences into the meaning of decision-making. Fourth, cognitive skills vary among
clients and over time. These skills are influenced by their knowledge and experiences,
their awareness of those experiences, and their ability to integrate knowledge and
experiences into their decision making. Fifth, the psychological state of the client
influences the context of decision making. Competing alternatives with uncertain risks
and outcomes may affect the psychological equilibrium of clients facing stressful
decisions.
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Transferability or applicability to other women with a similar diagnosis is not a
specific goal of this research. No attempt was made to generalize findings. Rich thick
description ofBRCA mutation carriers' experiences will enable readers to determine
whether the findings can be transferred because of shared characteristics (Creswell, 1998;
Erlandson, Harris, Skipper, & Allen, 1993). Study findings are presented as one possible
account of BRCA carriers experiences and should be considered emergent and tentative
(Glaser & Strauss, 1967; Strauss & Corbin, 1998). Since minimal research currently
exists on how women subjectively experience BRCA genetic testing and risk
management, coming to understand their perspective may help healthcare providers meet
their concerns. Becoming sensitized to experiences about genetic susceptibility deepens
understanding and allows for broadening perspectives, and this was the reason qualitative
design was used in this study.
The techniques of discriminant sampling, supplemental validation, and peer
review were used to enhance dependability and credibility (Creswell, 1998). Discriminant
sampling involved posing questions that relate categories developed through axial coding
and then returning to the data for evidence, incidents, and events that supported or refuted
the questions, thereby verifying the data. Supplemental validation was used after writing
the theory. The literature was referenced to give validation for the accuracy of the
findings or how the findings differ from the published literature. Peer debriefing was
accomplished by presenting analyses and conceptual abstractions of the data to two
expert qualitative researchers so that inquirer biases were probed, meanings explored, and
the basis for interpretations clarified (Lincoln & Guba, 1995). Two committee members
were asked to consider the researcher's analysis because they were in the unique position
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to be able to move between a narrowed and broadened view of the researcher's work.
They were familiar with both the study's background and the researcher's biases.
Discussion of the findings also occurred during the study. As categories and
subcategories emerged, these committee members could confirm or challenge the
researcher's analysis. During challenging, the researcher was asked to explain the
rationale for decisions and synthesize all data which supported various categories and
subcategories. Reflexive analysis was employed also to establish confirmability or
neutrality as described by Sandelowski (1989). This served to root the findings in the
informants' responses or data collected rather than the researcher's bias.
Another indicator of credibility of the findings comes from the informed clinical
community, those clinicians who understand the phenomena because of their experience
with it. This grounded theory account of BRCA mutation carriers and their testing and
risk management experiences was presented to clinical experts and to other professional
audiences.
Dependability and confirmability were also established by leaving an audit trail.
Detailed recording of all research activities were accomplished. Guba and Lincoln (1995)
recommend that both data and interpretations be traceable to their sources. Written
records of observations, directions, and analysis were kept by memoing, using code
notes, and observational, methodological, and theoretical notes. These written records
were stored and managed with the NVIVO software program.
Summary
This chapter has reviewed the research method and specific strategies which were
used to examine the BRCA genetic testing and risk management experiences of
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unaffected BRCA carriers. To summarize, grounded theory was chosen because of its
focus on meaning defined through interaction, its sensitivity to the unfolding nature of
events (processes), and its ability to generate middle range nursing theory. By studying
the complexities and variations of human social interaction, a better understanding of the
social processes surrounding the phenomenon of BRCA genetic testing and risk
management can be attained. The next chapters present the substantive theory derived in
this study through the use of the analytic techniques described.
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CHAPTER IV
FINDINGS - PART 1
The next two chapters present the grounded theory from analyzing interviews of
30 women who participated in this study. The substantive theory that emerged centers on
BRCA testing and risk management by unaffected women with positive and VUS BRCA
mutations. After careful questioning of these women and analysis of their responses,
managing susceptibility to hereditary breast and ovarian cancer emerged as the basic
social process of genetic testing and risk management for these women. Managing
susceptibility is embodied in the proactive stance these women assumed in obtaining
BRCA genetic testing and responding to prevent or mitigate the impact of breast and/or
ovarian cancer on their lives. Susceptibility is viewed as emic (internal) and defined by
the participants' belief that they are highly likely to develop breast and/or ovarian cancer
in the future. They also perceive they have some control to prevent the devastating effects
of these cancers. Figure 1 illustrates the categories and their relationship to Managing
Susceptibility to Hereditary Breast and Ovarian Cancer. The components of the process,
managing susceptibility, were fivefold: (a) gaining awareness, (b) confronting uncertainty
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Figure 1. Managing Susceptibility to Hereditary Breast and Ovarian Cancer: A theoretical model of
the process of BRCA genetic testing and risk management
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and getting tested, (c) disclosing results, (d) making risk management decisions, and (e)
reflecting on actions. Although the categories overlap and intersect, for descriptive
purposes they are delineated separately. Each category explains the actions/interactions
and consequences inherent in the process of managing susceptibility by women who are
unaffected BRCA positive and VUS mutation carriers. Hereafter the two groups are
referred to collectively as mutation carriers. Figure 2 delineates the categories,
actions/interactions, and consequences of Managing Susceptibility to Hereditary Breast
and Ovarian Cancer. This figure is presented on two pages only for readability purposes.
No explicit comparison is made between the positive and VUS BRCA groups except
where there are obvious differences.
These categories will be described in more detail, looking at the subcategories in
each to formulate a grounded theory.
Overview
Gaining awareness was the antecedent to all subsequent action in the process of
managing susceptibility for unaffected women mutation carriers. Whether these women
became aware of their risk for hereditary breast and ovarian cancer (HBOC) as a child or
adult, this awareness left them fearful, feeling vulnerable, and with a sense they were
"playing a waiting game" for breast or ovarian cancer, which would eventually be their
fate. After obtaining additional information from a family event, a health care provider,
or the media, they decided to get BRCA testing to further clarify their risk and reduce the
uncertainty.
Confronting uncertainty and getting tested was characterized by seeking further
clarification of their family cancer history and overcoming professional, insurance, and
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Categories
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Confronting
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Family
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Media
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Health care
•

Seeking clarification of family
history
Overcoming barriers
Health insurance
•
Bureaucratic
•
Professional
•
Speculating about test results
Developing theories
•
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test results
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•
Going it alone
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By way of phone
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Consequences
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worry
Feeling vulnerable

Testing brought to foreground
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•
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•
confusion about risk
Render positive or
•
negative
Range of emotions:
relief, acceptance,
•
empowered
shocked,
•
overwhelmed,
distressed, more
vulnerable

Figure 2. Representation of the first two steps in the process of Managing Susceptibility
to Hereditary Breast and Ovarian Cancer. The process is continued on the next page.
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o Personal
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Figure 2. (Continued) Representation of the last three steps in the process of Managing
Susceptibility to Hereditary Breast and Ovarian Cancer. The process is continued from
the previous page.
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bureaucratic barriers in the health care system. While waiting for their test results they
developed theories about why they would or would not be positive. Influenced by this
anticipation of results, when they received their results, they described a range of
emotional reactions; from relief, acceptance, and feeling empowered to shocked,
overwhelmed, distressed due to confusion and the frustration of uncertainty, and feeling
vulnerable. The finality of their result, questions about management, questions from
family and friends, and the prospect of lifelong surveillance were overwhelming. In
dealing with these feelings, participants disclosed their genetic information to others for
support and to fulfill their social obligations.
Using the words of these women to portray this integrated theory, the following
sections elucidate the first parts of the trajectory of managing susceptibility in women
BRCA mutation carriers. Although these categories and subcategories are presented in
this order, some may be overlapping or intersecting, and should not be construed as
mutually exclusive. Their experience begins with gaining awareness.
Gaining Awareness

Gaining awareness describes the process of these women as they discovered
BRCA genetic testing. This category consists of two subcategories (a) making the
connections and (b) responding to "get tested" messages.
Making the Connections
Childhood awareness. Most participants grew up knowing about the breast or

ovarian cancer in their family, which left them feeling "cursed," "fearful", or "at a higher
risk" than many of their friends. This awareness and the resulting sense of "fate", waiting
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for the breast or ovarian cancer to occur, were the driving forces that brought them to
BRCA testing, as these participants recounted:
Feeling cursed. 32 years, BRCA 2. I grew up afraid of getting breast cancer
because of my mother and her mother.... I sort of had it in the back of my mind
and I was probably somewhat in denial about it and didn't really know what to do
because it seemed like fate. Like one day I was going to get cancer and there
wasn't a whole lot I could do about it.. .. And I decided that I needed to do
something. I couldn't just live with this thing hanging over my head and feeling
cursed.
Fear -a waiting game. A 32 year old mother with a genetic VUS .... I've got so
many horror stories with my mother (breast cancer), and .. .I just knew especially
since my cousin got it (breast cancer), it's kind oflike a waiting game ... When is
it coming? So ... the fear that you live with every day unfortunately.
Feeling at higher risk. 22 year old, BRCA 2. I think it goes back to ... right after
my mother died, I started hearing more about a lot of her first cousins being
diagnosed or dying of breast cancer. And at that time I kind of thought .. .it's in
the family. I didn't really understand what the connection was, but I knew I was at
a higher risk than many of my friends.
Adult awareness. For the seven participants without an affected mother, who did
not grow up with the same fear and sense of vulnerability, a daughter's or sister's cancer,
or father's test results brought them as an adult to awareness of their risk. Most of the
time this lack of awareness of their breast or ovarian cancer risk occurred when the
cancer came from the paternal side of the family or there was a death or divorce which
caused the family to lose touch with the affected family members.
One 27 years old with a positive BRCA mutation had testing shortly after her
sister was diagnosed with breast cancer. Neither of her parents had cancer. They
subsequently found that her father carried the BRCA mutation and all five of her siblings
had the mutation. "So when this (breast cancer) happened with (my sister), it was kind of
an awakening." Another, a 30 years old whose father tested positive but did not share the
results openly with his children, recounted:
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It was really my mom that pushed me to do it (BRCA testing), and I started to
learn a little bit more about the family history, about my dad's half sibling that
had died of ovarian cancer. So that started to get me a little more paranoid about
wanting to get tested.
Another BRCA positive participant, a 51 years old mother, was shocked when her
daughter was diagnosed with breast cancer at 28 years and tested positive for both
BRCAl and BRCA2 mutations. This mother never knew her father, as he had left when
she was a year old, and later died of alcoholism. She explained that she was not aware
that breast cancer could be transmitted by her father :
And you know, it was kind of a shock because before (my daughter) was tested, I
really never thought there was family history of breast cancer, because I knew no
family history on my side. And I guess I had that fallacy that breast cancer only
came from the mom's side of the family. And I knew there was no cancer on my
mom's side. So there was kind of disbelief when she (daughter) came back
carrying both of the mutations.
Responding to "Get Tested" Messages
With an awareness of their increased risk of breast or ovarian cancer, participants
received messages from various sources, including (a) family, (b) media, and (c) health
care providers, which stimulated their interest in BRCA testing. Reasons given for
seeking BRCA testing included clarifying their susceptibility to breast and/or ovarian
cancer, to learn about offsprings' and other family members' risks, and to do something
which would reduce their risk for breast and/or ovarian cancer.
Family event. Sixty two percent (13) of the BRCA positive participants sought
BRCA testing after notification of a mutation in the family. Two with variants of
uncertain significances tested because a variant was identified in the family. These
participants were encouraged by their family: mother, father, daughter, or siblings to have
BRCA testing. A motivation for the testing was to receive information that they could
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use, but also, could be shared with other family members. As this 25 year old participant
described, her mother's testing had been done for her aunts:
After chemo and everything, her sisters ... because they're both younger and they
have all girls .... they were really pushing her to get tested .... They both were of
the age when my mother was diagnosed with breast cancer, so they wanted to
know for themselves.
For a 22 year old whose mother died of breast cancer, it was a cousin's diagnosis
of a BRCA mutation and her stepmother's diagnosis of breast cancer when she was 18
years, which provided the tipping point for her to confront her father about her family
history of breast cancer. She recounted how her father initially concealed her family
history due to her age, but her awareness and desire for openness influenced him to share
her family's breast cancer history. Her father's influence led to her testing as she detailed:
Right after my mother died, I started hearing more about a lot of her first cousins
being diagnosed or dying of breast cancer .... When I was eighteen my stepmother
was diagnosed with breast cancer. So I kind of had a flashback of everything. My
dad started to freak out and it was about at the same time that my dad received
information from one of my mother's first cousins in regards to this testing
(BRCA positive). And he didn't really talk to me about it. I kind of knew that it
was there but he thought that I was too young to deal with it. I believe I was
eighteen or nineteen ... But eventually I got to the point where I told him, "You
know I know that this is going on. I'd rather that you be honest with me with the
information that you have rather than feel like this is something that you need to
hide from me". So he at that point, opened up. Showed me the whole family
lineage. Showed me some of the things that I was facing .... Told me that he
wanted me to get tested.... So a few years later my dad .. .it wasn't serious
pressure, but I knew that he wanted (me) to get it done .... So I just said, "All right
Dad. I'm going to go and I'm going to get it done and we're gonna find out
what's going on and we're gonna deal with it."
For others, it was the combination of breast and ovarian cancer that motivated
them to get the testing, as this participant related:
I guess when my mom got ovarian cancer (after having breast cancer) and
somebody said, well you know, there's a link with ovarian cancer and breast
cancer, and the BRCA gene, and I started learning about that. That's when we
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figured, well, we really should get tested. If anybody's got a family history, it
surely does look like we do.
Media. The media was also a source of messages about BRCA testing for women

who perceived themselves as high risk. A 29 year old mother with a genetic VUS,
described how she gained awareness about BRCA testing by reading an article in a
women's magazine. She started accumulating information and prepared by getting her
insurance in order, as she explained:
After she (mother) died, ... I was reading a women's magazine, and it was the
story of two sisters. And she had done a diary ... (about) getting (BRCA) tested.
And she explained that if you have these particular newly discovered cancer
genes, that they're separate. There are sporadic cancers that everybody else gets,
or could get .... And then there's a gene, cancer gene where no environmental
factor, no health factor, nothing can really stop it, prevent it type of thing, if you
have this gene. And she and her sister were tested, and how she really didn't want
to believe it at first, but then her sister was diagnosed with cancer around 38. And
how she went through with the prophylactic mastectomy, and her sister as well,
... and that she was going to have her ovaries removed next, and all of this. And
when I read it, ... my mom died about the year 2000. I put it away in a file that I
labeled research, and I just began to gather more articles and more information, if
I came upon anything on the latest screening or the latest this or that, always with
the intentions of being tested one day when I had constant insurance.
Healthcare Professional. Sixteen percent (5) of the participants received

messages about BRCA genetic testing from a health care professional; their gynecologist,
breast specialist, primary care or other physicians based on their family history. As these
two participants reported, they found out during their annual check up and follow-up after
a needle biopsy, respectively:
I went for my yearly checkup. And I have a new doctor, and she's younger. And
she said, "(name) have you ever thought about genetic testing?" And I didn't
realize that genetic testing was happening. I mean, I've heard about it, but I didn't
realize that was an option for people living in (state/province). And my GP told
me about the genetics clinic and made a referral.
And I believe it was in meeting with her (breast cancer specialist) about needle
biopsy stuff because that happened not too long after my mom passed away .... it
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was in meeting with her that she said I might want to consider doing it (BRCA
testing).
Another participant who had considered participating in a university BRCA
research study thought initially there was no reason to test because she was doing all she
could do using surveillance. As she recounted, her physician and breast specialist
informed her of mastectomy as an option to prevent breast cancer and this provided the
stimulus for testing:
The University (name) .... They were doing a study on Ashkenazi Jews .... I
contacted them and decided at that time not to test. Because I had already been
doing every type of surveillance that I thought I could do and there was no reason
for me to test. ... After my mother died, my medical doctor ... said, "This is very,
very harsh, but I think the only thing that you can do to almost guarantee is the
mastectomy". And I was ... appalled. I went back to my breast specialist who then
talked to me about statistics and mastectomy and testing .... She kept telling me to
test. That there is ... that next step. And her concern was ... the cancer in my
family .. .it wasn't they got cured and lived. It was ... they were non-survivors.
In summary, this first category sets the stage and begins the managing
susceptibility process, which participants continued throughout their BRCA testing
experience. Whether awareness was gained in childhood or as an adult, participants
viewed their risk of breast and ovarian cancer as a looming, inevitable threat. Reasons for
seeking BRCA testing included clarifying their risk for breast and/or ovarian cancer, to
learn about offsprings' and other family members' risks, and to do something which
would reduce their risk of developing breast and/or ovarian cancer. Participants received
messages to get tested from family events, media, and/or health care providers. Viewing
this as an opportunity to reduce uncertainty about their risk, they proceed to getting
tested.
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Confronting Uncertainty And Getting Tested
Once participants had additional information from the media or confirmation of a
higher risk status from family mutation results or health care professionals, they
confronted their fear and decided to get tested. Hope of reducing the threat of developing
breast and/or ovarian cancer and to reduce uncertainty about their risk were the main
motivators for BRCA testing. As this participant explained, testing provided the
knowledge to empower her to manage her risk:
As soon as I found out that there was a gene in the family and that it was testable,
I knew I needed to know. It was ... for me the decision to test was not a hard one.
It was the decisions afterwards that were hard. To me knowledge is power. I know
it's a trite phrase but it's ... not trite .... !just didn't want to not know and be
speculating about what my risks were. I thought if there was information out there
that could make it clear to me whether I was or was not at high risk, I wanted to
know that.
Participants described four steps in the process of getting BRCA tested (a)
seeking clarification of their family cancer history, (b) overcoming professional,
insurance, and bureaucratic barriers, (c) speculating on test results, and (d) obtaining and
making sense of test results.
Seeking Clarification OfFamily Cancer History
Those participants with a known BRCA family mutation came to the BRCA
testing process with a good history of their family's breast or ovarian cancer, because it
had been worked out previously by a mother, father, sister, aunt, or cousin. However,
those first in the family to be tested, that self-referred or were referred by a physician,
often needed to obtain more information from family members to determine specifics of
their family cancer history. As one related, "That's when I started contacting relatives
and trying to put together a family tree". Sometimes this included contacting those
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estranged from the family. One participant described how she overcame "awkward"
family dynamics, those who were "emotionally distant", and feelings of guilt to obtain
the family cancer history that she characterized as "not polite conversation":
It was all this kind of vague, like well there's a lot of cancer in my family, was
about how I could sum it up. And it forced me to make contact with people who I
hadn't been in contact with in a long time and do research and actually talk to my
father about some of this stuff.... Then they all suddenly died after I'd been out of
touch with them for seven or eight years, and I had all these feelings of guilt and
just weirdness .... So it was just ... getting in touch with ... trying to find people to
contact in the first place .... But it was just ... awkward stuff to talk about. To call
up people you haven't talked to in ten years and say, "So I want to know what
kind of cancer he had". And it doesn't do to just say, "Oh, he had cancer." I
needed to find someone to tell me where this cancer was and that kind of thing. "I
need ... do you have an autopsy report?" Like just these things that aren't polite
conversation, especially with people who you've grown away from and who
might perceive you as having kind of ignored them and blown them off for many
years. So it's mostly family dynamics stuff was awkward.
Overcoming Barriers
Some participants encountered external barriers that had to be overcome before
obtaining genetic testing. These included health insurance, professional, and
organizational/bureaucratic barriers.
Health insurance. Because of the cost of genetic testing (comprehensive test
$2950, multi site (3) $450, and single site $350) some participants had to get their health
insurance in place before they could pursue testing. As one noted, "Once we got under
this health insurance, then I went ahead and began to pursue talking to my new primary
doctor about this (BRCA testing)". Seventeen (57%) participants had insurance and used
it to cover BRCA testing. Eight (27%) chose not to use their health insurance to cover
testing for confidentiality reasons and paid out-of-pocket. Four (13%) had testing in a
research sponsored program and Myriad Genetics paid for the testing of one (3%)
participant with insufficient funds.
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Despite having health insurance, two participants encountered problems getting
their health insurer to pay for BRCA testing or surgeries. It was their assertiveness,
perseverance, and Medicare changes regarding BRCA testing that helped them to win in
the end. As these participants recounted:
They (insurance company) fought quite a bit and I fought back and I appealed it
and they said, "We're not paying." And even after I did it they said they would
pay and then they started, "It's done in a specialized lab." and they said, "This lab
is not under our insurance." But I said, "This is the only one in the country that
does it, you know, I took the blood here at (name), which is your clinic. But they
have to send it. What can I do? They don't do it here" and, yeah, it was a big thing
with them .... at some point, somebody would have probably given up, but I
didn't. ... I woulda probably paid it from my money but I just felt ... that you
should do it. This is part of the testing that I should have.
(I) put off testing for 3-4 years due to insurance not paying. When I went to have
the genetic testing, they told me they did not cover it, period, flat out. And that's
one of the reasons I actually put off testing for probably three or four years,
because I knew it was going to cost two or three thousand dollars. And then after
my mother moved here ... about a year and a half ago, we found out Medicare
would cover her testing. I'm like, "let's you go ahead and do that, because that's
covered. Then that will tell us ... where we want to go from there".
Bureaucratic. Another participant described "bureaucratic run-around" and
"roadblocks" to testing created by her physician that caused her to delay testing until she
moved:
I began to approach ... the idea of testing with him (OB-GYN physician), given
my family history .... So I started approaching this and he said that it would be
very difficult to get genetic testing, and I think that he probably thought that I was
cancer-phobic at that point,just because of the family history. And he
recommended that in order for me to get testing, I would have to cull my
grandmother's records, my mother's records, I would have to get letters from their
physicians, I would have to see a psychiatrist and the psychiatrist would have to
say that it was in my best mental interest to have this test. I mean, it was
incredible. And I thought that he was throwing roadblocks in my way on purpose,
just giving me the bureaucratic run-around and fortunately, after that we moved to
(city where the testing was easier to obtain).
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Professional. Others encountered professional barriers, such as a physician who

had not heard of BRCA testing, as this participant who inquired about testing in 2004
reported:
She (primary care physician) had never heard of it (BRCA testing) in her life -kind of scary when the doctor hasn't heard of what you're talking about, and she
directed me to call my insurance company... directly, which I did .... Finally I got
in touch with a woman within the health insurance who did know and said that
yes, they set up counseling and testing.
Speculating About Test Results

After clarifying their family cancer history and overcoming barriers to testing,
participants who met their genetic counselor's or physician's criterion for high risk, had
their blood drawn for testing. While awaiting their BRCA test results to come back from
the lab, 23 (76%) participants speculated about what their results would be. Of those
speculating, 17 (74%) thought they would be positive, 5 (22%) thought they would be
negative, and 1 (4%) thought she would get VUS results. Participants developed theories
about why they thought they would or would not be positive, such as (a) physical
characteristics, (b) age, (c) family history, (d) luck or chance, and (e) degree of fear. By
speculating about their results in advance, some participants were able to rehearse what it
would be like as a BRCA mutation carrier and considered how they would manage their
susceptibility.
Physical characteristics. As one participant who speculated she would be positive

(and was) reported, "Since the day my sister got sick (breast cancer), I've always known
it (my risk) was high. Yes. I figured I had it (the BRCA mutation)". When asked why,
she responded, "Nothing concrete... I look like my sister, I'm built like my sister. It just
seemed like genetics would carry through". In contrast, one who anticipated she would
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not be positive like her sister, explained, "My sister and I, we're just so different in
character and the way we look and everything. So this was going to be in common? It just
didn't make sense."
Age. For a 46 year old participant who thought she would be negative, age was
the reason, she "had passed the age in which my sisters developed their cancer."
Family history. Others thought they would be positive because of their family
history: "And just because of my family history, I've always suspected some type of
genetic relationship." Another elucidated, "There was no doubt in my mind I'd be
positive. My family history. Too many young women (with breast and ovarian cancer)."
Chance. A 27 year old speculated she would be positive because all 5 of her
brothers and sisters were positive. She explained she would probably get retested if she
got a negative result:
I would have been very, very, very surprised and probably would have got
retested or I don't even know if I would have ever been okay with the fact that I
wasn't positive, because I just would have been so surprised.
By way of contrast, a 54 year old who did not understand at that time how BRCA genetic
mutations are inherited, speculated she would be negative because she thought there was
little chance that "two sisters in the same family would come up with the mutation."
Degree offear. A 52 year old with a positive mutation speculated she would be
positive due to her closeness to her mother's death and her fear, " ... I just had this gut
feeling that I had the mutation. Because when our mother died ... I'm the one that kind of
watched all of this. So I'm the one that had more fear." A 47 year old with a positive
mutation who speculated she would be positive described "a sense of doom" and felt she
would not live past 50 because her mother didn't.
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For those who did not speculate on results, one explains simply that she just
didn't have a feeling one way or the other:
Until the moment she (genetic counselor) told me, I continued to think it was a
flip of a coin. It could go either way. I hoped it would be negative, and I knew it
could be positive. No, I never had any kind of feeling that I knew what it was
going to be.
Obtaining and Making Sense of Test Results

About three to four weeks after testing, participants obtained their test results
either in person or over the phone from their genetic counselor, physician, or geneticist.
Some figured out their results before their genetic counselor or physician explained it.
They figured out intuitively, based on the presence of certain people in the room when
the BRCA test results were disclosed, and from inconsistencies in the way family
members who tested together were given their results, as these participants related:
I got a phone call and they ... said, "We need to change your appointment." And I
thought, "Hmm, that's kind of bizarre." And so my husband came with me and ...
we were waiting .... The nurse said to me before we got into the room, "Do you
mind if so-and-so observes because ... (name of new genetic counselor) will be
taking over (current genetic counselor)'s spot when (she) has her baby." And I
said, "Sure." So we walked in and this woman that I'd never met before comes to
shake my hand. And I looked at her and I said, "Oh you must be (name). And she
said, "No, I'm (name). I'm a psychologist." And I looked at her and I said, "Oh,
I'm positive. I know ... my test results. I know I'm positive". And I thought,
"Why else would they have this psychologist there?" And that was probably, I
assume, why they postponed the appointment. Cause the psychologist couldn't
make it at the original time. So we sat down and I said, "Look, just tell me, is it
good or bad? I don't want any extra information .... Don't ... be setting the stage.
Just give it to me straight." And she said, "It's bad." And so ... my intuition was
confirmed.
I think what happened ... the genetic counselor who did our testing, forgot that we
were sisters. So when (sister)'s negative results came in, she (genetic counselor)
was so excited she told (her) ... So when I didn't get my phone call, I knew.... she
did call me and say that ... she wanted to see me. But I knew. And I said to her at
that point when she called me, "I know that I'm positive."
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Yet another participant knew when her pregnant genetic counselor came off maternity
leave to give her the results:
I went in sort of knowing that ... it was positive. I know (genetic counselor)
didn't intend for it to be. She was on maternity leave ... And when it came back
... (genetic counselor) wanted to come to meet with me and I said, ''Nobody
comes from maternity leave to give me a negative answer. This must be positive."
.. .I mean, I sort of figured one plus one.... I asked her, "Why did you come?" ...
She was so wonderful. She said, "I started this with you. I want to also talk with
you ... after the positive result."
Before receiving their test results from their genetic counselor or physician,
participants made the decision to get their result in person or on the phone, and if in
person, to go accompanied, or alone.
Going accompanied. Sixteen women (53%) had a family member (sister, father,
husband/partner) or close friend accompany them when they obtained their results. A
family member/partner's emotional support was very important at this time as this
participant recounted, "My husband, he also was surprised and very supportive and has
been, when I kinda crumbled a bit there hearing the positive results". Another example of
a husband's support and what it meant is described in the following quote:
And my sister and I went in together. And also, ... I just knew I needed to have
(my husband) there. And my sister didn't have a husband there. And I think, "Oh,
gosh, thank goodness she was negative." Because I'm just so thankful that
(name), my husband, was there to kind of go through that with me as well,
because he got an opportunity to talk to the genetic counselor, as well as talk to
the geneticist. And I mean, it was a huge shock. ... I'll never forget her first line ...
And she just said that, "Your results are different" .... And she looked at me and
said, "(participant name), you do." And my husband and I just kind of clung to
each other and cried. [voice breaking] .... It very much felt like a cancer
diagnosis. I had to really remind myself that I don't have cancer. ...
Going it alone. Eleven (37%) of the participants were unaccompanied when they
received their results and three (10%) received their results over the phone. One
participant, whose husband was in a foreign country on business when she got her
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positive results, explained that being alone was not problematic because she liked being
self-reliant and relying on her inner strength:
Another participant expressed a similar self reliance: So, I was there on my own.
But I liked that. I like getting my inner strength going .... sometimes when you're
together you sort of rely on people, and although we have, I mean, we're together
more than probably twenty-five years, but I don't know ... there's some things
you have to feel and do on your own, so I was sort of, I don't know if happy, but
it was fine for me, him not being here.
I'm not a real emotional person. I don't get real stressed out, so I wasn't worried
and felt like I needed support, like I think some people might ... even if she says
there is a problem, I'm pretty level-headed. We'll just deal with it, so I didn't take
support or anything and I just went to talk to her (genetic counselor).
By way ofphone. Those who received their results by phone had mixed reactions.

One participant described it as "horrible". But when asked if she would choose to receive
her results on the phone again she replied, "Yeah.... because driving over there would be
just dragging it out." She explains her phone experience:
Oh, she phoned me with them. I believe we agreed ahead of time that she could
phone us with them. It was horrible. I was getting ready to take the kids to school
and we were rushing out the door and the phone rang. And it was just ... very
overwhelming.
Another would prefer to talk with a counselor in-person, but it was the circumstances at
the time and her desire to know that took precedence:
So I couldn't go in (to the clinic). I was going to be at (place of worship) all day,
and there was no way that I was making it in there, so it was either receiving the
results on the phone or not receiving them at all until the following week. I
wanted to know. So given the situation, yeah, I would do the same thing again,
but if I had the ability to talk to someone face to face, I definitely would do that.
This participant recalls how she received her results in her car on her cell phone.
This reminds us that timing and safety are important considerations. She related her
experience:
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I was in my car driving and I got the phone call. And she (physician) ... just was
very, very like dramatic and almost like to the point where it was humorous a
little bit. And she ... got on the phone, ... "you're going to be okay, you need to be
sitting down", and ... she told me that if I was driving, I really should pull over
and maybe it wasn't a good time to talk .... at first I was kind of was like, "Okay,
here we go, I definitely am positive." ... I did pull over because she kind of ...
forced me .... And she just said, "I'm calling to let you know that you're positive;
your test results came back".
Reactions to positive test result. Participants receiving positive BRCA test results
described a range of emotional reactions: from relief, acceptance, and feeling
empowered, to shocked, overwhelmed, distressed due to confusion and uncertainty, and
feeling vulnerable.
Like several of the other positive carriers, these three women with positive
mutation results described how having the positive result gave them a sense of"relief',
"it was an absolute gift to know", as they had more certainty about their risk, and it
empowered them to do something about it now:
Almost relieved. 32 year old. In a way, I was almost relieved to get a positive
result because it was ... I knew that having no specific mutation to test for, if I got
negative results I'd be in the same boat I'd been in all along. And I wouldn't
know if there was an unknown mutation that I had or if there had been something
that my mother had had that I had managed to not get or what was going on. So in
a way it was almost a relief to get some solid information about where my risk
was coming from and what I could do about it.
35 year old. And part of me almost hoped they were positive, because then .I could
get the surgery and not have to worry about anything anymore. Even if my results
were negative, I still would have felt that I was significantly at increased risk over
an average woman.
Empowered. I had to really remind myself that I don't have cancer. So there was
that. I had to also balance it with I do feel it was an absolute gift to know. And
that's how my husband feels as well. Because we can do something about it. I
don't have to die of cancer like my mom and my sister did.
Others were "shocked" and felt vulnerable. This 45 year old participant who
thought her test results would be negative explained feeling shocked:
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And so when I got my results back .. .I kind of didn't think I was gonna be
positive. I really thought it would be negative .... I remember my breath skipped,
.. .I just kinda went (gasps). It just took my breath away. I was just so shocked and
I cried a little bit right there in the office.
Another a 41 year old who though she would be negative reported feeling
shocked and overwhelmed. She described a delayed response to her positive test results
and feeling "lost", "scared", and "angry", like working through the stages of grief:
The impact of the test results didn't hit 'til three days later. I was just, like, in
shock. And I was on autopilot. I think I asked all the appropriate questions. I
remember at that key meeting, that I was there with my husband, I finally had to
say enough. I don't think I can take any more information .... And they very
quickly respected that and said, "Ok".... That was real helpful, but when you're
first told that, especially like me ... convinced that I did not have it (BRCA
mutation) .... And it just turned my life upside down. And I can remember so
clearly watching a movie with my family three nights later .... It hit me so hard ...
that feeling ... I just had to leave the room, because it just all hit me then. Lost.
Feeling really scared .... There's a point later where you just get angry, pissed off
type .... And I think you're working through it like you do the death process. Go
through those stages of grief.
For some, testing increased their sense of vulnerability. It provided an awareness
that not only was their high risk of breast cancer confirmed, but the mutation conferred a
high risk for ovarian cancer as well. This 32 year old participant described her
"insidious" new worry:
However, it was also a big eye-opener.... I had no idea about the ovarian cancer
link. That's something I'd never worried about.... And so suddenly I had this
whole new sort of insidious cancer to worry about, even more so than breast
cancer.
Reactions to variant of uncertain significance results. Among the nine

participants with genetic VUSs, their interpretations and responses to their BRCA test
results were very different. Some rendered the results problematic, like a positive result,
and some did not. Some accepted the limitations of this test and said they had been
prepared for the outcome. Others were disappointed due to their uncertain position with
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regard to the magnitude of their risks of developing cancer and risk management. For
clarification, in all cases, the BRCA test results documentation provided by participants
indicated a "variant of uncertain significance". Some had sought follow-up with Myriad
Genetics, but none of the VUSs had been reclassified as deleterious mutations.
Rendering it positive. Some participants with BRCA VUSs were quite distressed
by their results, because instead of the certainty they were looking for with this additional
genetic information, they were left in a state of confusion. The hard part was "not having
a definite answer". Some felt that even though they were not positive for the BRCA
mutation, they would still get breast cancer, as one reported below:
There was no question or not whether I would get it (breast cancer). And honestly,
I still feel that way. I know I don't have that mutation, but also they haven't
found, you know they know that there's another spot in that DNA, it has to be in.
One 34 year old, who was aware that a VUS result was a possibility during BRCA
testing, expressed her confusion, frustration, and hopes for scientific advances "before it
becomes an issue" for her. Although her genetic counselor "tried to emphasize the fact
that ... it did not equal a yes result" she construed that it did equal a positive result, that
way she would remain vigilant as she explained:
I was confused by the test results .... But I hate the fact that I don't know anything
else more than I did before I went and did the whole thing. Very frustrating. So I
think I'm just hoping that science will catch up with it before it becomes an issue
for me, which I don't know if it's a realistic hope .... I have decided ... not to
torture myself mentally, but that the healthiest interpretation that I can adopt is to
go ahead and equate the variant as a yes, you tested positive for this gene
essentially, so that I can do everything that I can and not slough off.
Although five (56%) participants with BRCA VUSs interpreted their results as
positive, despite the fact they had been counseled that the results were uncertain, some
explained that their physician had rendered the VUS problematic and "considered it
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positive". A 29 year old, who did not have genetic counseling prior to testing in a primary
care setting, and was not aware that her test result could be a variant of uncertain
significance, explained her confusion and how her physician rendered her VUS result
positive:
So now the results are back. He (the oncologist) looked at me and looked at the
chart and said, BRCA 1, nothing is detected. However, unfortunately I remember
specifically him using the word ''unfortunately on BRCA 2, there is a variation" -and that's the first I heard of that word, 'variant of uncertain significance'. He
said there is basically something different about that gene in my DNA panels.
And he gave me ... a little leaflet they had that said, "What does variant of
uncertain significance mean?" .... And I let him know that I still didn't understand
what he's telling me ... that this is not positive, but it's not like my BRCA 1,
where there's nothing detected. There's something, but yet it's not significant.
And he said that based on my family history and this coming back the way it was,
he considered it like a positive result. He really felt like now let's proceed
forward. He asked me who my gynecologist was and that he was sending my
results to the gynecologist and wrote a note on my chart about the oophorectomy
consult .... But it's changed everything, because the test result isn't clear. So it's
changed my life in the sense of without that clear result, I really feel confused a
lot more than I think I would have with the positive result.
Negative rendering. Four (44%) with BRCA variants of uncertain significance did
not interpret their results as positive and rendered their results less problematic. These
participants explained their interpretations and reactions:
57 years old. It didn't bother me at all to be honest. Finding out I had it (variant of
uncertain significance), I'm a realist .... So finding out that my body may have a
flaw is likely, not unlikely .... And I told my husband.... It didn't phase either one
ofus that much. I wish I would have had more. I tried to find out... I wouldn't
have reacted like my sister. I know that. When she found out she was just really
frightened, and maybe because I was older when I found out that I had it, I'm not
sure or maybe it's just we are different personalities. It just didn't phase me one
way or the other.
49 years old. Only I guess surprised that they found a variant, but then "We
haven't seen it before", they said, "and we don't know". So it's kind oflike wait
and see. So it's been five years and I had a doctor fax over the report and checked
with the lab a year ago ... , and so far they have no further knowledge if that causes
cancer or not .... I was fine with it. Just taking care of yourself, I guess, regular
checkups and always being aware that you have a history ... that I'll be fine.
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She (genetic counselor) explained to me that it was really not a result that we
could determine whether there was additional risk or not because it was, what did
she call it? "Undetermined ... that there was some variation but it wasn't the
typical variation that we see with increased breast cancer risk", so I thought,
"Okay. so what do we do now?" There really isn't much that you can do based on
that.
In summary, getting tested encompassed seeking clarification of their family
cancer history and overcoming such external barriers as health insurance, professional,
and bureaucratic obstacles. In preparing for their test results, participants speculated
based on theories they developed about whether their BRCA results would be positive,
negative, or inconclusive. Influenced by this anticipation and rehearsal of results, when
they received their results they experienced a range of emotional reactions: from relief,
acceptance, and feeling empowered to shocked, overwhelmed, distressed due to
confusion and the frustration of uncertainty, and feeling vulnerable. In dealing with these
feelings, participants disclosed their genetic information to others seeking support and
fulfilling family obligations. The next chapter will explore this disclosure ofBRCA test
results and how they made risk management decisions.
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CHAPTERV
FINDINGS - PART 11
This chapter will focus on those components of managing susceptibility to
hereditary breast and ovarian cancer that come after BRCA testing. These last three
components are (a) disclosing results, (b) deliberating and making risk management
decisions, and (c) reflecting on actions.
Disclosing Results
Seeking Support Through Disclosure

Shortly after receiving their BRCA test results, participants embraced the hard
part, the feelings of "fear," "sadness", and "shock", which brought the possibly of getting
breast and/or ovarian cancer to the foreground, as these women recounted:
And I was like, "Well, I'm a mutant. It's true. It's real .... " And it probably wasn't
for a few days until I sort of, I guess embraced or dealt with the hard part. The
sort of fear and the sadness. It's like ... I have this thing that could give me cancer
and I really don't want cancer.
It ... all hit me like a ton of bricks. It's like, "Oh my God, what am I gonna do?"
... and then that's when I just, I had this sense of urgency. I mean ... there will
come a point where you just feel like a time bomb .... you're sort of shocky at first
and you don't even realize the magnitude of it all immediately. I don't think that
you can.
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The finality of it, cost of testing, questions about management, time absent from work,
what they should tell their children, questions from family and friends, and the prospect
of lifelong surveillance was overwhelming. Questions about the future were on their
minds, as this 41 year old participant related:
... and then your thoughts just race, you know, what does this mean? ... for my
daughters? ...for my husband? ... for me? What is it? Who do I tell? Who do I not
tell, like I don't know, just a mishmash of things.
In dealing with these feelings, participants disclosed their BRCA test results to
others seeking "support" from family, friends, and peers. As one participant explained,
"Someone's gotta be in your comer to sort of have that little lifeline, at least for that first
week or two." They also selectively shared their BRCA test results to inform others so
"they could take action" or "be more aware".
Seeking support. Participants of all ages disclosed their test results to their
husband or partner, close family members, and closest friends. Later on they selectively
disclosed to extended family and a few disclosed it to employers, if they were planning
surgery and would need time off from work. As this 25 year old single participant related,
"The day I found out, my three closest friends, I really surrounded myself with them ...
they were very supportive." She further explained how she selectively disclosed her test
information to immediate family and friends and her mother told extended family:
When I told my father - I might have told him the next day or a couple of days
later. I told him in person. I told my stepsister ... I think in person, maybe on the
phone. I told her a few days later. I didn't tell my stepbrother; we're not really
close. My mother told my family. Well, we didn't tell my grandmother. But my
mother told her sisters, and I guess my stepfather told his family. I really only told
my immediate family and my friends.
In a deliberate and thoughtful manner, they disclosed the information to
remaining family and friends in person, by phone, sent letters, and some found electronic
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mail (e-mail) useful to relay the same information to several people simultaneously. One
sought the assistance of a genetic counselor to help draft a letter for extended family that
did not live close by. Another with a genetic variant of uncertain significance (VUS),
explained a carefully considered strategy of first alerting her aunts of a possible HBOC
risk by letting them know she was having the BRCA testing done. She then looked for an
opportunity within the normal processes of her family life, a Thanksgiving family
gathering, when she felt they were prepared:
Yeah, it was a family meeting of my mother's sisters. A lot of them knew that I
was going to have the test .... And they all knew that I was coming for
Thanksgiving, so when we went home after dinner, we were sitting around
talking, and I said, ... "Well, why don't we talk about this now?" because the
children were outside playing, and it was a good time. So we just talked and I told
them, "You know I had the test and this is what my results were." Told them what
it meant or as far as I understood it meant, what the geneticist said it meant, and
we kind of just talked.... And I was kind of like, so what would you guys do if
you were me? And all of them were in agreement that they would try to do
whatever the doctors thought would be best, the best step for prevention.
Most reported positive aspects of disclosing their BRCA genetic test results and
overall found their family and friends supportive. Participants expressed a closer
connection as a consequence of disclosing their results, "I think we're probably more
supportive of each other" and "Maybe made us a little bit closer because we have a
common problem. I mean, they actually don't know if they have the gene, but there's the
potential". For some it clarified why there was cancer in the family, as this participant
related:
My mom's family was excellent; they just were really supportive. And it kind of
answered some questions for them as to ... why we were going through this stuff
(cancer) with our family. And a lot of them didn't know that it was genetic .... So
it was good.
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A participant with a variant of uncertain significance explained telling friends, "I
could tell them and I could have the support that I needed." She described how she
needed to get her true feelings, the frustration and "gloom and doom" about the VUS out
of her system before she could move on. This she was able to do with her friend, but she
could not be as honest emotionally with her father and brother.
One friend in particular, I just really was upset. Kind of reviewed the fact that
(genetic counselor) had said it wasn't really all doom and gloom because we
couldn't be 100 percent sure that it was a disease causing variant, but that I was
sure that it was a disease causing variant, because it just had to be because my
mom had breast cancer ... And I think I was a little bit more at ease to share my
true feelings, gloom and doom reaction.... Whereas my dad and my brother were
so really good and mature about it. And I wouldn't change the way they reacted.
It was a very healthy reaction, really smart. But I think I needed to be dramatic
about it and kind of get it out of my system before I moved on. They were
supportive and they were sympathetic ... and really did all they could.
There was a greater degree of support, a connectedness, felt when members of the
family were going through the genetic testing together. They tended to have a family
support network or "group up for bad news" as these participants explained:
I think in the family ... we're a very close family and we were all going through it
at the same time, so it wasn't any more "Oh poor, (name)" as opposed to ''poor
(my other sister)" .... It was sort of a group thing .... We usually group up for bad
news.
I'm really grateful and thankful that I have other brothers and sisters that are in
the same exact spot as me and that we can talk about it and stuff.
Finding insiders and outsiders. Not all the women seeking support by disclosing
their BRCA genetic information found it. In telling others, participants encountered two
responses from others: that of the insider and the outsider. The insiders understood about
the meaning of the mutation and tended to "get it" - this was usually someone who had
the experience of a mutation or a VUS. The outsider did not understand what the
mutation meant to the participant and thus the support was lacking.
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Outsider. As one participant described, her brothers responded less on an
emotional level, she felt ''they didn't quite get it.. .. They just couldn't quite relate to what
it must feel like for me". She said some people just "didn't understand" when she
explained it. Another participant experienced a good friend as an outsider:
And I guess it was hard, because I was trying to explain a lot to her, and she
totally was not understanding ... because ... like going from my family who
everybody is kind of involved in it, and then trying to tell somebody who is like
on the outside, it was difficult. I don't think she understood how serious it was
when I was telling her ... 80 to 85 percent chance of getting breast cancer. She
was supportive, but ... I don't think it did a lot for me.
Insider. Most of the participants had some insider family members to whom they
could speak freely about the hereditary breast or ovarian cancer in their families. Often
this was a mother, sister, aunt, or cousin who shared the mutation. They talked about their
fears of breast or ovarian cancer, passing the mutation to their children, and their
experiences with risk management options.
Although surrounded by family and friends, there were times during the testing
and risk management they felt alone, "isolated". Disclosing it to other insiders who
understood helped them to feel they were not alone in this, as one participant recounted:
I think there was just the sort of psychological component of not feeling isolated.
Of feeling like, ... there were all these people out there (with a positive mutation
on FORCE website), ... no matter how much your loved ones and friends care
about you and want to understand, it's just different to have people who are like,
yes, like I am, who grew up, often many of them grew up afraid of cancer, the
way I grew up afraid of cancer.
The insiders had a common ground of shared experiences and concerns and
provided a sense of connectedness which helped the participants' fears and isolation to
dissipate. When they expressed their fears, they found someone who would listen with
compassion. These insiders helped to legitimize the participants' feelings and provided a
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comfortable environment where they could speak out about how they felt. Participants
found insiders in a chatroom on a BRCA support website, Facing our Risk of Cancer
Empowered (FORCE), with the Hereditary Breast and Ovarian Cancer Organization in
Canada, and the National Ovarian Cancer Coalition, as well as in hospital-affiliated
support groups. One participant explained the personal significance of her mutation and
the difference between the support of her husband and the women of FORCE:
And then my husband would say, ... "you're no different today than you were
yesterday (name)". And it's like, "You don't get it. Yes I am" .... See, because it
was real personal to me that way ... I think he was just trying to sooth me and to
be there for me. I think there's also a point in this whole process where husbands,
as supportive as they all are ... I guess more to one degree or another some are,
but, you're at a place where, unless you're in the same boat, you don't get it. You
can't possibly understand. And that's the beauty of FORCE because they all get
it .... and I don't need anyone to ever tell me that they understand, because I know
that they just can't.
Support and empathy were unique benefits participants found with their relatives
or support group peers who shared the BRCA mutation. They offered a special service
that could not be duplicated by genetic professionals or non-carrier family members.
Although they tried to use friends and family as a sounding board for their feelings about
having the BRCA mutations and the risk management options available, several found
that what they really needed was to draw on the strength and support of women who had
been through similar soul-searching. These were people who could understand and share
their fears of getting cancer and who knew about the risk management options to prevent
the development of breast and/or ovarian cancer. They also shared the impact of their
management decisions on their lives and understood issues such as employer attitudes
about employment, and health and life insurance concerns.
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However, few of the participants with BRCA variants of uncertain significance
were able to find such support in their families (because with two exceptions they were
the first in the family tested) and peers. Thus a few attended a high risk support group and
others sought groups with BRCA positive carriers. Through these groups they were
hoping to discover further developments about their VUS results.
Disclosing to Inform Others

In addition to disclosing their results to obtain support, participants wanted to
inform others about the BRCA mutation. Underlying this disclosure to inform was the
hope the information would stimulate relatives at risk to test for the BRCA mutation or to
take action and be more vigilant about screening for breast or ovarian cancer. Other times
it was to increase others' awareness about HBOC in general.
Duty to inform. Participants who were the first in the family to be tested,

experienced a sense of obligation and responsibility, "a duty" to inform others in the
family who could possibly share the mutation, for the other's personal sake and the sake
of their children, as expressed by this participant:
So that's something that I feel so strongly, that I have a duty. It's not just whether
or not I want to. It's I have to. And I have to do it in a way that's gentle and try to
give the information, but allowing them to make choices.
She detailed how she assessed receptivity and fulfilled this duty to explain the BRCA
information to her maternal cousins:
My mom's cousin, I called her on the phone. And I start off slowly. I just say" ... I
have some information about the breast cancer in our family ... And is this
something that you'd like? Can I tell you about it?" You know, to ask their
permission first. And then I just tried to do it very gently and let them know what
I've done and just again how wonderful the genetic counseling has been and how
informative it is.
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Implicit in their message was the need for the family member to find out their
risk, to minimize their chances of developing breast or ovarian cancer:
When I'm passionate about something.... and I feel that it (testing) somewhat
enlightened me, then I'm pretty good about saying, ... this is what I did and this is
kind of what I got from it and maybe you should think about it also .... You don't
want to push it on anyone, but you would just kind of like to put a thought in their
head.
At first it (disclosing BRCA information) was ... just to my immediate family.
My sister, my husband, my mother-in law, and then it was every member ofmy
family who would listen. That was after ... maybe about six weeks when I started
calling my family members. And telling them ... that I tested positive. And, that I
thought it was in their best interest ... to test.
In addition to communicating their BRCA test results to their family, some
wanted to be a resource for others, as they wanted as many people as possible to know
about the mutation. One participant was on a mission and said she told "Anybody and
everybody that would listen, because it's important for everybody to understand what it's
all about ... it could be in other families". Some shared it by writing and publishing their
story, speaking to lay and professional groups, and participating in chat rooms and in
research. They hoped in this way someone in the future makes the connection with the
genetic mutation as the possible cause for their familial breast or ovarian cancer. By
being open, they hoped also to reduce other women's fears of testing due to concerns
about discrimination.
Duty to inform, yet not upset. All who felt the duty to inform family members
indicated it was a sensitive issue and needed to be handled carefully. There was a tension
between their duty to inform their family members of their risk status and respecting their
needs. As one participant explained, "You can't underestimate how complex the issues
are in terms of family relationships and how it has tested family relationships". As
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detailed below, she feared she had pushed her sisters away. This resulted in them being
less open to talking about the BRCA mutation and increasing her sense of isolation:
My sisters have been very supportive of me. But our way that we deal with things
are very different.. .. my oldest sister hasn't tested. My fourth sister tested after
quite some time and kind of without telling anyone. And I've had a hard time
accepting ... Like in my mind you do whatever you need to do to make sure that
you stay healthy, and you gather all the information and it's pretty proactive I
think. That's my way I wanted to deal with this .... And it's been very hard for me
to accept that my oldest sister, who I love dearly, is terrified of being tested. So I
try to give information .... I wonder sometimes if I've been pushing. And I've had
to back off, because I think maybe I've pushed them away a little bit, so that
they're not as open to talking about it with me. And I don't want to do that.
Another explained that pushing the issue on family can create a rift. So she learned to
"kind of lay low":
You run the risk of creating a rift in a family when it's an issue for you and it's
not an issue for them and you want to make it an issue for them and they don't
want you to make it an issue for them.
In disclosing her positive results another described that she sent "a shock wave
through the family," but was doing a necessary service for them. One who felt like ''the
grim reaper" describes that telling her extended family was one of the hardest parts of her
BRCA testing experience. It was a balancing act, she wanted them ''to see the
importance" of testing, but at the same time she did not want "to step over the line," as
she recounted:
It (telling family) was absolutely horrible. I felt like ... the grim reaper. Coming in
and making phone calls .... And ... it made everybody uncomfortable .... And my
one cousin ... who I'm very close with .. .it took me a long time to get her to go
test. You know, she kept saying, "Well, .. .I'm older now." And I kept saying,
"No, you're not. You're right at that age. You have to go test." So then it
became ... I didn't want to overburden anybody. I didn't want to step over that
line, but I really wanted them to see the importance (of testing).
Others described how hard the disclosing was for them personally, as well as for
their family to receive this BRCA information. One described her family's reaction on

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

128

two levels, "it upset them a little that I have it (the BRCA positive mutation) ... and it
raises their own fear". It was also hard for her emotionally ''just because I knew that not
only are you absorbing (that) another one in the family (is at risk), but .. .it trips that
switch in you personally yet another time".
Most participants preferred to disclose the family's HBOC risk, unless there was a
reason that inhibited them, such as the family member's age, not wanting to worry
someone that was sick, or to prevent guilt feelings in someone who was ill. While most
thought it important that family members know their risk of a genetic mutation, they
carefully assessed others' receptivity. They did not anticipate the range or intensity of
personal and family reactions they experienced while disclosing their genetic
information. Some experienced a sense of reconnection with the family while others
discovered not everyone, including sisters, are of their mindset and really did not want
the information.

Blocking disclosure. A few families had members who weren't receptive to
hearing about the HBOC risk in the family and participants found their disclosure
blocked. This participant explains her rejection:
... I started talking to her about it and she like pretty much slammed the door in
my face. And I was pretty afraid to continue discussions with her. And I was
concerned for her because ... she's Ashkenazi and has had ovarian (cancer) so,
she's got a good chance of having it (BRCA gene) .... But then I talked to one of
her sisters. And her sister wasn't very approachable about it, so I just kind of
dropped it.
Another participant experienced indirect blocking of her communication. After
drafting a letter with the help of her genetic counselor, she sent it to her distant relatives.
There was a lot of silence, as she heard back from only two of them. This left her feeling
"isolated". She speculated that there is perhaps a fatalistic mindset in some of her family
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and realized that some people are not interested in sharing in this BRCA information. She
described trying to tell her non-receptive cousin with ovarian cancer:
One cousin ... and ironically it's one who now has cancer, she hasn't been tested
and she doesn't want to be tested and she doesn't really even want to talk about it.
So I've just been really, really careful about pushing it on people. Or tried to be,
cause I do have a sense that some people just aren't that interested.... there may be
... a mindset that says ... "Ifl get it, I get it, and I just don't want to know". It's ...
like, "why would I want to know this?" ... there's parts of my family that are very
religious, and I think they kind of feel " .. .ifit's God's will, then I'll get it or I
won't and I won't interfere in that" .... But the months and years after that, I did
have a sense of isolation because people in the family very rarely brought up the
subject and I tried not to because I didn't want to push it on them. And I think I
felt a sense of isolation.
One foreign born participant with a genetic VUS also experienced indirect
blocking of her disclosure, but this was due to language and vocabulary barriers. She
expressed how difficult it was to share her VUS results with sisters in another country.
"The vocabulary" to tell her sisters about her variant of uncertain significance was
technical and the information she received was obscure and fraught with uncertainty.
They had not heard of this new technology, nor could they afford it. Consequently, this
family was subjected to additional stresses resulting from their lack of understanding.

Selectively disclosing to children. Most participants with young children did not
disclose their BRCA test information to them, although, a few did. Two factors
influenced parents' disclosure ofBRCA results to children, the child's age and the
parent's philosophy about communication. Most felt that they would tell their children
when they were older, when they would understand and faced a potential risk themselves.
One participant who did not believe in keeping secrets because of her experience
in adoptions, felt her daughters would overhear conversations and misinterpret her BRCA
mutation as cancer Thus, she shared the information openly with her 9 and 12 year old
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daughters, as she wanted them to be a part of it. She gave this detailed account of why
and how she and her husband disclosed her BRCA genetic results to them:
We sat down with our girls and talked to them about it .... And we had talked
about this prior to as well .... we really felt that we could not keep it a secret. I
knew that they would be overhearing me on the phone and I was worried that they
would think that I had cancer or that they would be scared that it was something
worse. I just didn't want them to feel that they weren't part of it. So in as simple a
way as we could ... or as age-appropriate way as we could, we explained to them
what was going on. Tried to reassure them and I talked to them ... And so I told
them I had this gene that meant that I might get cancer. And to make sure that I
didn't, I was going to have this surgery, just like grandma had, to make sure that I
didn't get cancer.... I think it was a huge relief for them, because they had ... been
going through my mom's death. And I mean, because we were caring for her ...
that wasn't hidden from our girls. They had been a part of everything .... So that
was scary for them. So to know that I was going to have some surgeries to make
sure that I didn't get cancer was a good thing. And they still say that .... they
think it's just great that I'm doing this (prophylactic surgeries).
Although this mother did not disclose her BRCA positive results to her young
daughter, she did tell her 17 year old son. She explained the implications for his children
and recommended that he have the testing when older. She was concerned her son would
see literature lying around and misinterpret it as she had breast cancer. She recounted:
My son, on the other hand, watched my mother (die of breast cancer) ... he was
seven, very close to my mother.... and it was very difficult for him. And I knew
that there was going to be information coming to the house. I had seen somebody
from reconstruction, and ... he mailed me a book on ... mastectomies after
cancer.... Once I saw that ... I didn't want him (son) to think I had cancer. So,
after my testing I went up and I told him ... that I tested positive, but that I do not
have cancer. I wanted that to be very clear. And then I told him what it meant, and
I told him that he, too, might have the gene and might not. And what that meant
for him in terms of his children ... So I told him, when he was older, ... ifhe
wanted to, that ... I thought it would be to his benefit to test, but not now. Not at
this age.
Another mother who disclosed her test results to her 8 and 12 year old daughters,
gave a detailed account of her daughters' emotions, from feeling isolated and different
(stigma), repressed anger, and desire to be a "happy teen":
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I think most of the time they like to just ignore it all and go on with their happy
teen-age lives .... On the outside you don't see that it really affects them ... .
they're just totally normal kids, and yet I think somewhere underneath ... and
every so often ... it comes up .... And so .... they're thinking about it. They don't
really have anyone else to talk to about it. I think they probably feel a little
isolated and I think a little like the way I felt different because I didn't have a
mother. I think they feel different because they have a family who has a gene, a
cancer gene .... I think this is an experience that will, in some way, mold their lives
.... I hope it's not a bad thing .... And it's only rarely that they'll come and divulge
what they're thinking. And I did have one conversation when my daughter was
sixteen .... She (was) ... pretty emotional and I sat at the table and cried while she
talked about some of the stuff. But she said, ... and we'd been not getting along
for a few months ... , "you know, yeah it's got to do with this gene thing .... I guess
I'm kind of mad at you for this" ... because she said, "I want to be a happy teen. I
want to be carefree and I know that this is going to hit me sometime".... every so
often, you see a little glimpse that really it is in the back of their minds .... They
push it far back and they don't think about it a lot, but it does ... it sort of simmers
there and it does affect how they think about things.
In contrast, most parents did not disclose their genetic test results to their young
children. Instead they shared their surgical procedures and explained they were done to
prevent cancer in the future, linking the explanation to a family member's cancer or
surgical procedure they could relate to. These mothers recounted their experiences:
I told my kids about it (BPM). My mom had her implants replaced ... and stayed
with us for two weeks after that surgery. So I told my children, who are 5, 9, and
11, ... "Remember (grandma) came and stayed with us and she had surgery to
make sure she wouldn't get breast cancer, and I'm going to have the same
surgery". And I said, "So you all are going to have to be real helpful for a while,
just like we were with (grandma), and take care ofme for a couple of weeks. And
they kind of rolled their eyes and laughed.
My daughter, I told the truth (about BPM) as I thought she would be able to deal
with it. ... she's nine years old and developing ... And she's having some body
issues. I didn't want to make it worse. So what I said to her was that I had some
cells in my body that could turn bad, and make me sick. And that I found out
about them before that happened, so I was having them taken out. And then they
were gonna put in different cells from another part of my body to make up for the
ones that I lost. ... that's what I told her. As she ... started seeing, she asked
questions. And so I explained to her ... that it was in my breast area, and she's
like, "Ooh, don't say those words." Cause she's dealing with ... her own body
development and image and that satisfied her .... She could see that I was fine, and
at nine, I think that's all they wanna know.
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However, when parents decided not to disclose their BRCA mutation to the
children, to keep the secret until they are older, they restricted the number of people to
whom they disclosed their genetic information and received support from. In this way,
there was less likelihood that someone would spill the information inadvertently. Parents
who were less open and blocked communication with friends about the BRCA mutations,
as this mother explained:
I talked to maybe four or five other couples, good friends of ours, and that was it.
Nobody else knew about it (BRCA results) because ... I have three daughters and
they were ... the highest priority for me .... I need support, but if I talk to a lot of
people then somehow it will get to them and I didn't want it to get to them .... and
then my husband and I talked about it and he said we shouldn't and once we'd
decided we're gonna wait 'til eighteen or twenty, then I didn't want to make
everything so common knowledge with everybody because ... some people are
insensitive ... and might say something ... I don't want the kids to know, about it
from somebody else ...
Fear of health insurance and employment discrimination were other reasons
families decided to hold the information close, as this participant discussed:
But it was kind of a family decision to not really let many people know, because
of worries about future insurance problems or work related prejudice or
something like that. So we kind of as a family agreed to not really share the
information with too many people.
In summary, disclosing results was a strategy to seek support from family,
friends, and/or support group peers. It also served to inform others so they too would be
more aware and take necessary precautions to prevent breast and/or ovarian cancer. In
disclosing their results participants encountered two responses from others, that of the
insider and outsider. The outsiders did not understand what the mutation meant to the
participant and thus support was lacking. Insiders understood the meaning of the
mutation, as they had experienced the mutation or VUS test result. They had a common
ground of shared experience and concerns and provided a sense of connectedness which
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helped to reduce the participants' fears and isolation. They found insiders within the
family, as well in BRCA support groups, such as FORCE, HBOC, and hospital-affiliated
support groups. Value differences regarding openness in communication, sense of duty to
inform, age and maturity of children, and differences in receptivity led to selective
disclosure to family members and others about their BRCA mutations. Disclosing of their
BRCA results was an important step in breaking down their feelings of fear, isolation,
and vulnerability so they could proceed to further manage their susceptibility to breast
and ovarian cancer.
Making Risk Managem ent Decisions

For unaffected women with BRCA positive or VUS mutations, making a risk
management decision was a strategy to manage susceptibility to breast and ovarian
cancer, as well as the consequence of their knowledge and experience. Although
participants experienced a wide range of emotional reactions after receiving their BRCA
test results, they sought support and confronted their fears, pulling themselves together in
order to move forward, and regain control. In considering treatment options of
prophylactic breast and ovarian surgery, chemo-prevention, and vigilant surveillance
participants were choosing either to reduce their risk of breast and ovarian cancer or
"catch it early." Risk reduction options included the prophylactic surgeries and
chemoprevention with tamoxifen. Early detection ("catch it early") involved annual
vigilant breast and ovarian screening. Both the certainty and uncertainty of their BRCA
test results set in motion a series of interpretations and actions leading to risk
management decisions. This set of actions included seeking information, drawing on
resources, sustaining relationships, and deliberating and making decisions.
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Seeking Information
Decision making to try to reduce their risk of breast or ovarian cancer or "catch it
early" was "hard," "tough", "scary," "agonizing," "daunting" and made some feel like
they were on "an emotional roller coaster" because of the presymptomatic nature of the
testing and the uncertainty involved. Few risk management options are black and white
and the gray areas are many, due to a paucity of long term follow-up of unaffected
women with BRCA mutations and variants of uncertain significance. These decisions had
to be made by both those with positive and VUS results. As this 34 year old with a
variant of uncertain significance explains: "If it's an inconclusive result like mine was,
that doesn't mean that there's no decisions to be make. You still have the same decisions
as everybody else".
After obtaining information from their genetic counselor or physician on risk
management options available, participants sought information from lay and professional
sources to assist them in making informed choices. Knowledge gained in information
seeking after their testing was effective in reducing the bewilderment they felt in
discriminating between alternatives. Preferences for both the type and amount of
information varied among participants. For some, their physicians taking a non-directive
stance, not prescribing what to do, left them disappointed because they felt they must
make a decision when they did not have the requisite information. As this 32 year old
with a BRCA mutation explains:
You get the results of your mutation testing and they sit there like, well there's
... you could do this but there's not really any data to support that, that really
helps, and some people think you should do this .... It's like ... no one is going to
sit you down and say, here's what you need to do. So it's all up to you. And that
can be daunting.
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Acquiring information, figuring out "where to go and who to see" took initiative
and time. As this 47 year old who sought testing in 1999 and described her experience as
"agonizing", like "pushing a big boulder up a hill" explained:
They kept saying, ''there is no clear thing to do here. We don't have a specific
direction". And they continued to go on with "these are very personal choices and
you'll need to discuss this with your doctor". And that was it.. .. I felt like I had to
push this big boulder up a hill. Because I had to push to get into doctors and
figure out where to go and who to see and I didn't even know what order to see
the doctors in. (I saw) ... a gyn oncologist who I talked to about having my
ovaries removed and all the things that go along with that. I saw a breast surgeon
... about the option of having my breasts removed. Then I saw a plastic surgeon
and ... later I ... saw an endocrinologist to talk about hormone replacement
... actually I saw two different endocrinologists afterwards. So it was kind of
bouncing between those four doctors .... And I didn't get a lot of guidance
honestly from the genetics clinic.
Like the above participant, some preferred obtaining information about treatment
directly from professionals in clinical settings; including breast surgeons, plastic
surgeons, oncologists, gynecologists, and gynecologic oncologists. They also used
written materials provided by their physicians and genetic counselors. Others sought
information from members of support groups and read popular media sources and
scientific reports on the internet. This participant's belief that "knowledge is power" and
the key to "life saving decisions" was shared by several participants:
I think the most important thing is the information. Knowledge is ... so important.
And with this knowledge, you can make lifesaving decisions. And then you have
to remember even if you're positive, it does not mean you have cancer. You have
to keep reminding yourself of that. But that you can make such good decisions for
yourself and for your family. And that knowledge is power.
For some, gathering and sorting through all the information left them feeling
"very overwhelmed many times ....just the amount of information that I had to try to
process." Some sought professional publications, but found the medical language was
technical and hard to interpret. This 4 7 year old participant described her information
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search, difficulty understanding the medical language, and need for someone to translate
it for her:
And I wish I'd had easier access, clearer access to the medical and scientific
knowledge out there. I felt like it was really difficult to dig it all out and try to
make sense of it. Cause I'm not a doctor. A lot of this was written in medical
language. And it just wasn't there translated in ways I could understand. Well, I
could. I mean I did my best, but I often felt like I would have liked to have
somebody translate it for me.
Others compared their information with that given to a sibling with the same
BRCA results, as this 43 year old recounted:
I did online research, as much as I could find. I met with oncologists. I met with
breast surgeons. I met with my gynecologist, my family physician. And then, my
sister was meeting all of those same people, so we had doubled the input with half
the legwork.
Several of the participants emphasized how valuable it was for them to meet with
or talk (by phone or in chat rooms) with women who had similar histories and had been
through the decision making process and were happy and have moved on in their lives.
These women were role models who openly shared their knowledge and experience about
issues that seemed insurmountable at the time for the participant. Participants found
BRCA peer support groups not only had up-to-date information on research and
treatment, but also had links to other internet sites, so they could do their own
information gathering. These three participants describe their support group experiences,
the "wealth of information", including physician referrals:
The HBOC group ... these women have just been a wealth of information .... And
so I got to see, not only to talk to them, but I got to see the whole range of
options, women who had chosen surveillance, ... to have the surgery, ... who had
had trans flaps, ... had reconstruction through implants. And from them I could
hear different information, and then I got names of different surgeons.... So I
immediately had referrals. I went to my GP (general practitioner) and got referrals
to those doctors.
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(Through FORCE) I learned all about ... Medline .... I didn't realize that I could
just go and find abstracts of journal articles on line and read these studies firsthand myself as opposed to reading the interpretation of it in U.S.A Today, where
everything gets blown out of proportion ....
These support networks helped participants regain a sense of control over their
lives and reassured them about the decisions they were considering. As these two
participants recounted:
(FORCE has) been ... a good source of information for me .... I'm finding out
from other women what procedures they've had, what the effects have been, and
how it's gone, what surgeons they recommend, and what the pros and cons are of
the different procedures .... Yes, a lot of what I'm saying is like well... I've been
right all along in knowing I should do these things .... It's making me see that,
yeah, this is the right thing.
(FORCE) was an incredible source for me, to help me feel more comfortable
about my research and my decision and second opinions and things like that.
The decisions for prophylactic surgery were multifaceted, not just for BPM and
BPO. Bilateral prophylactic mastectomy included options for breast reconstruction. The
decision for BPO involved deciding whether fallopian tubes and uterus should also be
removed, and if hormone replacement therapy would be used to mitigate the symptoms of
menopause.
Participants discovered several different breast reconstruction options available
and described how their views on autonomy, trust, and control influenced their decision
making process. They either decided on what options they wanted and found a physician
to perform it or found a physician they could trust and went with what he recommended.
One participant discovered that plastic surgeons do not explain all the options for
reconstruction, just those they perform:
There's so many different types of reconstruction, it's sort of a whole sub-world
unto itself. .. Silicone versus saline is the least of it. There's keeping your nipples,
loosing the nipples, you know the diep flap, the glut flap, the back flap,
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expanders .... There's just a ton of decisions to make. It's not enough to decide
that you're having a mastectomy. That's like the least of it .... Every plastic
surgeon has their own surgery that they push. And you ... go online and you do
some research and you can make up in your mind what ... you want to do, and
then you find a doctor who does that. Or you can go to doctor after doctor 'til you
find a doctor that you like and trust and go with what they say.
It was through the FORCE website that some discovered complete information on
all the types of breast reconstruction available, as this 4 7 year old mother recounted:
... that (reconstruction) was the most difficult part of this .... cause the doctors
don't tell you the different options if they don't do them .... Through FORCE .... I
sort of feel like FORCE was such a lifesaver, because I really did feel like I was
drowning .... Everybody was giving me limited information as to what area of
expertise they had. And they all had an agenda.... But there was no one outside
FORCE ... who was just gonna be willing to give me information and let me
make a decision for myself.
Drawing on Resources

Decisions made for any of the risk management options were complex and
grounded in the trust, support, beliefs, and values from each individual's life experiences
and relationships with others. Past family and personal experiences, present sense of self
identity and their relationships, and aspirations for the future were all part of a
participant's decision making.
Participants who were interviewed at longer time intervals from their decision
making process, related clear accounts of their life experiences influencing their decision
making, which were consistent with the experiences of those who had made more recent
decisions.
Past experiences. Participants made decisions about their risk management

options by interpreting their past and applying it to their current situation. Family history,
past personal experiences, and the experiences of family, friends, and others provided the
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groundwork for participants' expectations about their susceptibility and risk managment
effectiveness.
Family history influenced their decision, as breast or ovarian cancer represented
death or loss of quality of life, as their family member(s) with these cancers did not
survive or had suffered through traditional treatments like surgery, chemotherapy, and
radiation. Participants chose risk management options they perceived gave the greatest
risk reduction and thus enhanced their chance of living out their lives. This allowed them
choices that their family member(s) did not have, as expressed by these participants:
Ifl had survivors in my family, I might have said," ... what's the worst that
happens is, with all the surveillance, they catch it early". But they didn't survive. I
mean ... with my mother's cancer it was a ... tiny little lump. I mean, no affected
tissue, no affected lymph nodes, nothing .... It (BPM) would put me into the 90th
percentile of not getting this illness that I saw my family members die of.
50 years old with a VUS who chose BPM. Well, if I have to make a decision
because I'm living with the unknown, and I'm feeling, thinking of my sister (died
recently of breast cancer) so close to me, telling me, "I didn't have that test, I
didn't have the opportunity, don't think twice what you have to do".
Other important elements in decision making were the participants' values and
beliefs about their quality of life and its impact on their children, should they develop
breast or ovarian cancer. This mother expressed her beliefs about quality of life:
46 year old mother who chose both BPM and BPO. I'd been so involved with all
my sisters (three with breast cancer), what they've been through and their scars
and their drains ... I've seen it all and it's not pretty and I just didn't want to have
to go through the chemo and the radiation or whatever.... I didn't want my son to
have to see me go through that ... (On getting her positive BRCA test results): I
knew right then and there what I had to do.
Past personal experiences. Past personal experiences also provided participants
with a framework in which to judge their options. Most participants had been doing
vigilant breast surveillance prior to testing. Both those who chose prophylactic surgery
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and surveillance expressed an awareness that mammograms were going to "find" breast
cancer, not prevent it, as expressed below:
Chose BPM and BPO. I've had mammograms every year since I was in my late
twenties. Well, I mean, it's better than not having them, but it's not going to
prevent cancer. It's only going to find it.
Chose surveillance. I feel like my surveillance is such that .. .I have the best
possible chance of catching it early and I have great faith that if it's caught early
and dealt with early, it's a very treatable disease. And I know dozens of women
who have survived it and I think that I could be one of them, worst case scenario.
Although participants who chose surveillance and surgery had reservations about
mammography, those who chose surgery expressed the greatest distrust. Even as one
participant who chose vigilant surveillance explains, she only felt she didn't "have breast
cancer" and had "peace of mind" when she had an MRI.
I do annual mammograms, annual breast ultrasound, monthly breast self-exam,
twice annual clinical breast exam and then I've had one MRI as part of a clinical
trial and I'm trying to have another one because that was definitely the screening
that gave me the most peace of mind. When that came back clear I was like, "Ok,
that's good". Because when I get a mammogram and even an ultrasound and
certainly the clinical exams ... when they say, "Well I don't see anything" or "it
looks ok", ... I'm glad, but I don't feel like "Oh, whew, I definitely don't have
cancer". I don't have that much faith in those technologies. I have some faith but
not exclusive faith. The MRI, when they didn't find anything I was like, "Ok, I
don't have breast cancer".
Equipped with their additional information about a BRCA mutation, which
confirmed an even greater risk for breast and ovarian cancer, those who chose surgery
wanted a treatment that was more definitive than surveillance. Several participants with
"lumpy breasts" or those who had previous breast biopsies were not willing to continue
with the cycle of "anxiety, tests, waiting, and results" that mammograms or biopsies
perpetrated on their lives. A 47 year old mother with a BRCA2 mutation articulated this
view:
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Mammogram, I just was not comfortable with the error rate and given the density
of my breasts and the difficulty that I've had with the lumps and the difficulty
mammograming them, I just didn't feel that that was an option.... And I've had
lumpy breasts all my life and I never knew what was a lump and what wasn't. ...
And I'd ... been doing surveillance those three years prior to (testing) .... The sixmonth checkup thing, that was not a lifestyle that I was willing to carry on with
for the rest of my life .... You have anxiety for a week before the appointment....
You get your mammogram and all these tests done and for a week later until all
the results come back ... , you're wondering what they're going to find. And every
six months you go through this cycle of anxiety, tests, waiting, results .... And
then the day after you get the ... good result back saying there's nothing there,
you think, well what if it's starting to grow now. And I just didn't want to live
like that.
Most women also did not have a favorable impression of the CA-125 test for
ovarian cancer screening, which was confirmed by their physicians. This participant
described her lack of trust in this test:
And the C-125 .... But what I've heard is it's not particularly effective. By the
time they actually see something, it can be quite advanced. And that was
confirmed kind ofby Dr. (name), the gynecologic oncologist. And so although
that's something that I do, I don't feel really good about that as a screening
method. And ovarian cancer is, from what I've heard, so much more fatal and
progressive.
Relatives past experiences. Participants' decisions were also influenced by the

past treatment experiences of relatives, friends, or support group peers. They were
distrustful of mammography because it had missed their mother's or sister's breast
cancer. For others, ovarian cancer went undiagnosed until an advanced stage. These
participants explained their distrust:
41 year old who chose prophylactic surgery. Mammography, for my mother, did
not help. That cancer was not there then all the sudden came up in two months. It
... in my opinion, it laid shadowed in a mammogram and was never picked up.
She has dense tissue, I have dense tissue. And I said mammograms, for me, are
not enough. And I don't want to end up like this because I'm trusting
mammograms.
41 year old who chose prophylactic surgery. You know, I've been doing
surveillance. I have very dense ... breast tissue. And I know my sister (with breast
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cancer) had a mammogram and it didn't show up anything. So I know how
ineffective that can be. It had spread already. And they couldn't even see cancer
on the mammogram. So for me surveillance was not an option, because I had been
doing that, and I lived with fear.
47 year old who chose the surgical options .... my sister was diagnosed (with
ovarian cancer) at stage III. I looked at the statistics for survival. They're horrible.
I looked at the surveillance methods. They were inadequate. It's a deadly, horrible
disease that isn't found early enough. And I looked at what the potential research
was coming up. And I just didn't see that something was going to be popping out
of the woodwork in the next year or two.

Maintaining self identity. Just as past experiences influenced participants'
treatment decisions, they also chose to maintain their current sense of self, personally, as
well as in their relationships with others. This was especially true for women in their
twenties and thirties. Most of these young women chose surveillance and to postpone
surgery to sustain normal roles for themselves and to preserve normal relationships with
family and significant others. They were concerned about their sexual experience, wanted
to marry, make decisions with a husband, have children and the opportunity to breastfeed
them before they made any surgical decisions. In the meantime, they wanted to get on
with a normal life. One 32 year old participant felt breast reconstruction "would take over
my life .... It would be a very major life altering choice and it's just not worth it to me at
this point." These young women felt they had the "gift of time" and set a time in the
future to reevaluate their risk management decisions or have the BPM and/or BPO. The
choice of age for reevaluation was related to their mother's age at diagnosis of breast or
ovarian cancer, or was suggested by a genetic counselor or physician. As one 22 year old
positive mutation carrier explained, she wanted to move this from the foreground, live
her life until she was 25 years, then she would start surveillance:
I just want to keep living my life as a twenty-two-year-old and not overdo things.
But I haven't even been to a doctor yet and .. .it's been nine months, but I want to
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live my life until I'm twenty-five ... I say that year because that's the year the
genetic counselor told me that that's when I need to get serious about things. So,
I've been talking to people. I've been finding out what other people have done.
A 32 year old participant with a variant of uncertain significance who chose
surveillance, wanted more children and the opportunity to breastfeed them. She related
that her decision making was shortened as a result:
Well, me being so young, I mean, I know you can do a mastectomy ... or a
hysterectomy.... See, I don't know if I'm through having children, so with my
case there was so much that my options were shortened to, because I wasn't ready
to go on to tamoxifen or any other type of medication. I wasn't ready to have a
mastectomy. I was getting ready to nurse a baby .... So it didn't change anything
... until I become older and I know I am through having children, only then would
my options pretty much change on what I needed to do.
Unlike the younger participants, women who were older did not plan to have
more children or were beginning menopause were ready to make their risk management
decisions. As described by these women in their mid-forties, the decision for removal of
their ovaries was not a difficult one:
And, so, all of us sisters just looked at each other and said, "Well we don't need
them (ovaries) anymore." ... and the other ones are already going through
menopause, and I was starting, so I thought, "Get them out of here." There's no
testing for it (ovarian cancer) ... , so I just said, "Take 'em. Wasn't gonna have any
more babies anyway."
I mean, being 47, I could say, "You're gonna go through this (menopause)
anyway." You know, had I been younger, I don't know ifl would have done it so
readily. But I think because of my age, and I just wasn't willing to take the risk
(for ovarian cancer).

Overcoming past beliefs. In contrast to most participants in their twenties and
thirties, one participant in her twenties did not postpone her surgery and had BPM. She
explained how she overcame a past belief, a fatalism which she attributed to her Catholic
faith. She consulted a priest who helped her understand she was not harming her body
with surgery, that she could change things so cancer was not her destiny. She then
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decided to become more proactive, "using the knowledge I was given" and the scientific
advances available to her, as she recounted:
Another big reason that I was hesitant to have the surgery (BPM) was because of
my religion .... I'm Catholic, and I kind of had this belief in my mind ... that I
would be harming my body ... , this body that I was given, and that I shouldn't
really change things. Ifl was meant to deal with having to have cancer, then I
should kind of accept that and deal with it and kind of suffer through that .... I
actually felt that pretty strongly for a long while until I talked more closely with
one of my good friends who is a priest. And he kind of convinced me otherwise
that it wouldn't be. And then I started looking at it more in the sense of that I
would be doing something proactive for myself, and that it would be using the
knowledge that I was given, and using the advances scientifically. The fact that I
can know that I have the gene and know what my risks are and do something to
try to change myself from having that in the future. So that started leaning me
more towards doing it (BPM).
To help her deal emotionally with concerns about body image, dating, and what BPM
would mean for her, this single 28 year old consulted a psychologist, as she explained:
I was referred ... (to) a psychologist who is on the staff at the breast center that I
go to. And I started meeting with her weekly and then biweekly, just kind of
talking through my concerns and my thoughts and feelings, and kind of tackling
the issue of what it's going to be like to try to date, start dating somebody after
having a mastectomy and reconstruction, how that would be really different and
difficult.

Considering future self. A desire to maintain their self concept, including their
"desire not to get cancer," led participants to think about their future. Participants made
decisions that permitted them to remain hopeful about the future, especially regarding
their roles as mother and wife. One single 28 year old participant viewed her risk
management decision as weighing whether she should have the BPM now, without
chemotherapy and a family, or do it later while taking chemotherapy and caring for her
family. She related:
And I could either do it (BPM) now without having to go through chemotherapy
and going through all the other things, or I could do it later, when I could
potentially at that point have a family or kids to take care of, and have to go
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through chemo, and weighing out my options that way. It kind of made me decide
that I should probably do it now while I am just kind of on my own and not have
to worry about all that other stuff'.
These women also wanted to be alive to support their husband and family, "see
my kids raised" or "graduate", "becoming a grandmother" as these three women
recounted:
One thing that played a part in making the decision was when somebody said to
me about, "Don't you want to be there for your kids in the future", and this is a
way to do that, ... potentially be there longer for them by preventing myself from
having cancer.
46 year old with an autistic husband and 9 year old autistic son who chose BPO
and BPM. Her husband attempted suicide earlier in the year: I worry about my
son, ... if I'm gonna make it to see him graduate .... So I worry that if something
happens to me, who's going to take care of my son? And then my husband can't
take care of my son because he's just not that material.
47 year old mother who chose both BPM and BPO: I think about becoming a
grandmother .... women in our family just hadn't been grandmothers .... my mom
never got to be a grandmother. She didn't even get to see any of her kids get
married and for me now to be able to think about ... yeah, I do think that I will be
around if my kids have children. I'll be around there to see it and be there and
know them. And that's why this (prophylactic surgery) is all worthwhile.
Sustaining Relationships
Most participants sustained personal relationships by involving their
husbands/partners and other family members in their decision making. They sought
various levels of input about the risk management options from family, but most felt in
the end it was a personal choice, they had to make the final decision. These women found
their spouses/partners supportive, which made decision making easier and helped reduce
their distress. This 30 year old with a 6 month old baby explains how she involved her
husband:
He's (husband) kind of"whatever you want to do is fine with me", ifl want to
have my ovaries out immediately and not have any more kids, I think it would be

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

146

a little disappointing, but he seems very understanding about whatever, do
whatever is the safe choice. So he's kind ofleaving it more up to me, he's not
steering me to do one thing or another ... and I keep him involved, I tell him, he
talks things though with me, so he's on the same page as I am as far as having my
ovaries out at 35.
Sometimes hearing professional confirmation that their wife's decision was a
good one helped a spouse be more supportive, as this 47 year old mutation carrier and
wife explained:
I think that he (husband) was very reluctant, although he would have done
whatever I thought best, until he came with me to the breast surgeon who said to
him, "Your wife's testing just saved her life." And I think after listening to her, he
was very comfortable with my decision. He's been incredibly supportive.... I
would have done what I did (BPM, BPO), but I think it would have put a strain on
our relationship, ifhe wasn't as supportive as he has been. And I think that once
he received professional confirmation of my decision, he was more comfortable
with it.
Conversely, while trying to sustain family relationships, some of the women in
their twenties felt pushed by family members toward a certain treatment option. This was
met with resistance, as these young women, too, felt it was important to maintain
independence in this "personal decision". One recounted her situation:
And most difficult for me was that my whole family was seemingly pushing me
to ... have a mastectomy, especially after ... I tested positive (and) my one sister
went in for her prophylactic mastectomy and then was found to have cancer. That
kind of put this whole push from my family for the rest of us to all have our
mastectomies, and no real personal kind of decision seemed to be playing into it
.... , which was kind of difficult for me to handle because it's a pretty personal
decision. And having people tell you what to do was kind of a difficult thing for
me.
Some participants found family members less supportive of their decisions to
have surgery and participants were faced with strong emotional responses. Because of the
strong reactions, they were more selective in who they told, and by not telling they
protected themselves from different opinions. A 41 year old participant, in trying to
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sustain her relationship with her mother and affected BRCA positive sister, found them
unsupportive, initially. They felt her choices of the prophylactic surgeries were too
extreme. As she explained, she "didn't need advice," their response hurt her so she
excluded them from her decision making, and told them after the fact:
By the time I told people, I had already thought about a few things, where I
should go with this and I've already talked with my husband and I've already
decided that we still have to research everything, but if it means taking out the
ovaries and taking out both breasts then I'm gonna opt for it. So when I did tell
people it was already ... "I don't need advice" .... At that point, my sister, ...
having gone through full blown cancer, said .... she hurts me really easily and she
said ... , "Don't panic. Think about it, I don't think you have to go to such extreme
measures." And this was not even deciding, it was just sort ofl wanted it to be out
there so that she would know that this is a possibility for me .... I've never relied
on somebody else's thinking or doing the decisions for me .... I talked to my
mother, ... she said ... , "Well, did you talk to doctors and did they talk some
sense into you?" ... "Did they calm you down?" ... So, actually my sister and my
mother, I didn't let them in on this process at all after that. I was really hurt from
both of them and they were the first ones I told.... they didn't know about my
ovary removal ... and I only told them about the mastectomy two weeks before,
sort of giving them a hint, you're not part of my process any more. I just want to
let you know if you feel like supporting, be there for me, ... They've been very
supportive since then, but, when I first started to talk about it they were so
unsupportive.
Relationships with healthcare team. Finding the right physician(s) was a key
element of participants regaining control and decision making. They felt it was up to
them to put together a team they could relate to in a personal way. They wanted someone
they could ''trust" and felt "comfortable" with and was highly competent. Physicians
helped in participants' decision making by providing information about the risk
management options (both advantages and disadvantages) and establishing rapport. As
one 41 year old participant described, finding a team she felt "comfortable" with was
hard work:
What was difficult about the decision-making process was actually deciding on
the kind of surgery and getting in to see the specialist and feeling comfortable
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with that team. That was hard! ... I knew once I saw my breast surgeon, Dr.
(name), I just really liked her and I felt instantly very comfortable with her. But
the original plastic surgeon that I saw, I just was not comfortable at all with him.
So I had to get a referral to another one .... I had to wait a long time to get in ....
So kind of once I had chosen my team and I knew the kind of surgery ... ( she
proceeded).
Reconnecting with a physician she trusted was the first step for this newly diagnosed 51
year old with a positive mutation:
Then the first thing I did was I had an Ob/Gyn who I loved; she had moved from
the area ... about 45 minutes away from here, so I had stopped going to her
because of the distance. But I totally trusted her. So when this (BRCA positive
test) came, I called and made an appointment to meet with her again, and I'm
back seeing her.
Physicians also provided ways to focus and frame the decision attributes which
helped participants to make a decision. This 52 year old with a positive test result, who
felt she had ''this sword of Damocles hanging over my head," explained how her
physician framed the issue around her anxiety:
... she (physician) looked at me and she said, "Well, what I would do and what
you would do might be different ... " And this was like probably the most helpful
piece of advice that anybody gave me throughout all of this .... "(participant's
name), you have to weigh the anxiety you have about disfigurement with the
anxiety that you have about developing breast cancer." And I just went to her and
I said, " ... now I get it. Ok. I'm gonna have to have surgery." Because the anxiety
of developing breast cancer was just increasing. You know, it was like I have this
sword of Damocles hanging over my head.
Deliberating and Decision Making

After having obtained sufficient information about risk management options, and
having drawn on personal, family, and professional resources and relationships,
participants began deliberating or examining the alternatives to select a particular option.
The participants looked at the advantages and disadvantage of the alternatives and sorted
out their feelings, weighing alternatives based on personal experiences, beliefs, and
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values. The time required for deliberation after testing was related to how much they had
considered various options before BRCA testing and their preferred decision making
pattern. Four decision making patterns emerged (a) acting on apriori decisions, (b)
following expert advice denovo, (c) following some and rejecting other advice, and (d)
postponing the decision until older.
Acting on apriori decisions. Several participants had considered having a BPM
prior to BRCA genetic testing. They had heard about prophylactic mastectomy in
connection with a sister or mother's breast cancer. For one 41 year old participant, her
physician recommended BPM when she was 25 years old. Once she had the additional
information of a positive BRCA mutation she knew she would elect BPM:
I was very determined that I was going to have the mastectomies.... In 1989 when
my sister died, we had a breast surgeon that the girls, we all saw. And he ...
recommended that we have prophylactic mastectomies done .... And so we were
all thinking about it then. I hadn't even had kids. I was 25 years old. So that had
been something that I had thought about for a long time. And then once I knew I
was positive for the BRCA gene, it was like ... of course I'm going to do this.
For another 41 year old who had seen that her mother's BPM prevented breast cancer,
testing provided the certainty she needed to proceed with this surgery. She recalled:
And since probably my early thirties we've known there was a strong family
factor, whether we had any proof of it or not, and saw that my mother had a
prophylactic mastectomy and did not get breast cancer. And I figured that's what I
needed to do, too. And so I have been considering doing it for ten years. I've been
putting it off, though.
After discovering her mother's positive BRCA results, this 41 year old mother waited
two years to test. She had already decided to have prophylactic surgery because of the
looming threat, "ticking bomb" of breast cancer, as she described:
Even before I had this (BRCA) test, ... it had been almost two years from when I
found out about my mom (BRCA positive) to when I decided to test. And I had
pretty much had my mind made up even before the test that if it came back
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positive ... that I would probably do the surgeries, just because, otherwise I'd feel
like a ticking bomb way too much without doing something.
For a 34 year old mother with a variant of uncertain significance, she decided to have a
BPM if she received any BRCA test result but a negative. She realized that a VUS result
was a possibility, as she reported:
I actually made the decision the day that I went home after my doctor's
appointment, before I even knew what the test (BRCA) results were. I knew that I
was going to have the surgery (BPM). Either I said that because he told me that
there was a chance that the test could come back inconclusive, and he explained
to me ... what that meant, as far as he understood it. And I came home and I
talked with my husband, and we decided at that point that if it didn't come back
no (negative), that I would have the surgery. And that was the end of that. In the
weeks before my surgery (BPM) I still had that fear that something could pop up
in those weeks, and I didn't feel good until I woke up from the surgery.
Following expert advice denovo. Those who took their physician's advice,
acknowledged the risk management decision was theirs, but deferred to their physician's
expert judgment. This trust in their physician's expertise was noted particularly in those
who chose surveillance as their final choice. One 32 year old mother with a variant of
uncertain significance who chose surveillance explained that she felt confidence in her
physician's ability to monitor her and thus did not choose BPM:
So the only comfort that I have and the only reason why besides I'm not quite
sure I'm through [having] children, is Dr. (name). That is the only comfort that I
have in waiting is knowing that she's totally qualified in helping me make
decisions .... But if I didn't have her, then my options I'm sure would have totally
changed ... it's totally because of her the reason why I haven't drastically maybe
did a mastectomy.
This 43 year old mother with a positive BRCA mutation, who chose both BPO
and BPM, initially felt prophylactic surgery was too extreme. She related how her
physician helped her see the advantages of prophylactic surgery, which changed her
perspective:
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Well, I never for a second considered having a mastectomy. I just thought it was
so out there and extreme, until I met with my ... sister's oncologist. ... And that
was really the first time that I even considered it (prophylactic surgery) .... He
said I could get my ovaries removed and then I wouldn't be able to go on
hormones because I'd still have my breasts. So I would be 43 and going through
menopause without any relief. And ... the type of cancer that runs in our family
has a high ... penetrance. . .. even taking out my ovaries, while that would
eliminate the risk of ovarian cancer, I was still faced with the real probability I
was going to get breast cancer .... then you have to go through chemotherapy and
radiation and whatever. He sort of let me see the light or the advantages to taking
care of it prophylactically.
Another participant, a 51 year old mother who chose both BPM and BPO, describes how
she wanted her physician to tell her she "had to do" the surgery, as this was a "huge
decision":
The mastectomy was harder .... what I was really looking for was the doctor to
say, "you have to have this done", because a double mastectomy, that was a huge
decision. I mean, I kept looking at my breasts and going, "Oh my God, they're
going to be gone" .... And finally the doctor I decided to go with, she took my
hand and she said, "(participant's name), this is something you need to do. Your
chances of getting breast cancer are in the 80 and 85th percentile. You need to do
it." And you know, I needed to hear that. All the research I was looking at was
telling me I should do it, but I needed a doctor to tell me I had to do it.

Following some, rejecting other advice. Those who analyzed and deliberated over
the options took control in a way that was more purposeful than the previous patterns.
These participants were more thorough in laying out the advantages and disadvantages of
each alternative. This participant described her deliberations with her husband:
We spent the weekend at this resort ... looking out at the beautiful scenery and
going through all this stuff. Talking about the options. Made little charts about ...
if I did this combination of things, what would the pros and cons be. If I did this
combination of things what would ... and what should the timing be ... And I
mean money wasn't an object because we don't have to pay for our surgeries ....
And insurance wasn't an object. It was just a matter of what was the right decision
for me. And by the end of that weekend it was very clear to me that I was going to
go ahead with the prophylactic surgery .... it just kind of solidified for me that I
felt ok about making that decision despite what other people were warning me
about and telling me.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

152

This group gathered additional information to answer questions about the options
and sought professional consultations with various experts, sometimes seeking second
opinions to validate information they had obtained. Having a physician who could inspire
confidence, was nondirective, yet helped them make a decision or affirmed their decision
was important as this participant related:
And she (physician) just said, I think this is a good decision for you as well. She
said, "I thought I would have to talk you into it, but I can see that I don't have to
do that." ... But again, it was after they knew where my state of mind was and
what I wanted kind of going into it. I don't know that they would have done that
had I not been pretty sure that that's what I ... was going to do.
These participants were aware there was uncertainty in any option they chose.
They made a choice when they were confident they had considered all the relevant
information and found an alternative that satisfied their most important requirements.
They required the most resources of time, expert opinion, and information to make their
decision. They also identified potential problematic outcomes that were the source of
some conflict, but reported a sense of control and confidence over the process of
selecting a risk management option. As this 54 year old participant who chose both
prophylactic surgical options detailed:
The pros (of BPM) is pretty much along the same line as the ovaries ... it was
going to give me the satisfaction, as much as possible, of removing the possibility
of getting the breast cancer and living longer without getting cancer, in those
areas, anyway. And, being able to live a life, not having to wonder at each
mammogram or at each physical, doctor's appointment or at each time I would
check myself, which I did monthly pretty faithfully, whether I was going to be
finding something. And, so the pros were I could see myself sleeping better,
living a life better, not having to worry about it and living longer. The cons
became more a thing of, a sexual thing between my husband and I of ... I'm not
going to have nipple sensitivity ... I might not even feel him touch my breasts ...
And so that ... really caused me a lot of, probably surprising amount of emotion,
that I said, "God, I'm really gonna miss that. That part of our, our bedroom life
... " And yet, it wasn't a matter because I was upset about that that I was thinking
of not doing it, it was just realizing that that was gonna be gone.
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Postponing the decision until older. As indicated in the previous section,
maintaining self identity, women with positive and VUS results in their twenties and
thirties wanted to sustain normal roles for themselves and to preserve normal
relationships with their family and significant others. They wanted to move this issue
from the foreground until a later point in time. This 25 year old single student reported
her desire first to marry and have children, was hoping for better options in the future, but
was planning on having prophylactic surgery in the future:
I'm not getting married any time soon, but I think that maybe once I get married
and, I don't know, maybe have my kids, maybe not have my kids, if I'm going to
do this before I have my kids, I'm going to have some kind of prophylactic
mastectomy .... If I end up having children younger, I might do it after, in which
case, I'm going to see. It's just so far in the future that they might have a cure for
it, or they might have so many new treatment options, that I'm really not
inundating myself with information about the current ones, because they're going
to be outdated by the time I make these decisions. I do plan on having
prophylactic hysterectomy after I have my children. And that's it. I mean, (in the
meantime) I'm just going to follow up really closely.
These women felt they had the gift of time and set a time in the future to
reevaluate their treatment decisions or have the BPM and/or BPO. One 30 year old new
mother with a family history of ovarian cancer, who wanted more children, planned on
having a BPO at 35 years. This age was recommended by her gynecologist, as she
related:
So when I told my doctor (gynecologist) the (test) results .... He said, "Thirtyfive, you need to have your ovaries out" and he said, "I would take your tubes and
uterus, you don't need them at that point" .... So, I am planning to do that at
thirty-five, if not before. If I am able to have more children and I'm done at thirtyfour, I'll have it out at thirty-four.
In the final analysis, it was the option's risk reduction capability that made it
salient or attractive to the participant, causing the option to overshadow consideration of
other available options. Participants balanced the gains of risk reduction, relief of breast
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and ovarian cancer worry, and fulfilling their obligations as mother and wife to remain
cancer free, against the potential losses of surgery; such as menopause, infertility,
changed body image, the continuing risk of developing ovarian and breast cancer in
residual tissue, and surgery(ies)' effect on family and employment. Some who chose
vigilant surveillance anticipated further consideration of their choice in the future. Table
3 provides a summary of the advantages and disadvantages of the various risk
management options (in order of precedence) expressed by participants.
Decisions made. Sixty percent of participants (71 % of those with a BRCA
mutation) chose one or both of the surgical options (BPM or BPO) to prevent breast or
ovarian cancer; 40% chose both BPM and BPO. Participants clearly preferred
prophylactic surgery over early detection measures to reduce their susceptibility to breast
and ovarian cancer. See Table 4 for a summary of participants' risk management options
chosen. Of the twelve participants that chose both surgical options (BPM and BPO), three
chose concurrent procedures and nine chose to spread the surgeries out over time. Six
additional participants chose only one of the surgical options (BPO: 2, BPM: 4). The
mean time from testing until surgery for BPM was 10 months (range 1-40 months) and
for BPO was 6.9 months (range 0-27 months).
The sequence in which participants had their surgeries varied with each
participant. Participants made this sequencing decision around their greatest fear or
perceived risk, as this 52 year old woman with a father with breast cancer recounted:
And I think what you find is that those of us who have lost a family member to
one or the other cancer, our fear is what we lost our closest loved one to .... I
didn't know my grandmother that much, so I wasn't fearful of ovarian, as much as
I was fearful of breast. So, I focused all ofmy mental energy at first on breast
cancer.... I could not deal with my ovaries until I was done with my breasts ....
they didn't have the ticking time bomb aura to them that my breasts did.
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Table 3. Participants' Perception of Advantages and Disadvantages of Risk Management
Options (attributes of options listed in order of precedence)
Bilateral Prophylactic Mastectomy (BPM)
BPM Advantages
Greatest risk reduction for breast cancer - most effective option
•
o Reducing breast cancer risk to the 90' s of not getting it
o No tissue, less chance of cancer
Will save my life
•
o Preventing/avoiding cancer in the future
o Living longer without getting cancer
o Avoiding chemotherapy
Being there for my children
•
Peace of mind, knowing I had done all I could physically
•
o Rid my life of this fear of cancer
o Not having to worry so much about breast cancer
o Reduced anxiety of getting breast cancer
o Not having to be scared like I was from May-July from mammogram to
ultrasound to MRI
A better quality of life
•
o Not having to go through mammograms and biopsies again due to
fibrocystic breasts
Breasts don't serve a physiologic purpose
•
o It's not a sexual thing for me
Getting breasts that don't sag (planning reconstruction)
•
o Reduce weight in breasts
BPM - Disadvantages
Risks of surgery and anesthesia
•
o Recovery and inconvenience
o Healing after surgery; pain, scars
o Extensive surgery
Reconstruction hassle - long recovery
•
o Possible complications like infections
o Getting exchanges, getting nipples put on
o It would take over my life
Removing healthy tissue
•
Not completely reducing the risk; 90% reduction, due to no long term studies
•
Body image concerns, not wanting to alter body
•
o Fear of feeling ugly, hideous
o Self image- "Not a woman anymore"
o Having something fake inside my body. Fake nipples
o Fake boobs, they don't feel the same or look the same
o Clothes don't fit properly
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Table 3. Participants' Perception of Advantages and Disadvantages of Risk Management
Options (attributes of options listed in order of precedence)
Bilateral Prophylactic Mastectomy (continued)
BPM - Disadvantages (continued)
Relationship concerns with male/partner, family
•
o Look good in clothing but not naked
o Feeling less feminine
o Loss of nipple sensation
o Not able to nurse my babies
o Explaining to the kids about the surgery
o Would impair feminine role modeling for teenage daughters
Cost - Need health insurance to cover cost
•
o Insurance doesn't cover
o Cost in terms of time off work
o No nearby family resources to assist with children after surgery
Too extreme at my age of 32
•
Bilateral Prophylactic Oophorectomy (BPO)
BPO Advantages
Greatest risk reduction
•
o Prevents or reduces risk/chances of ovarian and breast cancer
o Prevent ovarian cancer, the silent killer
o Survival; I'll live forever
o Better than dying of ovarian cancer
No good early detection program for ovarian cancer
•
Ovaries no longer of value
•
o Don't need ovaries any more, no more babies planned, starting menopause
o Control onset of menopause
o Wanted menopause early so it would be over with
o Be finished with menstruation
Provide peace of mind
•
o Rid the fear of ovarian cancer
Found ovarian cancer and thus saved her life
•
BPO - Disadvantages
Surgical menopause
•
o Menopausal symptoms, loss of estrogen and subsequent health effects
o Increasing risk of significant diseases: osteoporosis, heart disease, libido
concerns, vaginal lubrication, hot flashes, night sweats
o Surgical menopause is an assault - Premature aging, mind ages, memory
loss
No standard of care for treatment of surgical menopause in BRCA women
•
Not able to have children
•
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Table 3. Participants' Perceptions of Advantages and Disadvantages of Risk Management
Options (attributes of options listed in order of precedence)
Bilateral Prophylactic Oophorectomy (continued)
BPO - Disadvantages (continued)
•
•

•
•

Ovaries serve a physiological purpose
Removing perfectly good body parts on a "what if'
o May be unnecessary
o Another female organ ripped from me
Loss of femininity
Impairment of maternal role to role model for daughters
Surveillance - Breast and Ovarian

Surveillance Advantages
Breast screening - MRI are definitive
•
Ovarian screening- surveillance is better than surgical menopause
•
Confidence in physician checking breasts q 3 months
•
o Being followed closely, and getting follow up on anything that is suspect
Surveillance Disadvantages
Breast screening- Don't trust mammograms, didn't show sister's cancer
•
o Missed mom's cancer
o Screening not sensitive enough to find small cancers
o Error rate too high due to breast density
Didn't reduce my risk enough
•
Didn't relieve the breast and ovarian cancer worry
•
o Based on my chances, I'd live my life in fear
o Takes my time, my mind, and my emotions
Ovarian screening - not particularly effective
•
o By the time they actually see something, it can be quite advanced
o No good early detection of ovarian cancer
o CA-125 too many false positives - testing not that great
Radiation with mammograms may be harmful in high risk women
•
Chemoprevention with Tamoxifen
Tamoxifen Advantages
None stated
•
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Table 3. Participants' Perception of Advantages and Disadvantages of Risk Management
Options in order of precedence (continued)
Chemoprevention with Tamoxifen (continued)
Tamoxifen Disadvantages
•
Bad side effects, increased risk of uterine cancer, cataracts, deep vein thrombosis
o Hot flashes
o Risk of cervical cancer
o Weight gain-Had hard time losing weight while on tamoxifen
o Allergic to tamoxifen
o Couldn't tolerate it
•
Minimal reduction of risk, more for BRCA2 women
o Questionable results for BRCA 1 women
o Didn't reduce my risk enough
o 50/50 chance of preventing breast cancer
o Not as effective as BPM
•
Adverse to experimental meds
o Taking a drug which is on a clinical trial basis for women with BRCA
mutations
o Not sufficient research for women at risk in "previvor" (unaffected with
positive mutation) community
o Don't like taking medication or pills
•
Not a permanent fix; I'm young, protocol for 5 years, then what?
•
Potential harmful effects on fetus. Not supposed to have kids for next couple of
years
•
Tamoxifen didn't help mother, her cancer recurred in 5 years.
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Table 4. Genetic Testing and Risk Management Options Chosen
Total Sample n= 30
Year tested (median)
(ran2e)
Surgery Chosen

Decision Option Chosen

Time until BPM (mean)
(ran2e)
Time until BPO (mean)
(ran2e)
Estrogen use

Menopausal status

2002
1994-2004
Both BPO and BPM n= 12
BPOn=2
BPMn=4
Nonen= 11
Othern= 1
Both breast and ovarian
screening n= 9
Ovarian screening n= 4
Breast screening n= 2
Tamoxifen, breast and ovarian
screening n= 2
BPM and BPO n= 12
None n= 1 (age 22)
10 months
1-40 months
6.9 months
0-27 months
Birth Control n= 3
Hormone replacement n= 7
Nonen=20
Surgical menopause n= 14
Pre-menopause n= 3
Menopause n= 2
Non= 11

BRCA Positive n= 21
BRCAl = 12; BRCA2= 9
2002
1997-2003
Both BPO and BPM n= 11
BPOn= 1
BPMn=3
Nonen= 5
Othern= 1
Both breast and ovarian
screening n= 3
Ovarian screening n= 3
Breast screening n= 2
Tamoxifen, breast and
ovarian screening n= 1
BPM and BPO n= 11
None n=l (age 22)
11 months
1-40 months
6.9 months
0-27 months
Birth Control n= 1
Hormone replacement n= 6
None n= 14
Surgical menopause n= 13
Pre-menopause n= 1

Non=7

Variant of Uncertain Significance
n=9
2002
1994-2004
Both BPO and BPM n= 1
BPOn= 1
BPMn= 1
Nonen=6

Both breast and ovarian screening
n=6
Ovarian screening n= 1
Tamoxifen, breast and ovarian
screening n= 1
BPM and BPO n= 1
2.5 months
2-3 months
2 BPOs done prior to testing
Birth Control n= 2
Hormone replacement n= 1
Nonen=6
Surgical menopause n= 1
Pre-menopause n= 2
Menopause n= 2
Non=4
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Others made their sequencing decision around the capability of medical technologies and
their physicians' recommendations. As this 41 year old mother who had the BPO first
reported:
The entire team there pretty much said that oophorectomy was like ... a nobrainer. The medical oncologist, as far as the breasts said, " ... we have
diagnostics that we can catch this, we can catch it better than ovarian cancer,
which when it's discovered it's usually very late" and my family history certainly
indicates that, and they ... seemed more urgent in the oophorectomy part.
Some needed time between prophylactic surgeries to "grieve" the loss of their breasts and
ovaries. As this 52 year old woman who chose both prophylactic surgeries, but spaced
them 2 years apart, related:
I was not going to do this oophorectomy until after I had done my breast work. I
could not bear losing more than one body part at the same time. And I really felt I
needed some grieving time .... I mean this was really hard.
Thirty seven percent of the women ( 5 BRCA positive and 6 with VUS) chose
vigilant surveillance. This included women in their twenties and thirties who were
delaying their decision until they were finished with childbearing and breastfeeding. Four
in these age groups (3 BRCA positive and 1 with a VUS) indicated they planned on
having prophylactic surgery in the future. In the interim they chose vigilant surveillance.
Trust in the competence of their physician, use of MRI, and hope for new research
discoveries were influential factors in their decision for vigilant surveillance. They found
reassurance in their belief that with surveillance, if they developed cancer it would be
found early. It is important to note that the advantages and disadvantages of the surgical
options identified by those choosing vigilant surveillance were similar to those choosing
prophylactic surgery(ies). However, how they weighed the advantages and disadvantages
of the alternatives, based on values, beliefs, and desired outcomes were different.
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Only two participants chose the option of chemoprevention with vigilant
surveillance. Participants received less information about this option and it was not
usually recommended by their health care providers. Participants did not identify any
advantages of taking tamoxifen, but delineated several disadvantages, including risk for
endometrial cancer, cataracts, and thrombosis, its experimental nature in BRCA carriers,
and insufficient risk reduction. Several younger women did not choose this option
because of implications for child bearing.
Whether participants arrived at a risk management decision based on apriori
decisions, followed the expert advice of their physicians, accepted some and rejected
other advice, or postponed risk management decisions until older, they reflected back to
evaluate their decisions and put things in perspective.
Reflecting On Actions
Viewing Decisions With Satisfaction

All 30 participants expressed satisfaction with their decision to have genetic
testing, indicated they would do it again, and would recommend it to other women who
were at high risk due to a strong family history of breast and/or ovarian cancer. Although
the youngest participant, age 22, was satisfied with her testing decision, she indicated that
she "wouldn't have gone through it at the age that I went through it." And her
recommendation for other young women, "Do it (testing) for yourself and not for your
parents."
In addition, without exception, all those who had the prophylactic surgeries were
satisfied with their decisions. For two of the women, the prophylactic surgery "saved"
their lives, as early breast and ovarian cancer was discovered during surgery. Few had
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problems with their prophylactic mastectomy or oophorectomy itself, however some had
difficulties with breast reconstruction. Several agreed they were not prepared for the time
that reconstruction took. One participant encountered several problems which have taken
five years to resolve and she still has a nipple reconstruction revision to complete.
Despite this, she was satisfied with her decision for surgery as she explained:
Overall my experience ... it was difficult, but I don't regret it. The reconstruction
was the one decision that I, at times, wondered if I'd made the right decision. I
think ifl had not had complications ... it would have been an easier journey. I am
happy to have reconstructed breasts. I'm really happy about that. But it was a lot
harder than I thought it would be. And I was prepared for a year .... What I
wasn't prepared for, was for it to go on ... for five years to be continuing.
Viewing Decisions As Personal
Participants acknowledge that having testing and managing susceptibility to
breast and/or ovarian cancer are "individual decisions," yet ones set in context. This
participant advised using an intuitive approach, doing "what feels right for you":
You need to do what feels right to you. You will get advice. You will hear people
say, do this, do that, don't do this .... none of that matters .... You need to listen to
your gut and do what's right for you. When you get your results, if they're
positive, it's not the end of the world. And it's not a fun experience but there are
people who have gone through this. You are not alone. You can get through it, no
matter what you want to do .... Because so often people project their own fears
and their own thoughts onto you, and that's not doing people a service.
Viewing Decisions As Unsupported
Although most felt things had been taken care of medically with the surgeries, one
pointed out her emotional and psychological support needs were not met by her surgeons.
"They talked only about the procedures". The "whole loss part and grieving were not
addressed." But in the final analysis, prophylactic surgery offered an "amazing sense of
relief, this huge risk is gone."
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After the prophylactic surgery(ies) and reconstruction were finished, most felt
there was not a "cohesive plan" for follow-up. The reason follow-up was important was
their lingering uncertainty about the small risk of peritoneal cancer or cancer in residual
breast tissue. As this woman explained, she did not know how to do breast exams after
her breast reconstruction:
I think the ball has been dropped with me .... I have silicone implants .... I don't
know how you do breast exams on implants ... You know everyone keeps telling
me you're not gonna get cancer, although there's always the slightest risk. And
that it would be right at the surface, because the implant is behind the muscle, and
anything you have is right up front and that you would know immediately. But
certainly I need to see a doctor for peace of mind.
One seeking care at a comprehensive breast center explained, "They're not
exactly sure where I fit in. I don't have cancer. I don't have breasts. They didn't do my
surgery". She had been working with her genetic counselor to get a process set up for
follow-up, but it was moving very slowly. She explained:
It (follow-up) is non-existent. And I talked to my genetic counselor .... They
talked about putting together a task force of doctors, at least for the institution
where I was ... so when you leave the hospital they tell you what to do. They don't
tell you what to do. And I find that very worrisome. I went through all the
surgeries to be proactive, and I'm sort of in this 'now what'? category where I'm
not sure what to do. Neither do my doctors, I've gone to some specialists. I just
feel I have to take what they say and make my own decisions. I've yet to find one
doctor who I feel comfortable with. I'm looking .... I find that very .. .
disheartening. But the problem being that nobody wants to follow .... I don't
know. Do I go to a breast surgeon still? Do I go to a breast oncologist? Do I go to
a gynecologic oncologist? ... I don't know. There are just no guidelines.
Others concluded, "You have to take personal responsibility", be "very self
directed" in follow-up. Another participant who felt the women in her generation were

"paving the way" indicated there is no "cohesive plan" for follow-up, because "nobody
knows what to do ... everybody has a different opinion." Still others appealed to the
American Society of Clinical Oncology (ASCO) and other professional organizations to
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develop protocols for screening of women with BRCA mutations who have had
prophylactic surgeries:
I still feel pretty bad about the care that I've received as follow-up. Nobody ever
presented me with a plan of how to follow-up. And I am totally in charge of my
own follow-up .... So I do go back to my regular gynecologist every year for an
annual exam. I try to check my own breasts. I do ask my gynecologist
periodically to have a CA-125. But nobody has ever said, "Ok, this is what you
should do for follow-up." I even actually insisted on having a ... transvaginal
ultrasound .... So, I'm doing that myself too .... You know, it would really be
nice ... for ASCO or somebody to come up with some recommendations about
screening for women who have had prophylactic surgery ....
Some women sought follow-up with their primary care physician, gynecologist,
gynecologic oncologist, breast surgeon, or breast oncologist. However, there was not "a
single place" to go for follow-up that addressed all their concerns about the BRCA
mutation. An issue for those that had had a BPO was whether they could safely take
hormone replacement therapy. They questioned what the long term ramifications of the
BRCA mutations were and how they could stay current about new information, as this
woman articulated:
You know, like when I buy a toy or something for my kids, I have to register it,
like the car seats. So if there's recalls, they'll find me. But with this BRCA thing,
there's no like national registry, and they're not going to find me. So I feel like I
have to be more on the up and up with ... what the long-term ramifications are.

Viewing Decisions As Supported
Some of the participants found they could keep up-to-date about the BRCA
mutations by joining a BRCA support group which met regularly to discuss such topics
as new BRCA related research, nutrition, exercise, and stress reduction, and also
provided emotional support. These topics were important because several indicated they
felt maintaining a healthy lifestyle was important for their future without breast or
ovarian cancer. Several had engaged in "exercising", "eating right (lowering fat in their
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diet)", "seeking a balance in their life", "reducing stress" and wanted to "role model
healthy behavior" for their daughters.

Celebrating The Positive
In reflecting on the consequences of their decisions, participants pointed out the
following aspects (a) achieving peace of mind, (b) remaining vigilant, (c) a need to "pay
it forward", and (d) strengthened family relationships.

Achieving peace of mind. Some participants achieved "peace of mind". This was
especially true for those who had prophylactic surgery (ies) and those with variants of
uncertain significance who interpreted their results as negative. They were less worried,
less anxious about getting breast and ovarian cancer, as indicated by the comments from
these two participants:
34 year old with a VUS who chose BPM. I don't have nightmares anymore. It's
given me a peace of mind and it's made me more of an outspoken advocate for it
(prophylactic surgery).
35 year old who chose BPO and BPM. I am much less anxious about it (positive
mutation). I don't worry constantly about breast cancer. Like a load has been
lifted off.
Those with peace of mind also felt they had done all they could to prevent breast
and/or ovarian cancer, so they would not feel guilty if they should develop these cancers
in the future. If they are present to raise their children, it will have been worth it, as this
participant reported:
What I'm glad about is that I don't think about cancer .... I'm not afraid of cancer
any more. Now I feel like if I got cancer, and I could, and given my family
history, I mean who knows where I could get it, I would feel like I've done what I
could and I think I would be able to deal with it .... Cause I did the most that I
could at the time .... and now I'm living my life. And I'm raising my kids and ...
as they get older I will feel like a big motivation for having done the surgery will
have been fulfilled. I mean, I've been around to raise my kids. They didn't have to
grow up without a mom.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

166

They also started envisioning themselves getting older, becoming a grandmother:
4 7 year old. I really never envisioned myself as an old person either .... And I
guess because there was no reason for me to. All the woman in my family died in
their 50's. And it wasn't until my testing and my surgery that I can envision
myself as a grandmother one day.
Women who had achieved peace of mind had also let go of their fear and their
worry and were now more externally focused, on daughters, sons, sisters, and nieces as
these two mothers related:
41 year old. I worry about my daughters. I worry about my sisters, my nieces. I
don't worry about myself anymore. That feels so good to be able to say that ....
But I don't worry about getting breast cancer any more. And I know that my
chances, it's not completely gone. But you know what? I don't need to hold on to
that fear anymore. I've done all that I can do to let that go.
52 year old. But I worry about my daughter. Oh, just the thought of her having to
go through this is pretty ... scary. And I think it's difficult, not because I know
she'd have the same experience. But I worry about her because I actually fear that
if she's positive she won't look at it with the sense of urgency that I did, because
she's not watched her mother die of breast or ovarian cancer. And I really fear
that she's gonna minimize it because of that.
Remaining vigilant. Those who chose surveillance, both with positive BRCA
mutations and with variants of uncertain significance, had a heightened awareness of
their body and felt a need to be vigilant about surveillance. As one 41 year old participant
related, "I know that I need to be vigilant and be serious and take it seriously, because
I've seen cases where women were not doing anything and got cancer, and that's just the
last thing I want to have happen".
They also felt they had to take responsibility and be their own advocate for
follow-up, as expressed by this 54 year old participant: "I think it's, you have to take
personal responsibility to make sure you get physicals frequently enough and to pay
attention to symptoms and things like that".
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For those choosing surveillance, especially those who were delaying their
decision making for prophylactic surgery, there was a lingering uncertainty that maybe
they didn't make the right decision or were not giving it enough attention as expressed by
these participants:
45 year old. I don't think it's really changed my life, other than making me be
more diligent about my screening, although I feel like I was pretty diligent
already. It's maybe made me even more so ... And also, maybe one day I might
change my mind about the surgical prophylactic, if more research, if things would
change. I mean, this genetic testing is relatively new still. [Hardest part?] The
worry that I didn't make a right decision and have a surgical prophylactic ... It's
just because I'm having just the medication and the frequent screenings. What if
that's not enough?
25 year old. I mean, I'm worried this whole breast cancer thing is not in the
forefront of my mind. I've got so much else on my plate right now.

Paying it forward. A third consequence experienced after BRCA testing and risk
management decision making was a sense of altruism, some participants wanted to pay
back by helping others. One 41 year old participant, motivated by her loneliness when
making her decisions, described her desire "to pay it forward" by helping support and
share information with others going through this:
I am involved in circles that I never thought I would be involved in. I never
thought I'd be doing this ... on the phone with researchers .... My breast surgeon
here in town calls me and says, " ... would you speak to so-and-so. They just
found their results." .... Because when I found out my results and I was here in
(city) with all my treatment team, I offered my name and my number to the
people in mammography, to my breast doctor, .... genetic counselors .... I wanted
to be able to help other people that came up with this, because it was a real lonely
place when I found out .... I sort of have that mentality of that you have to pay it
forward. You know that there will be others that will come with this. That
whether ya find out in 1999 or you find out in 2004, the issues are going to be so
similar.
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Another, a 52 year old, did not want others to feel unsupported and isolated as she had.
The mutation had become part of her identity. She viewed her experience as spiritual, one
of personal growth:
I vowed when I went through this, that ifl had any power, ... I would not let other
women be so unsupported and isolated in their (experience) .... I think this is a
way that I can give back to the world .... I'm not a religious person but I think
I've gotten much more spiritual throughout all of this ... And to be honest with
you, if somebody said, "Oh, we could take away your mutation", if it meant that I
had to give back all the personal growth that I've achieved because ofthis ... , I
wouldn't. I would keep my mutation. Because it's been that much of a learning
and growth experience for me.

Strengthened family relationships. Several of the participants felt that the testing
and risk management had brought them "closer together" with family members,
especially spouses who had been through the decision making and difficult times with
them. The experience had helped them to reevaluate their priorities and realize that
"family is more important" as this 50 year old grandmother with a BRCA variant of
uncertain significance explained:
I don't go out like I used to go before with friends and enjoy. I don't know why.
I'm more closer to home .... It does change you. And I think that the family is
more important now. And my grandkids .... And sure, that's for the family's sake.
One participant gave a detailed account of her difficult times, the changing feelings and
emotions during her surgeries, and how working through these brought her and her
husband closer together:
In some ways it's brought my husband and me closer together. In some ways it's
been difficult because there were times when I was trying to sort out hormones
that I felt emotionally very volatile and I'd get into fights with him. I felt like kind
of asexual for a while where I had these big lumps on my chest that didn't feel
like breasts and I was probably kind of angry that I had to go through this. So
there were difficult periods but all in all, if I look back now, the overall sense I
have is that we're closer .... It was a very bonding experience to have to make
those decisions together and to have to work through that difficult period when I
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had that big surgery .... I think we feel pretty optimistic, really optimistic about
our future together.
A 32 year old participant also described a strengthened relationship, this one with
her father:
As far as my family, I think my father and I get along better now because ... his
view being that I wasn't dealing with the cancer thing and now I'm dealing with it
and he is, I think, very happy with that. And I'm happy that's it's not this weird
thing that we can't talk about without getting in a fight about it anymore.
Giving Advice To Other Women Seeking BRCA Testing
Participants had the following advice for other women seeking BRCA testing and
treatment: (a) get your insurance in order, both health and life insurance before testing;

(b) seek genetic counseling first, don't get testing done in a physician's office without
genetic counseling; (c) there is a community of women, "a sisterhood of a unique kind"
that is willing and able to provide support; and (d) "be prepared for any type of result, if
it's inconclusive, you have the same decisions as everyone else;" and (e) ''take your time,
keep an open mind and try to make sure you have people you can talk to openly and
honestly about how you're feeling."
In summary, making a risk management decision to manage their susceptibility to
breast and/or ovarian cancer was a strategy to manage their embodied risk from a BRCA
mutation or a genetic variant of uncertain significance. It was the consequence of their
knowledge and experience, as these women confronted their fear and regained control.
Both the certainty and uncertainty of their test results set in motion a series of actions and
interpretations leading to risk management decisions. After having obtained sufficient
information about risk management options, and drawing on personal, family, and
professional resources, participants' began deliberating, examining the advantages and

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

170

disadvantages of alternatives and sorted out their feelings, weighing alternatives based on
personal experiences, beliefs, and values. Four decision making patterns were used (a)
acting on apriori decisions, (b) following expert advice denovo, (c) following some and
rejecting other advice, and (d) postponing the decision until older. In the final analysis it
was the options risk reduction capability that made it salient or attractive to the
participant, causing the option to overshadow consideration of other available options.
After making a risk management decision they reflected back to evaluate their decisions
and put things in perspective. Participants viewed their decisions as satisfied, personal,
supported, and unsupported in follow-up. They celebrated the positive consequences,
including peace of mind, remaining vigilant, a desire to "pay it forward", and
strengthened family relationships.
These last two chapters explored the categories, actions and interactions, and
consequences of managing susceptibility to hereditary breast and ovarian cancer. The
following chapter will discuss these categories in the context of existing literature.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER VI
DISCUSSION OF FINDINGS
This chapter discusses the grounded theory of managing susceptibility to
hereditary breast and ovarian cancer in relation to other research and explores the
categories in the context of existing literature. Interrelationships within the categories will
be discussed as well.
This study examined ways in which unaffected women with positive and VUS
BRCA mutations assigned meaning, made interpretations, and responded to their
susceptibility to hereditary breast and ovarian cancer. A grounded theory was developed
based on the perceptions, beliefs, and feelings of these women. The study findings add to
the initial body of knowledge about BRCA genetic testing and risk management decision
making and provides some insights for assisting women in the decision making process.
This study used an inductive analytic technique to identify social and contextual
factors in decision behavior, took a systematic approach to the study of risk management
decision making in the context of participants' past and present experiences, and shed
some light on the complex processes occurring when participants made decisions and
appraised those decisions over time.

171

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

172

Grounded Theory ofManaging Susceptibility to Hereditary Breast and Ovarian
Cancer
Managing susceptibility, the social process identified in this study, broadly
describes the genetic testing and risk management decision making experiences of
unaffected women who are BRCA positive and variant of uncertain significance (VUS)
mutation carriers (hereafter referred to as BRCA mutation carriers). Managing
susceptibility pervades all of the actions, from gaining awareness of HBOC risk, getting
tested, disclosing results, making risk management decisions, and reflecting on the
decisions. Although the theory is categorized, the process is integrated and
interdependent. In this study, given the benefit of hindsight, unaffected women who are
BRCA mutation carriers described their experience of discovering their mutation and
making risk management decisions related to that new knowledge.
Gaining Awareness
The first condition in managing susceptibility, gaining awareness, embodied the
preparatory work to managing their risk of breast and/or ovarian cancer. Most
participants grew up with an awareness of their susceptibility to cancer because of the
loss of a mother, grandmother, or aunt to breast and/or ovarian cancer. This childhood
awareness left them feeling cursed and fearful, with a sense that these same cancers were
their fate. This is consistent with research on elevated perceptions of risk in women with
a family history of breast cancer (Hallowell et al., 1998a, 1998b; Lerman, Kash et al.,
1994; Lerman & Schwartz, 1993; MacDonald et al., 2002) and research by Wellisch,
Gritz, Schain, Wang and Siau (1991) who found daughters of mothers with breast cancer
perceived their chances of getting breast cancer to be much higher than a well-matched
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comparison group. Daughters reported that their life courses were altered by their
mothers' illness, which had ongoing emotional effects, in particular, integration of the
image of a dying mother into a sense of self. Emotional reactions were even more serious
for adolescents. As noted in this study, identification with mothers evoked recollection of
interruptions in family life during the mother's breast or ovarian cancer experience (e.g.
loss of parent and subsequent family disruption).
These heightened perceptions of risk may be explained by Aspinwall and Taylor's
(1997) theory of proactive coping, which indicates that once a potential stressor like
familial risk is detected, it must be appraised. Heuristics such as salience, accessibility,
representativeness, affect, and past experience influence the way in which people
interpret potential danger signals and match them to available schemas or scenarios in
long-term memory. This is a preliminary effort to understand what a warning sign such as
a strong family history may mean. In this study, family history provided salient cues for
interpretation of participants' breast or ovarian cancer risk, they were personally relevant,
and several histories were dramatic. Assessible cues, such as a mother or sisters recent
death or diagnosis, were fresh in their mind, thus a breast cancer diagnosis was ominous.
In addition, breast cancer represented loss of life or loss of quality of life based on their
past experiences. These experiences with family and friends were incorporated into their
risk assessments resulting in a heightened risk perception (Katapodi et al., 2005).
However, a few participants gained awareness of their risk as adults, as the result
of a daughter's or sister's cancer. This lack of awareness of breast or ovarian cancer risk
occurred when the cancer came from the paternal side of the family or there was a death
or divorce which caused the family to lose touch with affected family members. This
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sample had more affected maternal relatives than paternal relatives. The assymetry in
reporting of maternal rather than paternal history reinforces previous research which
indicated that those with a paternal history of breast or ovarian cancer are very unlikely to
have an affected parent and their affected relatives are thus more distant (Green,
Richards, Murton, Statham, & Hallowell, 1997).
Consistent with previous research, the most reported reasons that brought
participants to BRCA genetic testing were: (a) the presence of a known familial mutation,

(b) desire to help other family members by undergoing testing, (c) to relieve doubts about
whether a diagnosis of breast or ovarian cancer is or is not likely, (d) to learn about their
children's risks, (e) and to make health care decisions to reduce risk (Lerman, Seay et al.,
1995; MacDonald et al., 2002; Matthews et al., 2000; Shiloh, Petel, Papa, & Goldman,
1998). In contrast to the study by MacDonald et. al., this work found that reproductive
decision making was an element considered by women with BRCA mutation carriers in
their twenties and thirties. This difference may be explained by the fact that this previous
work dealt with women at high risk based on family history who were speculating on
factors considered important.
In addition to an awareness of their increased risk of breast and/or ovarian cancer,
participants also received messages from family, the media, and health care providers
which brought them to genetic testing. Sixty two percent of participants with positive
BRCA mutations sought testing after notification of a mutation in the family. Two with
VUSs were tested because a VUS had been identified in the family. For others, it was a
family member's diagnosis of breast or ovarian cancer that triggered self or physician
referral about a genetic mutation. Although a motivation for testing was to clarify their
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own risk and gain more certainty, it was also done for other family members and
children.

Co~onting Uncertainty and Getting Tested
Confronting uncertainty and getting tested was characterized by seeking further
clarification of their family cancer and overcoming professional, insurance, and
bureaucratic barriers in the health care system. Lending support to research by Lim et al.
(2004), participants believed "knowledge is power," the knowledge of their BRCA
mutation was seen as an advantage. Their concern about high risk had been validated and
this empowered them to take necessary action to reduce their risk of breast or ovarian
cancer.
When a BRCA mutation had been identified in the family, the family history
required was little more than background information in the genetic counseling session.
But when the determination of the presence of a BRCA mutation had to be made, the
cancer pedigree was essential because it was the data with which the counselor had to
work in order to assess the likelihood of a BRCA mutation in the family. Thus the
information that participants obtained about their family histories from other family
members was crucial and family communication was key. As in research reported by
Green et al. (1997) female relatives were much more likely than males to be asked for
family history information, supporting the idea that women are the "kin-keepers" in the
family. Obtaining family cancer history was at times difficult because of participants'
desire not to upset people with painful memories, having lost touch with a branch of the
family due to death or divorce, or not wanting to upset a vulnerable family member with
painful memories.
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External barriers which participants had to overcome before getting genetic
testing included obtaining health insurance, as well as professional and bureaucratic
barriers. Lack of health insurance and cost ofBRCA genetic testing (nearly $3000) have
been identified in previous studies as factors that influenced uptake of genetic testing in a
clinical setting (Geer, Ropka, Cohn, Jones, & Miesfeldt, 2001; Lee, Bernhardt, &
Helzlsouer, 2002). As reported by Lee et al. (2002), participants in this study identified
fear of insurance discrimination as a barrier to testing. Twenty seven percent (8) of
participants chose not to use their health insurance and paid for BRCA testing out-ofpocket for confidentiality reasons.
Women in this study, as well as those presenting at academic centers for
BRCAl/2 testing, arrived with a strong belief they had a BRCA mutation (Winer et al.,
1997). While awaiting their BRCA test results from the lab, 76% of study participants
speculated about their test results. Of these 74% (17) thought they would be positive,
while only 5 thought they would be negative. They developed theories about why they
thought they would be positive, such as physical or personality characteristics, age,
family history, chance, and degree of fear. This rehearsal helped participants to
conceptualize their experience and prepare for their forthcoming BRCA test result. In
other circumstances, rehearsal has reduced distress and helped with coping after stressful
events (Lazarus & Folkman, 1998; Taylor, Pham, Rivkin, & Armor, 1998).
Obtaining Test Results
The majority of participants in this study chose to receive their BRCA test results
in person, however three obtained results by phone. As reported in previous research,
those who received their results face-to-face from a genetic counselor or physician were
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better able to deal with the results (Frost et al., 2004). Receiving BRCA VUS test results
in a primary care setting, from other than a genetics professional, was problematic for the
only participant who sought care in a primary care setting. This participant was not
informed that a variant of uncertain significance was possible, which proved very
distressing for the participant and her spouse. All other VUS participants recalled a
discussion with their genetic counselor or physician regarding the possibility of uncertain
results. However, when it was the genetic counselor's first experience with a VUS,
confidence in the advice regarding a VUS result was diminished.
A majority (53%) of participants had a husband/partner, sister, father, or close
friend accompany them to the post test counseling session for emotional support. Subtle
clues from the genetic counselor allowed some participants to figure out their results in
advance. They knew their results were positive by the presence of unexpected
professionals in the post-test counseling session, or by noting a difference in how their
counseling session was set up in comparison with a sibling with a negative result.
Consistent with previous short and longer-term research, participants described a
range of emotional reactions to their BRCA test results: from feeling relief, acceptance,
and empowered to shocked, overwhelmed, distressed due to confusion and uncertainty,
and feeling vulnerable (Cella et al., 2002; Dorval, Patenaude et al., 2000; Dorval,
Patemade et al., 2000; Lerman et al., 1996; Lim, Macluran, Price, Bennett, & Butow,
2004; Schwartz et al., 2002; van Oostrom et al., 2003). Some with a positive mutation felt
it was "a gift to know" because it offered an explanation for their family breast and/or
ovarian cancer and they could now do something about their susceptibility. Some
indicated that if they had been negative, they would still have felt at higher risk than the
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average woman. Others were shocked, scared, felt lost, and angry, especially those who
thought they would be negative. This lends support to observations from a previous study
that mutation carriers, who did not expect to receive positive test results, reported
heightened distress after results disclosure (Dorval, Patenaude et al., 2000). After
disclosure participants' thoughts raced with questions about the meaning of a mutation
for themselves, their children, especially daughters, their husbands, and wondering who
to tell, and what it meant for them in terms of their lives and jobs. Testing increased their
sense of vulnerability. It provided an awareness that not only were they at increased risk
for breast cancer, but an ever more insidious problem, ovarian cancer.
For the nine unaffected women who received a result of"variant of uncertain
significance", five rendered it problematic, like a positive result, and four considered it
negative or uncertain. Those who interpreted the results as positive or problematic were
very distressed by their results, because instead of the certainty they were looking for,
they were left with more uncertainty. For participants in the current study, the hard part
was "not having a definite answer," which confirms observations by Frost et al. (2004) in
a study of affected women with test results of uncertain significance. Some felt they
would still get breast cancer with the VUS, that science had just not found other genes in
the DNA that was linked with breast and/or ovarian cancer. Others chose to consider it
positive so they would remain vigilant in their breast and ovarian cancer screening. For
one, it was a physician who rendered the VUS result problematic, considered it positive,
and made referrals for a BPO and BPM. Consistent with qualitative research by Frost et
al. (2004), dealing with a VUS result was even more problematic when they did not
receive genetic counseling to help prepare for this possibility.
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Those who interpreted their VUS result as negative and not problematic, chose a
wait and see approach. They continued with annual breast surveillance and followed up
with their genetic counselor, physician, or Myriad Laboratories to see if new evidence
had been found regarding their variant. This interpretation may have been age related, as
the mean age of those who rendered a VUS problematic was 36 years, while the mean
age for those who did not was 53 years. Perhaps those who rendered it less problematic
felt they were beyond the age in which other relatives had developed breast or ovarian
cancer.
Shortly after receiving their BRCA test results, participants embraced the finality
of their results, their feelings of fear and sadness, shock, and the reality of possibly
getting breast or ovarian cancer. Their emotional turmoil and anxiety were not prolonged
and decreased over subsequent months, which supports findings in previous research on
psychological distress levels after testing in individuals in BRCA families (Butow et al.,
2003; Lim et al., 2004; Lodder et al., 2002; Schwartz et al., 2002). Like other healthy atrisk women, they were able to accommodate the information of their increased risk of
developing breast or ovarian cancer over time. Deciding to overcome their distress,
participants in this study confronted their fears, sought support, and took action they
viewed as taking back control of their lives.

Disclosing BRCA Test Information
After obtaining BRCA test results, in an effort to cope with their susceptibility,
participants sought emotional support by disclosing their genetic information to others.
Findings confirmed other researchers' observations that shortly after testing participants
disclosed their results to their husband or partner, sisters, other immediate family, and
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closest friends (Claes et al., 2003; Green et al., 1997; Hughes et al., 2002; Richards,
1999; Wagner Costalas et al., 2003). Later on they disclosed to extended family and a
few disclosed results to their employers. In addition to seeking emotional support,
participants indicated other reasons for disclosing BRCA test information was to inform
others of their potential risk, to encourage testing in others, and to get advice about risk
reduction measures.
Findings that family factors including pre-existing relationships, patterns of
interaction, and tensions acted to promote or hinder disclosure of BRCA genetic
information supports other research studies (Claes et al., 2003; Forrest et al., 2003;
Hughes et al., 2002). Little and/or superficial contact seemed to be the major subjective
barrier to informing distant relatives. Findings confirmed observations by Hamilton,
Bowers, and Williams (2005) that disclosure of test results was a deliberate process of
selecting family members, the content of information disclosed, and style for telling.
Participants carefully considered the family member's receptivity and vulnerability
before disclosing. They were pragmatic and not like the 'prevaricator' style of telling
found by Forrest et al. (2003) who wait for 'the right moment' and try to squeeze the
information into an already scheduled event. They took a more proactive approach and
talked about disclosure as a more active, carefully considered, and thoughtful process.
Most unaffected women with positive and VUS test results reported positive
aspects of disclosing their BRCA results and overall found their family and friends
supportive. Some families felt closer, because of the bond of a common problem or
vulnerability. This finding lends support to other researchers' observations that there is a
higher degree of support, a connectedness, felt when members of the family were going
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through genetic testing together and shared the same results (Smith et al., 1999). Findings
also reinforce previous studies which showed that support of the partner, relatives, and
friends was important in coping with genetic testing and elevated HBOC risk (Kenen,
Arden-Jones, & Eeles, 2004a; Thompson, Gustafson, Hamlett, & Spock, 1992; Wylie et
al., 2003).
In disclosing their results to others for support, participants encountered two
responses: that of the insider and outsider. Insiders understood the meaning of the
mutation and were usually someone who had the experience of a mutation or VUS result
and provided emotional support. For participants from families in which a mutation had
been identified previously, they usually had insider family members they could speak to
freely. Often this was a mother, sister, aunt, or cousin who shared the mutation. They
talked about their fears of breast or ovarian cancer, fear or guilt about passing the
mutation to their children, adopting, and their experiences with various risk mnanagme nt
options.
The outsider did not seem to understand what the mutation meant to the
participant and thus support was lacking. Outsiders were found among family and
friends, but were noted here in brothers. Kenen et al. (2004a) also found that brothers
were more distant and seemed almost in a space apart when discussing HBOC in their
families. Research studies indicate that men and women frequently have different
communication styles, give and receive various amounts of social support, and differ in
their interest and willingness to discuss such matters as cancer (Kenen, Arden-Jones, &
Eeles, 2004b; Moynihan, Burton, Huddart, Dearnaley, & Horwich, 2003; Pretorius,
1996).
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Although family and friends were sounding boards for participants' feelings about
having the BRCA mutation or VUS, there were times they felt alone, isolated by the
responses they received. These findings lend support to Foster et al. (2004) observations
that support by some relatives is limited by differing opinions about BRCA testing and
different ways of coping with the threat. Several participants in this study found what
they really needed was to draw on the strength and support of women who had been
through similar soul-searching. These insiders had a common ground of shared
experiences and concerns and provided a sense of connectedness which helped the
participants' fears and isolation to dissipate. They helped to legitimize the participants'
feelings and provided a comfortable environment where they could speak out about how
they felt. They also understood issues such as employer attitudes about employment and
health and life insurance concerns. Participants found insiders in a chatroom on a BRCA
support internet website, Facing our Risk of Cancer Empowered (FORCE), the
Hereditary Breast and Ovarian Cancer Organization in Canada, National Ovarian Cancer
Coalition, as well as hospital-affiliated peer support groups.
These peer support networks helped participants regain a sense of control over
their lives and confirmed the decisions they needed to make for themselves and their
loved ones. These findings lends support to the need for peer support groups identified by
women at high risk for breast cancer in research by Appleton and colleagues (2000).
These findings also support previous studies that indicate that professionally led
supportive-expressive group therapy facilitates psychological adjustment in cancer and in
women with BRCA mutations (Esplen et al., 2004; Goodwin et al., 2001; Spiegel,
Bloom, Kraemer, & Gottheil, 1989; Spiegel & Classen, 2003). This is the first study to
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date to address the importance of peer support groups in unaffected women with BRCA
positive and VUS mutations.
In addition to disclosing their results to obtain support, participants also wanted to
inform others. Participants who were the first in the family to be tested experienced a
sense of obligation and responsibility to inform others in the family who would possibly
share the mutation, for the other's personal sake and the sake of their children. These
findings support previous studies (Foster et al., 2004; Green et al., 1997; Hallowell, 1999;
Kenen et al., 2004b). Implicit in the participants' message was the need for the family
member to find out their risk to minimize their chances of developing breast or ovarian
cancer. As in other research, participants disclosed to inform female relatives more than
male relatives and to immediate family members more than distant relatives (Claes et al.,
2003; Hughes et al., 2002; Wagner Costalas et al., 2003). In addition to communicatin g
their BRCA test results to their family, some wanted to be a resource for others, as they
wanted as many people as possible to know about the mutation. Some shared their stories
by writing and publishing, speaking to lay and professional groups, participating in chat
rooms and in research. By being open they hoped to reduce other womens' fear of
discrimination with testing.
Those who felt the duty to inform family members indicated it was a sensitive
issue and needed to be handled carefully. Findings confirmed other researchers'
observations that some people desire as much information as possible about their genetic
cancer risks, while others prefer to avoid the information due to the emotional impact on
self and/or family members (Geer et al., 2001; Kenen et al., 2004b; Lerman, Peshkin,
Hughes, & Isaacs, 1998; Lim et al., 2004). Women in this study had to balance their
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sense of obligation to inform family with their family member' s need to be protected
from upsetting information. Most preferred to disclose the family's HBOC risk, unless
there was a reason that inhibited them, such as vulnerabilities due to age, sickness, or to
prevent guilt feelings in someone who was terminally ill. The desire to protect family
members from harm while disclosing has been noted in other studies (Forrest et al., 2003;
Foster et al., 2004; Hamilton et al., 2005; Hughes et al., 2002; Kenen et al., 2004b).
Participants in this study did not anticipate the range or intensity of reactions they
experienced while disclosing their genetic information to family members. While some
experienced a sense of reconnection with the family, others found their communication
blocked, because not everyone, including sisters, are of the same mindset and really did
not want the information. Family communication patterns such as open and supportive,
directly blocked, indirectly blocked, self censored, and use of third parties were noted,
lending support to research by Kenen, Arden-Jones, & Eeles (2004b). Those with VUS
results were more uncertain about their own risk and experienced more difficulty in
explaining their results to family. Some participants experienced difficulties telling
relatives because they worried about its impact on family members and it also reopened
their own sense of vulnerability. These finding lend support to research that disclosure of
positive BRCA test results to relatives may result in increased psychological distress for
the discloser (Costalas et al., 2003; Foster et al., 2004; Lerman, Peshkin et al., 1998; Lim
et al., 2004).
Most participants in this study did not disclose BRCA test results to their young
children. In comparison, research by Hughes et al. (1999) and Tercyak, Peshkin,
DeMarco, Brogan, and Lerman. (2002) found that 50% and 53% respectively of mothers
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chose to disclose their BRCA mutation status to pediatric age children (under 19 years of

age for Hughes et al. and 8-17 years for Tercyak et al.), with older children more likely to
be informed than younger children. Findings support previous studies which showed that
disclosure ofBRCA results to children is influenced by the child's age and
developmental phase, and the parent's philosophy of communication (Segal et al., 2004;
Tercyak et al., 2002). In this study, some mothers who did not believe in keeping secrets,
or wanted their daughters to share in this experience, disclosed to daughters as young as 9
year old. Consistent with reports by other researchers (Forrest et al., 2003; Hamilton et
al., 2005; Kenen et al., 2004a; Segal et al., 2004), there was a desire to do the right thing
for children, protecting them for as long as possible, but also knowing they needed to be
told in time. Most mothers of young children did not plan on disclosing their BRCA test
results until they were old enough to understand the information and faced the potential
risk themselves. Participants in research by Segal et al. (2004) felt the 'ideal age' for a
child to be told about BRCA mutations was 19 to 25 years.
Although most parents with young children in this study did not disclose their
BRCA genetic information, they shared their prophylactic surgical procedures and
explained they were done to prevent breast and/or ovarian cancer in the future, usually
linking the explanation to a family member's cancer or surgical procedure that the child
was aware of. However, when parents decided not to disclose their BRCA results to
children, it restricted the number of people they told. This served to prevent information
from being inadvertently revealed to children at gatherings of family and friends. Other
families agreed to hold the information close to family due to fear of health insurance or
employment discrimination.
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In summary, these findings indicate that disclosure ofBRCA genetic information
was a coping mechanism to obtain support from family, friends, and peers. It also was
viewed as a mechanism to fulfill a social obligation to inform other family members of
their potential risk and encourage testing in others. Disclosing was a complex issue, a
family affair, and was influenced by both pre-existing familial communication patterns
and the individuals' understanding of and responses to their susceptibility for hereditary
breast and ovarian cancer. Disclosing of their BRCA carrier status was an important step
in breaking down participants' feelings of fear, isolation, and vulnerability so they could
proceed to further manage their susceptibility to breast and ovarian cancer.

Making Risk Management Decisions
Although participants experienced a wide range of emotional reactions after
learning their BRCA carrier status, their disclosure to family, friends, and peers seemed
to provide the support they needed to cope with their fears, regain control, and gain a
sense of mastery over their fear of breast and ovarian cancer. Findings reinforced
previous longitudinal studies that indicated BRCA testing generated specific concerns
and psychological reactions, however there were minimal adverse psychological effects
(Appleton et al., 2000; Croyle, Smith et al., 1997; Cull et al., 1999; Dorval, Paternade et
al., 2000; Lerman et al., 1996; Schwartz et al., 2002).
In considering risk management options of prophylactic breast and ovarian
surgery, chemoprevention, and vigilant surveillance, participants were choosing between
two outcomes, either to reduce their risk of breast and ovarian cancer or "catch it early."
Risk reduction options included prophylactic surgeries and chemoprevention with
tamoxifen. Early detection ("catch it early") involved annual vigilant breast and ovarian
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screening. Both the certainty and uncertainty of their BRCA test results set in motion a
series of actions and interpretations leading to risk management decisions. This set of
actions included seeking information, drawing on resources, deliberating and making
decisions, and reflecting on actions
After obtaining information from their genetic counselor and physician on risk
management options available, participants sought information from both lay and
professional sources to assist them in making risk management decisions. For some, their
physician's non-directive stance, not prescribing what to do, left them disappointed
because they felt they must make a decision when they did not have the requisite
information. Most participants had an information seeking coping style, as they expressed
their belief that "knowledge is power" and the "key to life-saving decisions". Findings
support previous studies that indicated alternatives that were not immediately salient
(preferred) tended to stimulate a need for more information or consultation, so the
participant was better able to evaluate it (Slovic, 1975; Tversky, Sattath, & Slovic, 1988).
Participants sought more information about the surgical options, especially breast
reconstruction options. Knowledge gained in information seeking was effective in
alleviating the bewilderment they felt in discriminating between the risk management
alternatives. These finding lend support to research by Pierce (1993; 1996) who found
that breast cancer participants making decisions for surgery sought information when
they were unable to discriminate between alternatives and experienced conflict.
Participants sought information from various sources, some preferred obtaining
information only from professionals in clinical settings, while others used written
materials ranging from scientific reports to popular magazines. The use of the internet for
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scientific reports and online support groups, such as FORCE was prevalent. Participants
emphasized how valuable it was to meet with or talk (by phone or in chat rooms) with
women who had similar histories, had been through the risk management decision
making process, and openly shared their knowledge and experiences about issues they
were working through. These support networks provided links to research and other
internet sites for gathering information about their risk management options and were
knowledgeable referral sources for genetic professionals, oncologists, gynecologists, and
plastic and breast surgeons. Peer support networks helped participants regain a sense of
control in their lives and provided reassurance about the decisions they were considering.
These findings confirmed other researchers observations that social networks help
alleviate the damaging effects of stressful life events by providing potential coping
resources such as emotional, informational, and practical support (Fawzy, Fawzy, Arndt,

& Pasnau, 1995; Leszcz & Goodwin, 1998).
In making risk management decisions, participants drew on the resources of their
life experiences and relationships with others. Their decisions were based on a broad set
of values and beliefs about the perceived effects of risk management on their personal
lives and their families. Past family and personal experiences, present sense of self and
their relationships, and aspirations for the future were all part of the participants' decision
making considerations. These findings reinforce previous studies which reported that
patients' decisions to accept treatment were personalized, to match their views of
themselves within the context of their life stories (Hallowell et al., 2004; Kelly-Powell,
1997). Pierce and Hicks (2001) indicate that individuals make decisions filtered through a
personal understanding of the problem and potential solutions. For several participants,
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risk management decision making resurfaced memories of interruptions in family life
during an earlier cancer-related experience of their mother, sister, or daughter. Also, the
sense of loss associated with their susceptibility to breast and ovarian cancer impacted
their concept of current and future self. Concepts used by other researchers to
demonstrate the perceptions of participants regarding the effects of risk management on
everyday live and reliance and trust on health care providers were salient (Appleton et al.,
2000; Frank, 1990; Hallowell, 2000; Hallowell et al., 2004; Lim et al., 2004; Pierce,
1996; Ward, Heidrich, & Wolberg, 1989).
Most participants sustained personal relationships by involving their
husbands/partners and other family members in their decision making. They described
both supportive and unsupportive responses from extended family members to their
decisions about risk management, especially prophylactic breast and ovarian surgery.
They sought various levels of input about the risk management options from family, but
most felt in the end it was a personal choice. They described their spouses as supportive,
which made decision making easier and helped reduce their distress. This lends support
to findings by Wylie et al. (2003) which showed that the role of spouses in BRCA
mutation carriers' social support system is significant. Perception of their spouse's
anxiety and spouse's support at the time of testing were predictive of the womens'
psychological distress up to 2 years after BRCA testing. The interaction of the two
variables were even more predictive. Findings from this study further support the
importance of family context in understanding risk management decision making for
susceptibility to HBOC (Lim et al., 2004).
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After obtaining sufficient information about risk management options and
drawing on personal and professional resources, participants' began deliberating,
examining the alternatives to select a particular option. For some, decisions were
immediate while others were more deliberative, depending on the salience of the
alternative and its respective attributes.
Four decision making patterns emerged: acting on apriori decisions, following
expert advice denovo, following some and rejecting other advice, and postponing the
decision until later. These patterns were related to the way participants approached the
decision, gathered information, and the amount of control they preferred in decision
making. Two of these patterns are similar to styles of decision making identified by
Pierce (1993; 1996), that of the deferrer and deliberator. Deferrers selected an alternative
with relative ease, choosing a recommendation made by their physician, deferring to his
or her expert judgment. Participants' reports indicate that their physicia n's presentation of
risk management options may have influenced their choice through framing effects, as
has been reported in previous studies (Llewellyn-Thomas, McGreal, & Thiel, 1995;
Pierce, 1993; Tversky & Kahneman, 1981). It is important to note here that as new
medical evidence on the effectiveness of the risk management options for BRCA carriers
evolved during the period participants were making decisions, physicians' knowledge
and willingness to make recommendations also may have changed.
Deliberators were similar to participants who 'followe d some and rejected other
advice'. These participants' decision making was similar to the normative models of
decision making and resembled the vigilant decision maker identified by Janis and Mann
(1977). They carefully considered the risk management alternatives, identified
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advantages and disadvantages of the alternatives, weighed attributes based on personal
preferences, and validated the information with expert consultation.
However, two styles were dissimilar to Pierce's (1993) research. One,
'postponing a decision until older', was not similar to the delayer identified by Pierce, as
the decision to postpone prophylactic surgery(ies) included the decision to comply with
vigilant breast and ovarian cancer surveillance at the present time. It was not because
they could not arrive at a decision because the alternatives were close together in a valued
dimension. In this study, participants' plans for surgery(ies) were delayed until they had
completed a family or an older chosen age, based on when a mother or sister had
developed breast or ovarian cancer, or an age recommended by their genetic counselor or
physician.
The fourth style, 'acting on apriori decisions', did not have a corollary in this
previous work (Janis & Mann, 1977; Pierce, 1993). These findings, however, support
previous research in breast cancer in which Hughes (1993) found that treatment selection
was related to the amount of information subjects received prior to their clinic visit from
informal sources such as friends, family, and media This suggested that patients'
treatment decisions may be influenced or biased by early information, regardless of the
source. These findings also confirmed other researchers' findings that some participants
had been strongly considering their chosen risk management option before genetic testing
and the additional BRCA test results provided the certainty that this was the right choice
(Lerman, Daly, Masny, & Balshem, 1994; Meiser, Butow, Barratt et al., 2000).
Most participants chose risk management options they perceived gave the greatest
risk reduction and thus enhanced their chance of living out their lives. Other important
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elements were the participants' values and beliefs about their quality of life and its impact
on their children should they develop breast or ovarian cancer. Testing and risk
management allowed them choices their family members did not have.
Sixty percent of participants (positive and with VUS) chose a prophylactic
surgery options (BPM or BPO). Seventy five percent of those with positive mutations and
33% of those with variants of uncertain significance chose one of the prophylactic
surgical options. Forty percent of participants chose both surgical options. Positive
mutation carriers clearly preferred prophylactic surgery over early detection measures to
reduce their susceptibility to breast and ovarian cancer. Although the preference for
prophylactic ovarian surgery over early detection to reduce the risk of ovarian cancer has
been reported in other studies (Lodder et al., 2002; Meijers-Heijboer et al., 2000; Scheuer
et al., 2002), this has not been the case for prophylactic breast surgery in the United
States where choice for BPM has ranged from 0%-15% in unaffected carriers (Botkin et
al., 2003; Lerman et al., 2000; Scheuer et al., 2002). However, two studies in Holland
(Lodder et al., 2002; Meijers-Heijboer et al., 2000) found that 51 %-54% of unaffected
female carriers had a BPM within 2 years after testing (50% - 64% had a prophylactic
oophorectomy). Variability in uptake ofBPM may be explained by differences in
recommendations across locations, cultural differences, population characteristics across
studies (differences in age distribution), value differences toward body integrity,
femininity, and preventive surgery, and differences in health care funding systems in
different countries. In addition, collectively all previous studies reporting on uptake of
prophylactic surgeries in unaffected carriers, recruited participants from 1994-2000 when
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research reports on the effectiveness of BPM and BPO in unaffected mutation carriers
were not available. Also, most studies report on following women for only 12-24 months.
As reported in studies of high risk women, factors that influenced participants'
prophylactic surgical decisions included their sense of susceptibility (subjective risk
perception) to breast or ovarian cancer (Hallowell, 1998; Hallowell, Jacobs, Richards,
Mackay, & Gore, 2001; Hatcher et al., 2001; Hurley, Miller, Costalas, Gillespie, & Daly,
2001; Meiser et al., 1999; Stefanek et al., 1995), sense of family obligation (Hallowell,
1998), witnessing a mother, sister, aunt, or daughter's experience of breast or ovarian
cancer (Hallowell et al., 2001; Hatcher et al., 2001), age, fertility, and menopause
(Hallowell et al., 2001; Meiser et al., 1999; Tiller et al., 2002), fear related to body image
changes (Hallowell, 1998), breast reconstruction availability (Contant et al., 2002), and
fear of surgical procedures and complications (Hallowell, 1998; Hallowell et al., 2001 ).
Findings that several participants choosing prophylactic surgery(ies) regarded screening
modalities for ovarian cancer (transvaginal ultrasound and CA 125 testing) and
mammography for breast cancer as having limited predictive power, and wanted to avoid
the anxiety associated with yearly screening, confirmed other researchers observations
(Lerman et al., 2000; Tiller et al., 2002).
Thirty seven percent of the women (5 BRCA positive and 6 with VUS) chose
vigilant surveillance. This included women in their twenties and thirties who were
delaying their decision until they completed childbearing and breastfeeding. Four (3
BRCA positive and 1 with a VUS) in these age groups indicated their plans for
prophylactic surgery in the future. In the interim they chose vigilant surveillance. Trust in
the competence of their physician, use of MRI, and hope for new research discoveries
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were influential factors in their decision for vigilant surveillance. They found reassurance
in their belief that with surveillance, if they developed cancer, it would be found early. It
is important to note that the advantages and disadvantages of the surgical options
identified by those choosing vigilant surveillance were similar to those choosing
prophylactic surgery(ies). However, how they weighed the advantages and disadvantages
of the alternatives, based on values, beliefs, and desired outcomes were different.
Unlike previous studies these women reported adhering to recommended breast
and ovarian cancer screening guidelines (Lerman, 1998). Perhaps this is because
participants' psychological distress in this community sample was not as great as those in
earlier studies conducted in research institutions. This also may be due to personality
characteristics or style of coping with threatening information.
Only two participants chose the option of chemoprevention with vigilant
surveillance. Participants received less information about this option and it was not
usually recommended by their health care providers. This finding may be partly related to
the lack of scientific evidence of the effectiveness of tamoxifen in women with BRCA
mutations (King et al., 2001). Participants did not identify any advantages of taking
tamoxifen, but delineated several disadvantages; including risk for uterine cancer,
cataracts, and thrombosis, its experimental nature in BRCA carriers, and insufficient risk
reduction. Several younger women did not choose this option because of implications for
childbearing.
Cameron and Leventhal (1995) have suggested that perceived control over disease
influences beliefs of vulnerability. Most women in this study believed they had some
control over their susceptibility to breast and ovarian cancer and some women believed
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that adherence to vigilant surveillance and having a close relationship with a health care
provider could result in early detection and thus survival from breast or ovarian cancer.
These findings lends support to research by Katapodi, Facione, Humphreys, and Dodd
(2005) which indicated women that had a trusting relationship with their health care
provider had a sense of control over breast cancer and perceived they were at a lower
risk.
Making a risk management decision was a strategy to manage susceptibility as
well as a consequence of their knowledge and past and present life experiences and
relationships with others. Decision making involved consideration of both individual and
social factors. Participants balanced the gains of risk reduction, relief of breast and
ovarian cancer worry, and fulfilling their obligations as mother and wife to remain cancer
free, against the potential losses of surgery; such as menopause, infertility, changed body
image, the continuing risk of developing ovarian and breast cancer in residual tissue, and
surgery(ies)' effect on family and employment. Whether participants arrived at a decision
based on apriori decisions, followed the expert advice of their physicians, through
deliberation - accepting some and rejecting other advice, or postponed treatment until
older, they reflected back to evaluate their decisions and put things in perspective.
Reflecting on Actions

All 30 participants expressed satisfaction with their decision to have genetic
testing and indicated they would do it again, as well as recommend it to other women at
high risk for breast and ovarian cancer. In addition, those with prophylactic surgeries
expressed satisfaction with their decision choice( s), despite some difficulties with breast
reconstruction, which is consistent with finding from other studies (Frost et al., 2000;
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Hatcher et al., 2001; Lloyd et al., 2000; Meijers-Heijboer et al., 2000; Stefanek et al.,
1995; Tiller et al., 2002). A few experienced complications after surgery, such as a
"frozen shoulder," pain due to overstretching the capsule during saline injections, and one
described replacement of her implant due to an infection. Overall, it tended to take
participants longer than they had expected to recover from surgery. Findings of a sense of
relief from the fear of developing breast and/or ovarian cancer after prophylactic surgery
supports a 5 year follow-up study ofBRCA carriers by van Oostrom and colleagues (van
Oostrom et al., 2003). Findings also reinforce previous research findings that high risk
women perceived the benefit of anxiety reduction outweighed the potentially adverse
effects of prophylactic surgical procedures (Tiller et al., 2002).
An additional finding was the importance of social context in determining
participants' experience of prophylactic surgery. Although telling others in the family
about their decision for surgery was motivated by a desire to obtain support and
reassurance, for some it brought strong emotional reactions, adverse opinion, and lack of
support. As a result, some decided not to tell certain family members or reduced the
information communicated. This meant their support network was decreased, which
contributed to feelings of isolation. Several developed contacts with BRCA carriers in
peer support groups who shared a similar experience.
Participants viewed their decisions as personal, supported by professional and
peer support groups, but unsupported in follow-up. Most indicated there was not a
cohesive plan for follow-up; they just did not fit, as they did not have cancer, had
prophylactic surgeries, and the medical systems they encountered did not know what to
do with them. They had to be self directed and take personal responsibility, as there was a
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lingering uncertainty about the small risk of peritoneal cancer or cancer in residual breast
tissue. This finding regarding follow-up has not been reported in other literature on
unaffected positive or VUS mutation carriers. In reflecting on the consequences of their
decisions participants indicated they had achieved peace of mind, were altruistic and
working to "pay it forward", experienced strengthened family relationships, and those
who chose screening, remained vigilant.

Conclusion
In this age of genetic technology and discovery of new genes, it is important to
continually assess the impact of this technology on the lives of those who engage in them.
The women who participated in this study regarded breast and ovarian cancer as a
predictable outcome, given their family history, and felt they had a responsibility to their
family to prevent this danger if possible. Their attendance at genetic counseling was the
first step in taking responsibility for their perceived susceptibility and was influenced by
feelings of obligation to their children or other family members. Their BRCA information
was perceived as information about the family. Thus participants disclosed their test
results because of a sense of duty to inform their family members of their risks and risk
management, no matter how difficult it was for them personally. They also felt they had a
responsibility to persuade their family to act on the information. Their risk management
decisions stemmed from a feeling of duty to children, having a responsibility to remain
healthy so they could nurture their children and protect them from seeing a mother die or
having to care for them. Engaging in risk management was seen as providing them with
control over their susceptibility to breast and/or ovarian cancer. Those choosing
prophylactic surgeries wanted to prevent cancer, as they were not satisfied with the
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limitations of vigilant surveillance which provided only early detection of cancer. By
taking these measures they not only gained some control over their lives, but as
importantly, could maintain their identity as mother and nurturer of others. Their
strengths and abilities may serve as indicators needed for successful coping with BRCA
genetic information.
The similarities of previous studies related to genetic testing and risk management
serve to validate this study. This discussion of the findings presented the shared
discoveries and added the unique experiences of unaffected positive and VUS mutation
carriers, to provide a cohesive theory of managing susceptibility to hereditary breast and
ovarian cancer.
At this point, I am including two powerful and poignant poems, written by two
participants which so eloquently express the experiences of women managing their
susceptibility to hereditary breast and ovarian cancer (see Figure 3). May these be cogent
reminders to each of us of the need for emotional support as we continue to grope, cope,
and understand our humanity, as life is lived in our genomic age.
The final chapter provides a critique of this study and offers implications and
recommendations for health policy, nursing practice, and research.
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Legacy of Fear
"Are you scared, Mom?"
My seven-year-old daughter asks.
"Yes, honey, a little bit", I respond,
Trying to keep my voice sounding calm and reassuring.
More than you'll know I think, quietly, inwardly ..•
My fear comes in so many ways.
That my beautiful daughters, now seven and ten,
Will know this fear, just as I have.
Just as my mom, my sisters, my brother, my husband have.
More than anything,
I prayed that this would not be there for them.
But I can't stop it
And the fear continues.
It feels like a time bomb, waiting to explode in my life.
Should I have children? •.. tick, tick •••
Did I book my mammogram? .•• tick, tick •..
Should we have another child? .•.•tick, tick...
What was that I felt in my breast? •.• tick, tick •••
Do I need life insurance? •••• tick, tick•••
What about the ultrasound? ... tick, tick•..
Should I get tested? ••.. tick, tick •••
And we wait
And we wait
And we wait
BRCAl - my fear has a name.
I hate this name, but now there is a face to it.
Part of me knew it would be there.
I can look this fear in the face now.
I hate you.
I hate what you have done to my beautiful mother, my beautiful sister, and my
beautiful daughters.
I hate what you have done to me.
But I have power over you now.
I will cut you out of me
And you will not hurt me anymore,
Or scare me.
You will not explode in my body.
I will win.
"Mommy, are you scared?"
Yes, my beautiful, precious, innocent daughters.
For you, I am scared.
"Will this happen to me?"
My daughter asks.
Tick, tick, tick••..
FKJ December 2002

Figure 3. Participant's Poem: Legacy of Fear
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Skin
Stretched
Over saline sacs
Breasts
They call them
Reconsttucteq
Numb
Colq, scarreq
But in a breast-obsesseq worlq
They succeeq
To qeceive
Them
I remember

Her small hungry mouth latching on
The urgent sucks slowing
Her tiny fingers'
Soft touch
Sleeping
Warm
Wet kisses
Breasts rising, responqing
Reaching for his touch
Nakeq skin embracing
Feeling
Gone now
To save my life
I remember
And I cry
Jo.m1Je
October 25, 1999

Figure 3. Poem ofBRCA 2 positive participant coming to terms
with her BPM and Reconstruction
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CHAPTER VII
IMPLICATIONS AND RECOMMENDATIONS
Growth in our knowledge of the human genome over the last decade has resulted
in the availability of genetic testing for familial susceptibility to hereditary breast and
ovarian cancer. Knowledge of genetic mutation status potentially provides high risk
women with the needed information on which to make decisions about options to reduce
their breast and ovarian cancer risk. This study has formulated a grounded theory of
Managing Susceptibility, reflecting the experiences of unaffected BRCA carriers' testing
for hereditary breast and ovarian cancer and subsequent risk management decision
making. This chapter provides a discussion of the critique of this study and offers
implications and recommendations for health policy, nursing practice, and research.

Critique of the Study
Strengths
A strength of this study, over previous studies related to BRCA mutation testing
and risk management, is that it was a community sample, from 14 states and Canada. It
represented unaffected BRCA carriers' experiences in several different cancer genetics
institutions, not just in a single research institution. The sample size was sufficiently large
to allow saturation of categories to be reached and the purposive sample of women
201
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reflected a range of perspectives. Other strengths include the range of ages of
participants, from 22 years to 60 years. This age diversity of unaffected women
participants served to enhance the validity of the resulting theory. Women in this study
were unaffected prior to testing, thus preventing confounding by cancer status. In
addition, this study explored genetic testing and risk management decision making in
both BRCA positive unaffected women and those with BRCA VUS results, which have
not been reported previously in the literature. Furthermore, it explored the impact of time
since receiving test results and making a risk management decision, as some women had
received their test results and had their surgery several years ago, while others were in the
process of their decision making (median year tested - 2002, range 1994-2004; median
time from testing until BPM surgery - 10 months, range 1-40 months; median time until
BPO - 6.9 months, range 0-27 months).
The methodology enabled rich data to be gathered, with findings derived from
participants' own accounts. Additionally, adherence to methodology to establish
trustworthiness was a strength of the study. Credibility was established by using
consistent interviewing techniques, using reflexive analysis, keeping methodological and
theoretical memos, and using peer examination. Peer examination and discussion of the
data also helped to achieve dependability and trustworthiness. Transferability was
enhanced by providing dense background information to allow others to make
comparisons.
Limitations

The predominance of Caucasian, well educated participants of middle to upper
middle income status, who volunteered to be interviewed might be considered a
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limitation. However, due to the cost ofBRCA testing and risk management options, this
represents the socio-demographic features of women in general seeking genetic testing.
The interview data represented retrospective accounts and was influenced by what
participants remembered. However, women were able to give rich and relatively
unprompted accounts of their experiences of both their BRCA testing and decision
making experiences. While the high decision satisfaction for BRCA testing and risk
management options chosen may be real, it may also be due to positive response bias
from cognitive dissonance. This phenomenon has been documented in unvalidated
patient satisfaction measurement (Carr-Hill, 1992) and is relevant to surgical decision
making (Homer, Sheard, & Jones, 2000).
Implications

Implications and recommendations are indicated in the following three areas:
health policy, nursing practice, and further research.
Health Policy

Findings suggest that participants were concerned about both insurance and
employment discrimination, to the extent that some participants paid for the testing outof-pocket rather than use their health insurance. Fear of health insurance discrimination
represented the greatest barrier to utilization of cancer genetic counseling in a study by
Geer et al. (2001 ). Legislation protecting individuals from genetic discrimination by
health insurers and employers might help clients feel that they and their relatives will not
be harmed by seeking BRCA genetic testing. Although recent federal and state
legislation, such as the Health Insurance Portability and Accountability Act (HIPPA) of
1996, have begun to provide protections against genetic discrimination in health
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insurance, more needs to be done. The HIP AA prohibits group health insurance plans
from treating most genetic informatio n as a preexisting condition and from using genetic
informatio n to determine eligibility (Anderlik & Lisko, 2000). However, it does not apply
to those not insured under group plans, e.g. individual plans. It also does not prohibit
other discriminatory practices, such as mandatory testing, raising premiums, or setting
caps on insurance, if these conditions are equally applied to all persons enrolled in the
plan (White, Callif-Daley, & Donnelly, 1999).
To prevent genetic discrimination in insurance and employment, federal
legislative reform is needed. Nurses can advocate for such legislative reform through the
legislative arms of their professional nursing organizations. Current legislation, Senate
Bill 306, the Genetic Informatio n Nondiscrim ination Act passed the Senate in February,
2005. However, the companion U.S. House of Representatives bill, HR 1227, was
th
introduced in the 109 session but awaits consideration in committee. This bill seeks to

create a national standard to bar genetic discrimination by health insurers and employers
(Genetics and Public Policy Center, 2005). Similar legislation has been introduced in
previous sessions of Congress, but has not made it to the joint conference committee.
Since genetic discriminat ion has been less of a threat than anticipated (Hall & Rich,
2000a, 2000b), education of clients about this informatio n may help remove barriers to
genetic testing services.
Findings of this study also suggest that individual economics played a role in
decision making both for genetic testing and risk manageme nt options chosen, which
confirmed other research (Geer et al., 2001; Olopade, 1996). Policy makers must
recognize the implications of employing technology that is costly to families who seek
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this testing. As discussed, some of the participants and their providers spent a good deal
of time negotiating with insurance payors to cover costs of testing and surgical treatment.
Future goals should include the provision of funds for genetic testing and risk
management options by third party payors, including Medicaid. Nurses can advocate for
just distribution of health and insurance costs, so that people are not penalized for genetic
attributes over which they have no control.
Nursing Practice

Although the value of genetic counseling by cancer genetics health professionals
in preparing for genetic testing is supported by participants in this study, counseling did
not fully prepare them for the emotional strain they would experience in making risk
management decisions. Few indicated there was contact with the genetic counselor or
other genetics health care professional after disclosure of their test results. After testing,
participants sought information from multiple sources regarding risk management and
indicated that putting together a surgical and oncology team was difficult work, like
"pushing a boulder up a hill." A coordinated effort between the genetics, oncology,
surgical, and nursing teams to provide informational support is important to prevent
further distressing these women during their decision making experiences.
Emotional care must also be provided for unaffected BRCA carriers as they take
on risk management decisions. Many of these women, at least initially, were unaware of
support systems outside their immediate family and had to discover support systems
independently. The prevalent use of peer support groups to obtain emotional support and
information about risk management options underscores the need for professionally led
supportive-expressive group support programs for BRCA positive and VUS carriers, to
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facilitate psychological adjustment and decision making (Esplen et al., 2004). Advanced
practice nurses in genetics can conduct such groups, providing information and clarifying
or correcting factual misinformation during group sessions.
Study findings also stress the importance of long-term follow-up for both breast
and ovarian cancer for unaffected carriers who have chosen the prophylactic surgery(ies)
risk management options. Advanced practice nurses, in concert with other health care
providers, need to develop a comprehensive approach to follow-up for unaffected BRCA
carriers within their health care facilities.
The observation that participants speculated about their BRCA test result, which
helped in preparing for their test results, may indicate there is a role in counseling to help
individuals predict their results and reactions, to protect against emotional stress.
Identification of those who anticipate negative results, but receive positive results, will
allow for targeting of those individuals for further evaluation and counseling and for
follow-up. Those women with variants of uncertain significance who render their results
problematic may experience more distress and need follow-up evaluation and counseling.
Communication about BRCA test results within the family should receive special
attention during counseling, especially when tested clients are the initial messengers. It is
important that clients give consideration to whom and how they will communicate this
information to their family members. It is important that they are able to provide correct
information to their family. This study found that variant of uncertain significance test
results are not easily understood and consequently difficult to communicate. Even when
patients can recall some of the counseling information, subtle personal communication
may color the communication. These findings reinforce that written material from genetic

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

207

counselors may be a helpful aid in this process (Green et al., 1997; Hallowell & Murton,
1998; Richards, 1999).
Training of advanced practice nurses and other health care professionals needs to
include information regarding the impact of BRCA test results on risk management
decisions, particularly the impact of variants of uncertain significance test results. This
study found that some VUS carriers perceived their test result as positive, others rendered
them negative. These perceptions impacted their risk management decision making and
long term follow up.
Future Research

The experience of risk management decision making in unaffected positive and
VUS BRCA carriers remains a fertile area for further research. First, studies could
examine decision making with a larger sample of unaffected positive and VUS carriers.
With more statistical power, significant differences between positive and VUS carriers
may be revealed regarding disclosure of test results and risk management decision
making. All of the women in this study volunteered to be interviewed and voiced
satisfaction with their decisions. The voices of women who do not feel satisfaction with
their decision making needs to be contrasted with those who were satisfied. Another
modification would be a prospective study to examine decisions of young unaffected
women over time. This study used data from participants from 22 to 60 years of age.
Looking at decision making across multiple time points, such as age 35 and 40 years in
those diagnosed with BRCA mutations in their twenties and early thirties, would reveal
whether those who indicated their desire for prophylactic surgery in the future, after
having children and meeting family obligations, have changed.
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There are limited data on uptake of genetic testing and risk management decision
making among nonwhite populations. Further research is needed to define factors
influencing testing and risk management decision making in these populations. The
decision making styles of other ethnic groups may reflect differing viewpoints on the
same issues or other issues may emerge in the risk management decision making
expenence.
Future research is needed to define which individual or familial qualities
encourage adaptation and mastery by those undergoing genetic testing. Results of this
study and that of Dorval (2000) suggest that the ability to anticipate accurately one's
distress reactions to test disclosure may be a predictor of psychologic outcomes after
genetic testing. Identification of those at increased risk for heightened distress after
disclosure will allow for targeting those individuals for further evaluation. Future
research is also needed to examine the use and effectiveness of internet and online
chatrooms to provide emotional and informational support and help women make sense
of their experience of susceptibility to HBOC.
This study of BRCA genetic testing and risk management raises questions about
the process and content of communicating with children about cancer risks, and the
impact of these communications on parent-child well being. Research is needed to
evaluate the process and content of post-test disclosure and the impact on participant,
child, and family functioning. Given the complexities of risk management decision
making and psychological adjustment associated with genetic testing, a better
understanding of the consequences of disclosure to family members can help nurses and
other clinicians provide better counseling to these individuals. Research is also needed on
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the impact of BRCA positive and VUS results disclosure on relationships with relatives.
Research from the perspective of relatives who do not want the genetic informatio n is
needed to better understand their perception s about informing family members and
factors influencing their decisions to block disclosure.
All the women who volunteered for this study were unaffected with breast or
ovarian cancer prior to testing. Most had made a risk manageme nt decision and had
moved on with their lives. The decision making voice of women affected with cancer,
before genetic testing, needs to be contrasted with these unaffected women. The
developme nt of quantitative decision making aids or tools with subsequent intervention
studies also present further options.
In summary, indications for changes in health policy, nursing practice, and further
research have been identified. Health policy must be changed through federal legislation
to prevent insurance and employmen t discrimination. Legislation protecting individuals
from genetic discrimina tion by health insurers and employers might help clients feel that
they and their relatives will not be harmed by seeking BRCA genetic screening. Policy
makers must recognize the implications of employing genetic technology that is costly
and provide for funding of genetic testing and risk manageme nt options by third party
payors, including Medicaid. Advanced practice nurses must recognize the informational
and emotional support needs of women seeking BRCA testing, during disclosure and
during risk manageme nt decision making, and ensure a coordinate d approach to followup care. Lastly, research possibilities include risk manageme nt decision making in
unaffected carriers of other cultural and economic backgrounds, as well as women
affected with cancer prior to genetic testing. Future research is needed to define which
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individual or familial qualities encourage adaptation and mastery by those undergoing
BRCA genetic testing. In addition, the development of quantitative decision making aids
or tools with subsequent intervention studies present further options.
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